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SUMMARY 
       Human urine accounts for approximately 1% of domestic wastewater by volume, yet 
urine contributes a disproportionate mass load to wastewater—greater than 80% of N, 50% 
of P, and 60% of pharmaceuticals. As such, the destruction of pharmaceutical excreted in 
urine can be an efficient approach to minimize the environmental pollution of these 
compounds in wastewater, surface water, and drinking water.  However, research about the 
removal of pharmaceuticals and their metabolites in urine has been scarce. Previously 
proposed approaches either suffered from strong scavenging effects from urine 
components or required further chemical treatment to degrade these pharmaceutical wastes, 
generated from physical separation. Thus, more effective treatment should be introduced 
to eliminate pharmaceuticals and metabolites in urine.  
            This dissertation focuses on developing Fe(VI)-based advanced oxidation 
technology for the destruction of pharmaceuticals in source-separated human urine and 
related conditions, with a particular aim to elucidate the involved reaction mechanisms. 
First, the study was performed to investigate the degradation of selected pharmaceuticals 
in synthetic hydrolyzed urine (pH 9.0) and in phosphate buffer (pH 9.0) spiked with urine 
components. The comparison between synthetic urine and phosphate buffer matrices 
uncovered the specific impacts of inorganic and organic urine constituents on Fe(VI) 
oxidation. Second, further research was conducted to delineate the reaction kinetics and 
mechanisms of Fe(VI) oxidation of pharmaceuticals in the presence of bicarbonate or 
creatinine, both of which enhanced the Fe(VI) oxidation efficiency. By evaluating 
the reactive moieties and oxidation products of pharmaceuticals in such systems, the 
 xxv 
underlying oxidation mechanism involving the formation of high-valent iron intermediate 
species (Fe(V)/Fe(IV)) and their contribution to the enhanced pharmaceutical degradation 
was elucidated, and the usefulness of the Fe(VI)-activated systems was demonstrated.   
          Several Fe(VI)-activated systems were further investigated via dynamic kinetic 
modeling to provide new fundamental insights of the kinetic behaviors of Fe(V)/Fe(IV) 
during Fe(VI) oxidation process. First, kinetic modeling and density functional theory 
(DFT) calculation of Fe(VI) self-decay at alkaline conditions (pH 9 and 10) were 
performed, and the results indicated different reaction kinetics and mechanisms upon the 
protonation of Fe(VI). A new kinetic model containing Fe(VI) decay involving Fe(V) and 
Fe(IV) at pH 9.0 was successfully derived to predict Fe(VI) disappearance and 
H2O2 generation (a product) under varied conditions, which provided the basis for Fe(VI) 
oxidation simulation at pH 9.  Second, the Fe(VI)-Fe(III) reaction system was investigated 
to evaluate the enhancement effect of ferric ion on Fe(VI) self-decay at pH 9.0. The Fe(VI)-
Fe(III) kinetic model was constructed to characterize the Fe(III) acceleration of Fe(VI) 
self-decay into Fe(IV) based on the Fe(VI) self-decay model at pH 9.0 developed 
previously. Furthermore, Fe(VI)-Fe(III)-substrate model was constructed to evaluate the 
enhanced effect of ferric ion on Fe(VI) oxidation on 18 pharmaceuticals. The structure-
activity relationship between compounds’ molecular descriptors and 2nd -order rate 
constants between Fe(IV) and substrates derived from Fe(VI)-Fe(III)-Substrate was 
assessed. Third, the Fe(VI)-ABTS reaction system at pH 7.0 phosphate (10 mM) buffered 
solution was systematically investigated to quantitatively probe iron intermediate species 
(Fe(V)/Fe(IV)) in Fe(VI) oxidation. The proposed Fe(VI)-ABTS-substrate model was later 
developed to successfully determine reactivity pf Fe(V) to different substrates.  
 xxvi 
         Overall, the research outcome of this dissertation filled several knowledge gaps for 
applications of Fe(VI) in pharmaceutical removal in human urine and related conditions, 
which will be useful toward the management of contaminants of emerging concern. The 
new knowledge will also help accelerate a broader application of ferrate oxidation 
technology in various contamination treatment and mitigation. Moreover, this research 
exemplified probing Fe(V)/Fe(IV) kinetic behaviors during Fe(VI) oxidation via the useful 
tools of dynamic kinetic modeling. The new models developed in this study could inspire 
and facilitate future studies to better understand the fate of Fe(V)/Fe(IV) in other Fe(VI)-
activated systems and even uncover Fe(V)/Fe(IV) reactivity and selectivity to different 







CHAPTER 1. INTRODUCTION 
1.1 Background  
The U.S. population spent nearly $310 billion on medication in 2015.1 A large 
portion of the prescribed pharmaceuticals are excreted unchanged or as metabolites in urine 
and feces which follow municipal wastewater streams. Unless wastewater treatment plants 
(WWTPs) are equipped with highly advanced treatment processes such as reverse osmosis 
or advanced oxidation processes (AOPs), most pharmaceuticals and metabolites are not 
removed and eventually end up in the natural environment, threatening the aquatic 
ecosystem because of their toxicity and potential to induce drug resistance.2 Numerous 
studies have reported the detection of pharmaceuticals in drinking water, surface water, 
groundwater and wastewater at ngL-1 to µgL-1 levels.3-6 The extensive occurrence of 
pharmaceuticals in the aquatic environment and potable water demands more efficient 
treatment of these micropollutants from the source. At the same time, there is a growing 
need to intensify the resource recovery potential of domestic wastewater.7 For instance, 
intensifying nutrient recovery from wastewater is considered the first step in transforming 
WWTPs into water resource recovery facilities of the future.8-9 As such, nutrient (nitrogen 
(N) and phosphorus (P)) recovery from wastewater can create a renewable and local supply 
of fertilizer that can contribute to more sustainable agricultural practices and food 
security,10-11 while also decreasing the discharge of nutrients to the environment and the 
consequent harmful impacts.12-13 
The one percent. Human urine accounts for approximately 1% of domestic 
wastewater by volume yet urine contributes a disproportionate mass load to 
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wastewater—greater than 80% of N, 50% of P, and 60% of pharmaceuticals.14-16 As 
such, source separation and treatment of urine has been proposed as a disruptive innovation 
to the status quo approach to wastewater management.7, 17-24 Urine diversion is 
accomplished using urine-diverting flush toilets (e.g., WC-Dubbletten, BB Innovation & 
Co AB; EcoFlush, Wostman) and waterless urinals (e.g., Steward, Kohler; WES Waterfree, 
Sloan). The source-separated urine is typically piped to a storage tank in the building and 
stored for 3–6 months to allow for pathogen inactivation.25-28 Urine diversion systems have 
been successfully implemented in residential and workplace locations for extended periods 
of time, e.g., apartments in Sweden, Denmark and South Africa (5–9 years),29 apartments 
and office buildings in Switzerland (1 year),25 and office buildings in Germany (3 years).30 
Although liquid urine can be applied directly as fertilizer locally,31-34 the pharmaceutical 
micropollutants in urine may accumulate in the soil and plants and therefore exert 
hazards,35-36 or contaminate the nutrients to be separated from urine.37 Hence, urine 
diversion systems appear practical. However, engineering strategies that are efficient in 
concentrating nutrients into useable fertilizer, powerful in pharmaceutical micropollutant 
destruction, practical to implement, and acceptable to society are critically needed. Lack 
of such knowledge is an urgent problem because it is preventing sustainable wastewater 
management - a paradigm shift focused on resource recovery and holistic management of 
contaminants of emerging concern.  
Mitigation of environmental pharmaceutical micropollutants at the urine source is 
the focus of this proposed study. The effective destruction of pharmaceuticals in urine can 
minimize energy-intensive treatment required at centralized wastewater treatment facilities 
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to remove these micropollutants, and reduce the potential of pharmaceuticals in posting 
ecological harm in the receiving waters and contamination in drinking water sources.  
1.1.1 Chemistry of Human Urine 
Understanding the chemistry of human urine is central to developing effective 
processes for pharmaceutical destruction in urine. Human urine contains urea (CO(NH2)2), 




2–), inorganic cations (Na+, K+, 
Ca2+, Mg2+), endogenous metabolites (e.g., creatinine, creatine, hippuric acid, and citrate), 
and likely pharmaceuticals. The composition of human urine depends on whether the urea 
is unhydrolyzed, which is the case for fresh urine, or hydrolyzed, which occurs in the 
presence of urease-containing bacteria. The net reaction for urea hydrolysis is written as 
follows:38 CO(NH2)2 + 3H2O → 2NH4
+ + HCO3
– + OH–, which increases the pH of urine 
and results in supersaturated conditions for precipitation of struvite (Mg2+ + NH4
+ + PO4
–3 
+ 6H2O → MgNH4PO4·6H2O(s)) and hydroxyapatite (5Ca
2+ + 3PO4
–3 + H2O → 
Ca5(PO4)3OH(s)).
39-40 Accordingly, based on a thorough literature review with emphasis 
on urine diversion systems,39, 41-44 representative characteristics of unhydrolyzed (fresh) 
and hydrolyzed urine are summarized in Table 1.1.   
 
Table 1.1 The composition of human urine; concentrations in mM, except pH, I (M), 
COD (mg/L as O2). 
 




2– Na+ K+ Ca2+ Mg2+     COD 
Fresh 5–7 0.15 530 33 150 10 16 9 120 45 3 3 8200 
Hydrolyzed 9 0.5 18 320 100 8 10 280 96 41 0.9 0.2 4500 
Notes: Ionic strength (I); chemical oxygen demand (COD); NH3, PO4
3–, and CO3
2– are total species concentrations. 
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      Data on endogenous metabolites are almost exclusively for fresh urine and from the 
medical literature. Recent work has confirmed 2,651 human urine metabolite species,45 
with creatinine, hippuric acid, citric acid, glycine, taurine, and L-cysteine being the most 
prevalent and at the highest concentrations (1–15 mM).45-47 The decrease in chemical 
oxygen demand (COD) measured in stored urine upon the transformation of fresh to 
hydrolyzed urine suggests that endogenous metabolites are degraded to some extent.48 In 
addition, medical literature on the preservation of human urine samples shows that 
creatinine, hippuric acid, and citric acid were partially degraded by microbial activity, 
whereas the concentration of glycine was increased due to microbial activity.47 
Pharmaceuticals are excreted in urine either unchanged as the active ingredients or altered 
as various metabolites,16, 20, 49 which is discussed in the next section. Thus, urine 
composition must be considered when identifying appropriate processes for 
pharmaceutical destruction in urine. 
1.1.2 Pharmaceutical Active Ingredients and Metabolites in Urine 
The global population is expected to spend in excess of $1.1 trillion on medicines 
by 2017.1 A large portion of the consumed pharmaceuticals are excreted in unchanged form 
(i.e., active ingredient) or as metabolites in urine and feces.49 Although the excretion rate 
can vary widely among individual pharmaceuticals, Lienert et al. estimated that 
pharmaceuticals are excreted at 64(±27)% via urine and 35(±26)% via feces, and for 
excretion in urine, about 42(±28)% of the pharmaceuticals are excreted as metabolites.16 
Dominant metabolic pathways include hydroxylation, carboxylation, and 
glucuronidation,49-50 all of which make pharmaceuticals more hydrophilic. Urine not only 
contains a greater portion of the excreted pharmaceuticals but also carries a higher toxic 
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potential of pharmaceuticals to aquatic organisms. Based on modeling techniques to predict 
toxicity, it was determined that 67% of 42 pharmaceuticals exerted at least half of their 
total toxicity in urine, and 24% exerted toxicity exclusively via urine.20 Another compelling 
reason for urine source separation is that pharmaceuticals are present at 2–3 orders of 
magnitude higher concentrations in urine than in domestic wastewater.49-50 Thus, removing 
pharmaceuticals in source-separated urine is expected to be an effective way to prevent 
many of these micropollutants from entering the environment and thereby reduce toxicity 
to aquatic organisms and humans. 
Both pharmaceuticals and their metabolites should be considered in urine 
treatment. In fresh urine, the concentration ratio between pharmaceutical and its 
metabolites varied widely.51-52 For example, 77.5% of trimethoprim was excreted in 
unchanged form,53 whereas it was 9.5% for sulfamethoxazole.54 Currently, information is 
scarce regarding the concentrations of pharmaceuticals versus metabolites in hydrolyzed 
urine. However, considering that microbial and enzymatic activities in WWTPs can 
transform some pharmaceutical metabolites back to the parent compounds,55 such 
transformation is likely to also occur in hydrolyzed urine. So far, only a few studies have 
compared the photodegradation rates of some pharmaceuticals versus their metabolites 
under sunlight or UV irradiation.56-60 To date, very limited studies have investigated the 
removal of pharmaceutical metabolites by advanced oxidation technologies (AOTs). Thus, 
treatment of pharmaceutical metabolites is a major information gap that requires new 
research to address the gap. 
1.1.3 Removal and Destruction of Pharmaceuticals in Urine 
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To date, research regarding the removal of pharmaceuticals and their metabolites 
in urine is still quite limited. Nanofiltration membranes,37 strong-base anion exchange 
resins,61-62 electrodialysis, and struvite precipitation21, 63 have been investigated. All of the 
above methods, however, only physically separate pharmaceuticals from urine and 
generate pharmaceutical wastes that still need to be treated. Ozonation was investigated for 
destruction of pharmaceuticals in urine; however, very high doses of ozone were needed 
to achieve 50% reduction of pharmaceutical concentrations, due to strong scavenging 
effects of urine matrix on ozone.64  
Recent studies have investigated the applications of UV/H2O2 (a hydroxyl radical 
(·OH)-based AOP) and UV/peroxydisulfate (PDS) (sulfate radical (SO4·
-)-based AOP) for 
degrading pharmaceuticals and metabolites in synthetic fresh and hydrolyzed urine.65-67 
These two AOPs were selected because both ·OH and SO4·
- are known to react rapidly 
with many pharmaceuticals.68-74,75-82 The studies examined several antibiotics (e.g., 
sulfamethoxazole (SMX)), trimethoprim (TMP), and the major metabolite of SMX, N4-
acetyl-sulfamethoxazole (acetyl-SMX)). It was confirmed that all these compounds are 
highly reactive to ·OH (k = (6.09−9.26)×109 M-1s-1) and SO4·
- (k = (0.77−16.1)×1010 M-
1s-1).65-67   However, the actual degradation of pharmaceuticals by the radicals in the fresh 
urine matrix was significantly suppressed (nearly 90%) due to radical scavenging by citrate 
and urea. In the hydrolyzed urine matrix, the pharmaceuticals’ degradation was 
significantly affected by Cl-, HCO3
-/CO3
2-, and NH3 in urine.  Based on the experimental 
data and kinetic modeling, it was found that Cl- had no apparent impact on UV/H2O2, but 
increased ·OH concentration while significantly consuming SO4·
- radicals in UV/PDS. 
Carbonate species reacted with ·OH or SO4·
- to generate carbonate radical (CO3·
-), which 
 7 
degraded SMX and TMP (k = (1.25−8.71) × 108 M-1s-1 and 3.45 × 107 M-1s-1), but could 
hardly degrade acetyl-SMX. Ammonia reacted with ·OH or SO4·
- to generate reactive 
nitrogen species (RNS) that could react appreciably only with SMX. Overall, UV/PDS 
performs better than UV/H2O2 in the hydrolyzed urine matrix in terms of process 
efficiency.65, 67  No antimicrobial property was detected for the transformation products of 
either SMX or TMP by both AOPs. However, higher (by 20-40%) acute toxicity products 
were generated by UV/PDS.66    
As evidenced by the above studies, human urine constituents such as NH3, 
carbonate, chloride, and various organic metabolites may exert significant scavenging 
effects on radicals during AOPs, leading to lowered degradation and sometimes complete 
inhibition of degradation of target pharmaceuticals. For UV/H2O2 and UV/PDS, they both 
suffer a significant degree of scavenging effects when applied in the urine matrices. The 




- radical is strongly influenced by NH3 and Cl
-.65, 67 The application of AOPs to 
degrade pharmaceuticals can be conducted post nutrients-recovery of urine that removes 
N and P, thus eliminating the scavenging effect by NH3. However, removing HCO3
-/CO3
2- 
and Cl- will require highly energy-intensive processes, and currently there are no economic 
incentives for that. Therefore, developing an AOT that is more resistant to the matrix 
effects of urine for the degradation of pharmaceuticals is highly desirable. Ferrate 
(Fe(VI), FeVIO42-) is such a potential AOT because it reacts much more slowly with NH3 
than ·OH and SO4·
- (rate constants of NH3 with ·OH, SO4·
- and Fe(VI) are 9.0 × 107, 1.4 
× 107 and 0.12 M-1s-1, respectively)83-85 and Fe(VI) has very low reactivity to HCO3
-/CO3
2- 
and Cl-.86   
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1.1.4 Oxidation Process by Ferrate (Fe(VI)) 
         Over the past decade, Fe(VI) has emerged as a novel oxidant to remove contaminants 
and micropollutants from water.87-104 While several studies have been carried out on 
Fe(VI), most of the studies have focused on evaluating the performance of Fe(VI) in 
removing various contaminants, and relatively limited efforts have been devoted to 
understanding the mechanisms of Fe(VI) oxidation reactions that involve iron intermediate 
species (i.e., Fe(V) and Fe(IV)) (Figure 1.1) generated via one- or two-electron transfer 
pathways.105-106       
         As shown in Figure 1.1,86, 99, 107-109 the oxidation of substrate (X) by Fe(VI) can occur 
by several possible pathways. Steps include: (i) 1-e- transfer to form FeV and a radical, with 
Fe(V) reacting to form oxidized substrate (X(O)) and FeIII; (ii) 2-e- transfer to form Fe(IV) 
and a radical, with FeIV oxidizing the substrate; (iii) 2-e- transfer to yield Fe(IV) and a 
dimer, with Fe(IV) oxidizing the substrate; and (iv) oxygen atom transfer (OAT) to produce 
Fe(IV)  and an oxygen atom added to substrate (X(O)). Fe(V) and Fe(IV) can then yield 
 









different final reduced species (Fe(II) or Fe(III) or both Fe(II) and Fe(III)) via 1-e- and 2-
e- pathways. Other possible reactions (not shown) include: (i) further reactions of Fe(V) 
and Fe(IV) with oxidized species (oxidized substrate (X(O)) and oxygen atom addition to 
substrate (X(O)); (ii) further reactions of Fe(VI), Fe(V), and Fe(IV) species with radicals 
(e.g., Fe(VI) + X● → Fe(V) and X(O)); (iii) the reactivity of substrate with substrate 
radical; (iv) self-decomposition of radical and Fe(VI), Fe(V) and Fe(IV) species (e.g., X● 
+ 2OH- → X(O) + H2O, Fe
VO4
3- + 4H2O → Fe(OH)3 + H2O2 + 3OH
-; 2FeVIO4
2- + 3H2O2 
+ 2H2O → 2Fe(OH)3 + 3O2 + 4OH
- ; 2FeIVO4
4- + 7H2O → 2Fe(OH)3 + 1/2O2 + 8OH
-); and 
(v) reactions of iron species of different oxidation states with each other (e.g., Fe(VI) + 
Fe(II) → Fe(V) + Fe(III); Fe(IV) + Fe(II) → 2Fe(III)). Some studies have attmpeted to 
obtain insights on the steps of the reaction mechanisms through theoretical correlations of 
rate constants of the reaction of Fe(VI) with the 1-e- and 2-e- thermodynamic reduction 
potentials.86, 110 However, the direct experimental evidence of the formation of either 
Fe(IV)/Fe(V) and X●   is missing. Applications of state-of-the-art techniques such as freeze 
electron paramagnetic resonance (EPR) and millisecond time-scale stopped-flow 
spectrocopy will enhance the elucidation of the oxidative chemistry of ferrates (Fe(VI), 
Fe(V), and Fe(IV)) with subtrates. 
      Most recently, researchers have focused on the discovery of activated-Fe(VI) systems 
in which activators (e.g., ammonia,111 acid,112-113 sulfite/thiosulfate,114-116 bicarbonate,117 
Fe(II)/Fe(III),118 2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS),119  
Mn(II)120 and carbon nanotube121) can enhance the degradation of substrates or even 
facilitate the removal of substrates resistant to Fe(VI) oxidation. However, the previous 
work heavily relied on qualitative analysis of possible reactive species formed in-situ 
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(radical vs. Fe(V)/Fe(IV)) via quencher experiments and/or EPR  spectroscopic techniques, 
and only limited studies122-123 have attempted to quantitatively investigate the kinetic 
behaviors of Fe(V)/Fe(IV) for their self-decays vs. oxidation of substrates. Therefore,  more 
comprehesnive and robust dynamic kinetic modelling are in need to serve as the vehicle to 
probe the kinetic behaviors of the intermidieate species ( Fe(V)/Fe(IV) and activator-based 
radicals) and resolve some inconsistencies in previous literature, which were soly based on 
empricial generalization. 
1.2 Research Objective 
The overall objective of this study is to develop Fe(VI)-based AOT for the destruction of 
pharmaceuticals in source-separated human urine and related conditions, and to elucidate 
the involved reaction mechanisms. The research objective will be achieved by pursuing the 
following four specific aims to:   
(i) Investigate the degradation of selected pharmaceuticals and their metabolites in 
synthetic hydrolyzed urine (pH 9.0) and in phosphate buffer (pH 9.0) spiked with or 
without the urine component(s). The selected pharmaceuticals will represent high usage 
and a wide range of structural properties. The comparison between synthetic urine and 
phosphate buffer matrices will provide an initial assessment of inorganic and organic urine 
components (e.g., NH3, HCO3
- and creatinine) that exert significant influence on Fe(VI) 
reactions.  
(ii) Based on the results from Aims i, identify the reactive moieties and oxidation 
products of pharmaceuticals with Fe(VI). The accomplishment of Aims i-ii will give 
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insights on the mechanism of the oxidation of pharmaceuticals by Fe(VI) in buffered clean 
water and in synthetic urine matrices. 
(iii)     Determine the reaction kinetics of Fe(VI) self-decay at urine pHs (9.0-10.0). We 
propose to extend the kinetic modeling of self-decay of Fe(VI) in pH 7.0 solution from the 
literature and expand it to urine pHs (9.0-10.0) in order to exam Fe(VI) decay kinetics at 
alkaline condition. We utilize computational chemistry based on density functional theory 
(DFT) to address the knowledge gap of self-decay mechanism of deprotonated Fe(VI) at 
alkaline condition. 
(iv)  Investigate the intermediate iron species in activated-Fe(VI) systems to further 
understand the kinetic behaviors of Fe(V)/Fe(IV) via dynamic kinetic modeling. Fe(III)- 
enhancement effect will be incorporated into the Fe(VI) self-decay model at pH 9.0 to form 
the Fe(VI)-Fe(III) system at pH 9.0, while ABTS-enhancement effect will be incorporated 
into the Fe(VI) self-decay model at pH 7.0 to form the Fe(VI)-ABTS system at pH 7.0. 
The new kinetic models of these two activated-Fe(VI) systems can provide useful tools to 
facilitate the understanding of the behaviors of Fe(V)/Fe(IV) species and uncover 
Fe(V)/Fe(IV) reactivity and selectivity to different organic pollutants based on kinetic 
simulation. 
1.3 Organization of the Dissertation  
         This dissertation begins within an introduction of urine chemistry and current urine 
treatment technologies, as well as a concise review of the application of Fe(VI) for 
destruction of pollutants, including a new trend of involving activated-Fe(VI) systems over 
the past few years.  
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          In Chapters 2 and 3, the effects of major inorganic and organic constituents in 
hydrolyzed urine on Fe(VI) oxidation of selected pharmaceuticals were examined. 
Specifically, in Chapter 2, the effects of chloride, bicarbonate, and ammonium on Fe(VI) 
oxidation of carbamazepine (CBZ), naproxen (NAP), trimethoprim (TMP) and 
sulfonamide antibiotics (SAs)) in the synthetic hydrolyzed urine were examined. As a new 
finding from this work, the enhancement effect of bicarbonate on Fe(VI) oxidation of 
sulfonamide antibiotics was investigated in-depth to elucidate the oxidation mechanism 
involved in the Fe(VI)-bicarbonate system. In Chapter 3, the effects of creatine, hippuric 
acid, and creatinine on Fe(VI) oxidation of CBZ, NAP, TMP, and SAs were examined, and 
the enhancement effect of creatinine was discovered. Thus, a new kinetic model that can 
successfully describe the pharmaceutical removal in the Fe(VI)-creatinine system was 
developed for the first time to elucidate the contribution of Fe(IV) species in the enhanced 
reaction. 
         In Chapter 4, the decay of Fe(VI) at alkaline condition (i.e., pH = 9.0 and 10.0) was 
investigated by kinetic modeling and density functional theory (DFT) calculation. The 
results revealed new sights on the kinetic behaviors of deprotonated Fe(VI) species as well 
as the oxidation mechanism of Fe(VI) at higher pH conditions. Meanwhile, a kinetic model 
for Fe(VI) self-decay reactions involving Fe(V) and Fe(IV) species was successfully 
constructed to predicted Fe(VI) disappearance and H2O2 generation (a product) under 
varied conditions at pH 9.0. Results of this study provided the basis for further exploration 
of the Fe(VI)-Fe(III) reaction system in Chapter 5. 
       In Chapter 5, the Fe(VI)-Fe(III) reaction system in which pharmaceutical degradation 
was enhanced compared to that by Fe(VI) only was investigated. The Fe(VI) self-decay 
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kinetic model developed in Chapter 4 was expanded for the Fe(VI)-Fe(III) reaction system 
to explain the effect of additional ferric salts to enhance the pharmaceutical degradation 
rates by Fe(VI) oxidation. The developed Fe(VI)-Fe(III) kinetic model confirmed the role 
of Fe(III) in accelerating Fe(VI) self-decay owing to the reaction between Fe(VI) and 
Fe(III) to generate Fe(IV) intermediate species. Furthermore, the Fe(VI)-Fe(III)-Substrate 
kinetic model was developed for the enhanced pharmaceutical degradation, which could 
be used to determine the reactivity of Fe(IV) to 18 different pharmaceuticals with various 
organic functional groups. Based on the results, a preliminary structure-activity 
relationship between compounds’ molecular descriptors and their 2nd-order rate constants 
with Fe(IV) was derived. 
       In Chapter 6, the Fe(VI)-ABTS reaction system, another activated-Fe(VI) system, was 
investigated to learn the mechanistic insight of the Fe(V) and Fe(IV) species. The reaction 
kinetics of Fe(VI) oxidation of ABTS at different ratios of [ABTS]0/[Fe(VI)]0 (i.e., >1, =1, 
and <1) in pH 7.0 phosphate (10 mM) buffered solution was thoroughly investigated. A 
more comprehensive and robust kinetic model for the Fe(VI)-ABTS system, including 
interactions between high-valent iron species (Fe(VI), Fe(V), and Fe(IV)), ABTS, and 
ABTS●+ radical was proposed and validated. Furthermore, the Fe(VI)-ABTS-Substrate 
model was developed to successfully determine the reactivity of Fe(V) to different 
substrates. 
       Lastly, Chapter 7 summarizes the main findings of the dissertation, and offer 
perspectives on future research directions. 
1.4 Originality and Merit of the Research 
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               The findings of this dissertation are original and provide a unique perspective in 
the application of Fe(VI) in urine treatment, as well as a mechanistic level of investigation 
of the activated-Fe(VI) systems.  
               Specifically, the research output of this dissertation significantly advanced the 
fundamental science of ferrates chemistry in an environmental engineering context. The 
results of this project highly complemented other research efforts focusing on resource 
recovery of urine (e.g., e.g., Swiss Federal Institute of Aquatic Science and Technology,41 
NSF-funded RCN-SEES: Coordinating Phosphorus Research to Create a Sustainable Food 
System,124 Water Environment Research Foundation,8, 125 and NSF INFEWS centers126), 
and provided feasible and effective technology that allows combining resource recovery 
and destruction of contaminants of emerging concern in a holistic manner. Mitigation of 
pharmaceutical micropollutants in urine is still an under-explored area, and knowledge is 
limited. This project facilitated narrowing such a gap. The knowledge gained not only can 
help contaminant cleanup in urine, but also is useful across many fields involving various 
waste streams.    
           Moreover, the findings of this dissertation exemplified probing the high-valent iron 
intermediate species behaviors during Fe(VI) oxidation process via dynamic kinetic 
modeling. For the first time, we have thoroughly exploited two Fe(VI)-activated systems 
(i.e., the Fe(VI)-Fe(III) system and Fe(VI)-ABTS system) based on kinetic modeling to 
generate results that can bridge the knowledge gap in how to quantitatively determine the 
intermediate reactive species in such systems, which were previously based on empirical 
generalization. The kinetic modeling tools presented in this dissertation can inspire future 
studies and facilitate the understanding of Fe(V)/Fe(IV) behaviors in other Fe(VI)-
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activated systems and even help uncover Fe(V)/Fe(IV) reactivity and selectivity to 
different organic pollutants based on the kinetic simulation. 
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CHAPTER 2. PHARMACEUTICALS DEGRADATION BY FE(VI) 
IN SYNTHETIC HYDROLYZED URINE: IMPACTS OF 
INORGANIC CONSTITUENTS  
2.1 Abstract 
        Destruction of pharmaceuticals excreted in urine can be an efficient approach to 
minimize environmental pollution of these compounds. However, urine typically contains 
very high concentrations of chloride, ammonium, and bicarbonate, which may hinder 
treatment processes. This study evaluated the application of ferrate(VI) (FeVIO4
2-, Fe(VI)) 
oxidation to degrade pharmaceuticals (carbamazepine (CBZ), naproxen (NAP), 
trimethoprim (TMP) and sulfonamide antibiotics (SAs)) in synthetic hydrolyzed human 
urine and uncovered new effects from urine’s major inorganic constituents. Chloride 
slightly decreased the pharmaceuticals’ removal rate by Fe(VI) due to the ionic strength 
effect. 0.5 M ammonium in undiluted hydrolyzed urine posed a strong scavenging effect 
on pharmaceutical removal. Interestingly, lower concentrations (≤ 0.25 M) of ammonium 
could enhance the pharmaceuticals’ degradation by Fe(VI), likely due to the reactive 
ammonium complex form of Fe(V)/Fe(IV). For the first time, bicarbonate was found to 
significantly promote the oxidation of aniline-containing SAs by Fe(VI) and alter the 
reaction stoichiometry of Fe(VI) and SA from 4:1 to 3:1. In-depth investigation indicated 
that bicarbonate not only changed the Fe(VI):SA complexation ratio from 1:2 to 1:1, but 
provided stabilizing effect for Fe(V) intermediate formed in situ, enabling its degradation 
of SAs. Overall, the relatively low scavenging but selected enhancement effects from urine 
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constituents render Fe(VI) a promising oxidant for the removal of pharmaceuticals in 
hydrolyzed urine.  
2.2 Introduction 
 According to the National Ambulatory Medical Care Survey in 2014,127 the number 
of pharmaceuticals prescribed or provided in the U.S. was about 3.2 billion. A large portion 
of the pharmaceuticals are excreted unchanged or as metabolites in urine and feces, and 
eventually are in sewage treated at wastewater treatment plants (WWTPs). Except for 
highly advanced treatment processes such as reverse osmosis or advanced oxidation 
processes (AOPs), most WWTPs cannot effectively remove the pharmaceutical 
micropollutants in sewage, resulting in their release to the natural environment and posing 
risks to the aquatic ecosystem owing to their toxicity and potential to induce drug 
resistance.128 As human urine accounts for < 1% of municipal wastewater by volume but 
contributes a major mass load of pharmaceuticals,15, 129-130 degrading pharmaceuticals in 
urine would be an efficient way to reduce the harm of excreted pharmaceuticals to the 
environment.  
       Urine can be separately collected by urine-diverting flush toilets and waterless urinals 
and piped to storage tanks.131-132 Fresh urine after excretion naturally transforms into 
hydrolyzed urine within hours by bacterial processes.133 The hydrolyzed urine collected in 
the urine-diversion system can be a candidate for pharmaceutical removal as well as 
nutrient recovery. However, research to-date on the removal of pharmaceuticals and their 
metabolites from urine has been scarce. Nanofiltration membranes,37 strong-base anion 
exchange resins,61-62 electrodialysis 21, and biochar134 have been investigated to physically 
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separate pharmaceuticals from urine but generate pharmaceutical wastes that still require 
treatment. Studies have investigated ozonation,64 UV/H2O2, and UV/peroxydisulfate 
(PDS)135-136 for the destruction of pharmaceuticals in urine. However, the strong 
scavenging effects of the urine matrix, particularly from the high concentrations of 
chloride, ammonium, and bicarbonate, significantly decrease the pharmaceutical removal 
efficiency. Thus, developing a new AOP that is more resistant to the urine matrix effects 
for the degradation of pharmaceuticals is highly desirable. 
     Ferrate(VI) (FeVIO4
2-, Fe(VI)) is considered an environmental-friendly oxidant to 
destruct pharmaceuticals in the hydrolyzed urine. Over the past decade, Fe(VI) has 
emerged as a novel oxidant to remove contaminants and micropollutants, including 
pharmaceuticals.92, 95-100, 102-104 Fe(VI) is likely less susceptible to urine matrix’s 
scavenging effects than other common AOPs. Unlike hydroxyl radicals (●OH) and sulfate 
radicals (SO4
●-), Fe(VI) reacts much more slowly with NH3 at pH 9.0-9.3 (rate constants 
of NH3 with Fe(VI), 
●OH, and SO4
●- are 1.2 × 10-1, 1.0 × 108 and 1.4 × 107 M-1s-1, 
respectively),84-85, 137 and has negligible reactivity to HCO3
-/CO3
2- and Cl-.89 Furthermore, 
the natural pH (~ 9.0) of hydrolyzed urine is optimal for Fe(VI) oxidation processes due to 
excellent stability and easy handling of Fe(VI) at this alkaline pH,138-139 and thus no sample 
pH adjustment is needed to promote Fe(VI) reaction.  
     Therefore, the objective of this study was to assess the efficacy of Fe(VI) to degrade 
pharmaceuticals in hydrolyzed urine matrix. Several pharmaceuticals (carbamazepine 
(CBZ), naproxen (NAP), trimethoprim (TMP), and various sulfonamide antibiotics (SAs), 
including sulfamethoxazole (SMX)) that are frequently detected in the environment 3, 5, 140 
were selected as the representative contaminants. Experiments were conducted using 
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synthetic hydrolyzed urine (SHU)141-142 with modifications or buffered solutions to 
delineate the specific effects of chloride, ammonia, and bicarbonate. As will be discussed 
later, enhanced reaction rates of pharmaceutical degradation in simulated urine and buffer 
solution matrices by Fe(VI) were observed by ammonia and bicarbonate. To the best of 
our knowledge, the finding of the bicarbonate enhancement effect during Fe(VI) oxidation 
is among the first. Additional experiments including stoichiometry determination between 
Fe(VI) and 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonate) (ABTS) were conducted to 
obtain mechanistic insight on the enhanced effect of bicarbonate.    
2.3 Materials and Methods 
2.3.1 Chemicals and Reagents 
Carbamazepine (CBZ), naproxen (NAP), sulfamethoxazole (SMX), sulfamethizole 
(SFZ), sulfamethazine(SMZ), 3,5-dimethylisoxazole (DMI), 3-amino-5-methylisoxazole 
(AMI), 4-aminophenyl methyl sulfone (APMS), 2,2’-azino-bis(3-ethylbenzothiazoline-6-
sulfonate) (ABTS), 1,10-phenanthroline, aniline, p-toluidine, N,N-dimethylaniline 
(DMA), and trimethoprim (TMP) were purchased from Sigma-Aldrich.  Potassium 
ferrate(VI) (K2FeO4) was synthesized in Dr. Sharma’s lab at Texas A&M University 
(TAMU) and shipped to Georgia Tech (GT). All the chemical standards were of 97% or 
greater in purity and used directly without further purification. Reagent-grade deionized 
(DI) water (resistivity > 18 mΩ∙cm) was prepared from a Nanopure Millipore (Billerica, 
MA) water purification system. The stock solutions of individual pharmaceuticals were 
prepared in phosphate buffer (10.0 mM) at pH 9.0 at concentrations of 50.0 M (CBZ, 
NAP), 200.0 M (TMP), 250.0 M (DMI, AMI, APMS, aniline), or 800.0 M (SMX, 
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SMZ, SFZ). The stock solutions were freshly prepared prior to the experiments, stored at 
5 C and used within one week. The structures and chemical properties of the target 
pharmaceuticals are shown in Table 2.1. 
Table 2.1 Chemical properties and structures of compounds investigated in this 
chapter.  
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C18H18N4O6S4 514.7 pKa = 2.08 
 




C8HN 121.1 pKa = 5.15 
 
2.3.2 Reaction Matrices 
SHU was prepared following the literature recipe135 as described in Table 2.2. SHU 
contained 0.5 M total ammonia (NH3 + NH4
+), 0.25 M total carbonate (HCO3
- + CO3
2-), 
0.1 M chloride, 7.40 mM creatinine, 1.28 mM creatine, 0.17 mM hippuric acid, as well as 
Na+, K+, SO4
2- and phosphate. SHU pH was adjusted to 9.0 using concentrated solutions 
of NaOH and NaH2PO4. For comparison, SHU without ammonium was also prepared by 
removing NH4OH addition and adding additional 250 mM NaHCO3 to substitute 
NH4HCO3 in the recipe. To evaluate the effect of individual urine constituents, phosphate 
buffer (10.0 mM) solution at pH 9.0 (PB9) was spiked with specific urine constituent at 
various concentrations, and compared with the PB9 control matrix without urine 
constituents. At pH 9.0, ammonium (NH4
+) and bicarbonate (HCO3
-) are the dominant 
species in concentration. However, in the subsequent discussion, ammonium and 
bicarbonate referred to the total ammonia and total carbonate, respectively, without 
excluding the minor species. 
 22 






Creatinine 113.12 7.40 
Creatine 131.13 1.38 
Hippuric acid (HA) 179.17 0.17 
NaCl 58.44 60.00 
Na2SO4 142.04 15.00 
KCl 74.55 40.00 
NH4OH 35.04 250.00 
NaH2PO4 119.98 13.60 
NH4HCO3 79.06 250.00 
NaHCO3 84.01 250.00 
Note: To prepare NH3-Free SHU, NaHCO3 was used to 
substitute NH4HCO3, and NH4OH was not added. 
 
2.3.3 Oxidation Experiments  
          PB9, modified PB9 or SHU solutions (50.0 mL) were first spiked with the target 
pharmaceutical (10.0 M). Then, 2.97 mg of potassium ferrate(VI) solid was weighed and 
added immediately to the reaction solution (achieving 300.0 M) to initiate the oxidation 
process. Sample aliquots were taken from the reaction solution at predetermined time 
intervals and quenched immediately by sodium thiosulfate (2.5 mM).143 The pH was 
checked before and after the reaction by a pH meter and change was never larger than 0.2 
pH unit. The degradation of pharmaceuticals was monitored by high performance liquid 
chromatography (HPLC) - diode-array detection (DAD), and the transformation products 
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of SMX by Fe(VI) were analyzed using solid phase extraction (SPE) followed by HPLC-
high resolution mass spectrometry (LC-HRMS) analysis.  
2.3.4 Analytical Methods 
An Agilent 1100 series HPLC system equipped with a UV diode-array detector (DAD) 
and a Zorbax SB-C18 column (2.1 mm × 150 mm, 5 μm) was used to monitor the loss of 
parent compounds of pharmaceuticals. Detection wavelengths for SMX, SMZ, SFZ, DMI, 
AMI, aniline, TMP, CBZ, NAP, p-toluidine, DMA and APMS were set at 275, 285, 260, 
210, 230, 236, 254, 285, 231, 235, 220and 205 nm, respectively. Gradient elution was used 
with (i) 0.1% (v/v) formic acid and methanol for SMX, AMI, CBZ and NAP; and (ii) 0.1% 
(v/v) formic acid and acetonitrile for TMP, DMI, aniline, p-toluidine, DMA, SFZ, SMZ, 
and APMS.  
The oxidized products (OPs) of SMX by Fe(VI) in the presence or absence of 
bicarbonate were identified using solid phase extraction, followed by liquid 
chromatography-high-resolution/accurate mass (HR/AM) spectrometry (SPE-LC-HRMS) 
analysis. The reaction solutions withdrawn at certain degradation times were filtered by 
0.45 µm glass-fiber filters and then concentrated by a Visiprep SPE apparatus (Supleco, 
USA) with Waters Oasis HLB cartridges (WAT106202, 6 cc/200 mg). Before extraction, 
each HLB cartridge was sequentially conditioned with 5 mL methanol and 5 mL water. 
Then, the cartridge was loaded with 100 mL sample, washed with 5 mL water, and vacuum 
dried for 5 min. Finally, the extracted degradation products were obtained by eluting the 
cartridge with 2 × 2 mL methanol. The degradation products were kept in sealed vials and 
shipped with ice overnight to TAMU, where the samples were analyzed by LC-HRMS. 
 24 
The full-scan analysis of untargeted products was performed on a Q Exactive Plus 
OrbiTrap mass detector (Thermo Scientific, Waltham, MA) coupled to a binary pump 
HPLC (Ultimate 3000, Thermo Scientific) in a positive ion mode using an electrospray ion 
(ESI) source. For data acquisition, the sheath, aux and sweep gasses were set at 50, 10 and 
1, respectively. The spray voltage was set to 4 kV, and the S-lens RF was set to 50. The 
aux gas heater and capillary temperatures were maintained at 375 and 350 C, respectively. 
Full MS spectra were obtained at 70,000 resolution (m/z 200) with a scan range of m/z 50-
750. Full MS → ddMS2 scans were obtained at 35,000 resolution (MS1) and 17,500 
resolution (MS2) with a 1.5 m/z isolation window and a stepped NCE (20, 40, and 60). 
Samples were maintained at 4 °C before injection. The injection volume was 10 µL. 
Chromatographic separation was achieved on a Hypersil GOLDTM C18 selectivity LC 
column (50 mm × 2.1 mm, particle size 3 μm) at 25 °C using a solvent gradient method. 
The mobile phase was water (0.3% formic acid) (A) and methanol (B). The gradient 
method used was 0-2 min (10% B to 80% B), 2-3 min (90% B to 20% B), 3-26 min (90% 
B), 26-27 min (10% B), and 27-35 min (10% B). The flow rate was 0.2 mL/min. Sample 
acquisition was performed by Xcalibur (Thermo Scientific). The high-resolution MS data 
were processed using Compound Discoverer 2.1 software (Thermo Scientific) and online 
molecular structure libraries (i.e., m/z cloud and ChemSpider). 
The room-temperature electron paramagnetic resonance (EPR) experiments were 
performed at room temperature using a Bruker ELEXSYS-II E500 spectrometer 
(Rheinstetten, Germany) at the X-band frequency of 9.4 GHz. The reaction solutions were 
pre-added with DMPO (100.0 mM), and then transferred to 2 mm EPR tube for the 
carbonate radical measurements.144 The related operating parameters were selected: center 
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field, 3340.0 G; sweep width, 160.0 G; sweep time, 30 s; attenuation, 25.0 dB; scan times, 
10.  
The stopped-flow spectrophotometer (Applied Photophysics SX-20 MV, Surrey, UK) 
coupled with photodiode array (PDA) detector was used to try to capture the Fe(V) spectra 
and the total reaction time was selected in the range of 0.1 s to 1000 s. The UV-vis spectral 
measurements were performed on the reaction solutions containing 300.0 μM Fe(VI) and 
10.0 μM SMX at pH 9.0 (10.0 mM phosphate buffer) with or without 0.25 M bicarbonate. 
2.3.5 The Reaction Stoichiometry of Fe(VI) and SMX (or ABTS) 
2.3.5.1 Reaction between Fe(VI) and SMX. 
 The reaction stoichiometric molar ratio of SMX and Fe(VI) in the presence of 0.25 M 
bicarbonate was determined by mixing different amounts of stock solutions of SMX and 
Fe(VI) into the 0.25 M bicarbonate solution that was maintained at pH 9.0 using phosphate 
buffer (PB). The stock solutions of SMX and Fe(VI) were both prepared in 10.0 mM PB 
at pH 9.0 in the presence of 0.25 M bicarbonate. The concentration of SMX was fixed at 
100.0 M, while Fe(VI) concentration varied from 100.0 to 600.0 M.  It is important to 
point out that Fe(VI) could also react with bicarbonate and phosphate buffer in water; thus, 
Fe(VI) and buffered solution with 0.25 M bicarbonate were also mixed together to monitor 
the self-decay of Fe(VI). The amount of Fe(VI) reacted with SMX only can be obtained 
accordingly by subtracting the self-decay of Fe(VI). Fe(VI) concentration was determined 
at 508 nm (ε(FeO4
2-, 510 nm) = 1.03 × 103 cm-1 M-1) with UV-visible spectrophotometry. 
2.3.5.2 Reaction between Fe(VI) and ABTS.  
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The reaction stoichiometric molar ratio of ABTS and Fe(VI) was studied in 10.0 mM 
phosphate buffer, or in 10.0 mM, 100.0 mM, and 250.0 mM bicarbonate solution, 
respectively. All solutions were at pH 9.0. Experiments were conducted by adding a 
constant amount (1.0 mL) of ABTS stock solution into varied concentrations of Fe(VI) 
solutions (25.0 mL). The Fe(VI) solutions were prepared in the above different types of 
buffer solutions (with phosphate or bicarbonate) at 5.0-25.0 µM of Fe(VI). The ABTS 
stock solution was at an excess concentration of 2.5 mM prepared in DI water with NaOH 
to make sure the initial pH maintained at 9.0. Formation of ABTS●+ was monitored at 415 
nm (ε(ABTS●+, 415nm) = 3.4 × 104 cm-1 M-1) with UV-visible spectrophotometry. The 
consumption of ABTS was determined at 340 nm (ε(ABTS, 340 nm) = 3.66 × 104 cm-1 M-
1, ε(ABTS●+, 340 nm) = 5.4 × 103 cm-1 M-1) after the reaction, and then the concentrations 
were calculated according to the methods proposed in a previous study.145 1,10-
Phenanthroline was used to confirm the final oxidation state of iron after Fe(VI) oxidation 
of SMX, and the method followed a previous study.146 
2.3.6 Complexation of Fe(VI) and SAs 
The complexation between Fe(VI) and SAs was studied using UV-visible 
spectrophotometry.  Different SAs at concentrations 25.0-800.0 M were added into 8.0 
mL PB9 and modified PB9 solutions with either 0.05 or 0.25 M bicarbonate, respectively. 
Two mL of 500.0 M freshly-prepared Fe(VI) stock solution (in 10.0 mM PB9) was added 
to initiate the complexation. Within 15 s, sample aliquot was taken and transferred into a 
quartz cell and analyzed by a UV-vis spectrophotometer (Agilent 8453) at 190 to 1200 nm. 
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The Fe(VI) and SA complexation was detected by the difference in the UV absorbance 
of the Fe(VI)+SA complex in comparison to the UV absorbance of the free Fe(VI) plus 
that of free SA at 390 nm, as shown by the eq. 2.1 below: 
             Δ(absorbance)= Abs(Fe(VI)+SA) - Abs(Fe(VI) only) - Abs(SA only)                              (2.1) 
The complexation reaction may be expressed in two ways as below: 
Fe(VI)   +  SA  =  Fe(VI)-SA                K1:1 = [Fe(VI)-SA]/([Fe(VI)][SA])           (2.2) 
Fe(VI)  + 2 SA =  SA-Fe(VI)-SA          K1:2 = [SA-Fe(VI)-SA]/([Fe(VI)][SA]
2)         (2.3) 
where Fe(VI) and SA are individually the concentrations of uncomplexed Fe(VI) and SA, 
and K1:1 and K1:2 are the 1:1 and 1:2 complexation constants, respectively. 
To determine the complexation constant K, the Δ(absorbance) was measured in a 
complexometric titration with affixed total Fe(VI) concentration but varying SA 
concentrations. The results were applied to the Benesi-Hildebrand equation to obtain the 
value K1:1
147 by plotting 1/[SA] versus 1/Δ(absorbance) and the value of K1:2
148 by plotting 
1/[SA]2 versus 1/Δ (absorbance) according to the following equations: 
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                                (2.5) 
               where     ∆ε = ε(Fe(VI)+SA) - ε(SA) - ε(Fe(VI))                          (2.6) 
Δ(Absorbance) was the difference in the UV absorbance of the Fe(VI)+SA complex in 
comparison to the UV absorbance of the uncomplexed Fe(VI) plus that of uncomplexed 
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SA; Fe(VI)t was the total Fe(VI) concentration; and ∆ε = ε(Fe(VI)+SA) - ε(Fe(VI)) - ε(SA) 
(the molar absorptivity of Fe(VI)+SA complex minus the absorptivities of uncomplexed 
Fe(VI) and uncomplexed SA). By plotting 1/[SA] versus 1/Δ(Absorbance), the 
complexation constant K1:1 could be calculated from dividing the intercept by the slope. 
By plotting 1/[SA]2 versus 1/Δ(Absorbance), the complexation constant K1:2 could be 
calculated from dividing the intercept by the slope. Complexometric titration experiments 
were conducted at a fixed Fe(VI)t (100.0 μM) with varying [SA] (0 – 600.0 μM) (assuming 
[SA] ≈ [SA]0, because [Fe(VI)+SA] << [SA]). 
The absorbance was measured within 15 s immediately after Fe(VI) and SA was mixed 
together for complexation. Preliminary study of SMX loss within 15 s was conducted to 
exclude the possible interference of SA degradation products by monitoring the absorbance 
increase at 390 nm. From Figure 2.1, less than 2% SMX loss was observed under varying 
[SMX]:[Fe(VI)] ratios within 15 s. This suggested that the degradation of SA with 15 s 
was negligible. In contrast, free Fe(VI) concentration, detected at 508 nm, decreased 
significantly as the initial SMX concentration was increased, indicating that Fe(VI)-SMX 
complex started to accumulate to some degree since the self-decay of Fe(VI) is very 


















Figure 2.1 Free Fe(VI) & SMX loss under different [SMX]:[Fe(VI)] 
ratios within 15 s. [SMX] = 25.0 - 600.0 M, [Fe(VI)] = 100.0 M, [PB] = 




2.4 Results and Discussion 
2.4.1 Impacts of Urine Constituents on Pharmaceutical Degradation by Fe(VI) 
The removal (based on loss of parent compounds) of four pharmaceuticals in SHU using a 
low dose of Fe(VI) (300.0 M or 0.06 g(K2FeO4)L
-1) ranged from 20% to 35% within 1 
min (Figure 2.2) due to strong scavenging effects from some of the urine constituents. 
Ammonium was found to be a major scavenger due to its exceedingly high concentration 
in urine (NT = 0.5 M) in spite of a low rate constant with Fe(VI) (k = 0.119 M
-1s-1).85 The 
scavenging effect of ammonium was confirmed by separate experiments, in which 300.0 
M Fe(VI) was rapidly consumed by 0.5 M ammonium in PB9, leading to negligible 
removal of pharmaceuticals. To overcome this inhibitory effect, Fe(VI) dosage was 
increased to 900.0 M and 86% removal of SMX in SHU was achieved (Figure 2.2). 
Figure 2.2 Effect of Fe(VI) dosage on the removal of pharmaceuticals in 
synthetic hydrolyzed urine (SHU). Initially, [pharmaceutical] = 10.0 M, 
[Fe(VI)] = 300.0-900.0 M, pH = 9.0, T = 25.0 C, reaction time < 1 min, and 
n = 2 
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When the Fe(VI) oxidation was conducted in comparable, but NH3-free SHU, 
significant degradation of pharmaceuticals occurred, and the associated pseudo-1st-order 
rate constants (kobs in min
-1) were obtained (Figure 2.3). Specifically for CBZ, NAP, and 
TMP, the scavenging effect of the NH3-free urine matrix was obvious: the oxidation rate 
constants of pharmaceuticals by Fe(VI) were approximately half of those in the PB9 
matrix. Surprisingly, the degradation rate of SMX by Fe(VI) in the NH3-free SHU was 
only slightly lower than that in the PB9 matrix, indicating the possible structure-specific 
enhancement effects from urine components. In the following discussion, kobs (in min
-1) 
was used to compare the impacts of inorganic urine constituents when they were present 




Figure 2.3 Effect of urine matrix (without ammonium) on Fe(VI) oxidation of 
pharmaceuticals (A);  The kinetics of  Fe(VI) oxidation of pharmaceuticals in PB9 (B) 
and in hydrolyzed urine without ammonium (C). Initially, [Pharmaceutical] = 10.0 




2.4.1.1 Effect of Chloride  
Compared to PB9, chloride (0.1 M) in PB9 slightly inhibited the oxidation rate of 
pharmaceuticals by Fe(VI) (Figure 2.3), compared to the strong scavenging effect of 
chloride on SO4
●--based AOPs.135-136 Previous studies reported that the dissociation 
constants of Fe(VI) (H3FeO4
+) as pK1 = 1.6, pK2 = 3.5, and pK3 = 7.3. The value of pK3 for 
the mono-protonated Fe(VI) species, HFeO4
-, decreased with increasing ionic strength 
according to the eq. 2.7:150  
       𝑝𝐾3 = 4.247 +
888.5
𝑇
+ 0.8058𝐼0.5 + 0.5144𝐼 −
529.43𝐼0.5
𝑇
                                (2.7)                                              
                        where I = ionic strength and T = absolute temperature.  
Additionally, HFeO4
- was the major reactive species in the oxidation of SMX by Fe(VI) at 
pH 6.93-9.50.151 A lower pK3 value would lead to a decreased fraction of HFeO4
- at pH 9.0 
and thus slower reaction. By dividing the kobs by the corresponding fraction of the HFeO4
- 
species, the obtained empirical rate constants (i.e. kobs/α(HFeO4
-)) showed less than 10% 
of difference with or without Cl- for all four pharmaceuticals (see Table 2.3). These results 
suggested that the mild inhibitory effect of chloride was presumably due to the ionic 
strength that influenced the acid dissociation constants of Fe(VI).  
2.4.1.2 Effect of Ammonium  
Compared to PB9, ammonium (0.01 M) in PB9 resulted in 7-20 times of increase in kobs 
for the oxidation of four pharmaceuticals by Fe(VI) (Figure 2.3  and 2.4). Moreover, when 
ammonium was added at different concentrations (0−0.05 M), the obtained empirical rate 
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constants (kobs/α(HFeO4
-) according to different ionic strengths under different ammonium 
concentrations) increased linearly with ammonium concentration for the oxidation of SMX 
by Fe(VI) (Figure 2.4). The relationship in Figure 2.4B is the impact of ammonium after 
correcting the ionic strength effect, indicating a truly linear enhanced effect of ammonium 
on the oxidation of SMX by Fe(VI). A similar phenomenon was recently found in the 
oxidation of flumequine by Fe(VI) in the presence of 0.5-10.0 mM ammonium.111 In that 
study, the authors proposed that ammonium conjugated with Fe(V)/Fe(IV) intermediates 
to form more reactive ammonium complexes of Fe(V)/Fe(IV), which could enhance the 
oxidation rate of flumequine by 5-12 times. High-valent iron complexes containing 
nitrogen ligands tend to have high reactivity with substrates.152-153 Note that the negative 
impact of ammonium on several advanced oxidation processes (AOPs) is well known and 
has been seen in the treatment of urine using ozone,64 UV/H2O2, and UV/PDS.
135-136   
Indeed, a very high concentration of ammonium (e.g., 0.5 M in the synthetic hydrolyzed 
urine (SHU)) can  still pose a strong scavenging effect on Fe(VI) oxidation. However, 
unlike other AOPs, the enhanced removal of pharmaceuticals by 300 µM Fe(VI) was 
observed when ammonium concentration was equal to or lower than 0.25 M (i.e. 
[Fe(VI)]:[ammonium] ≥ 0.0012,  Figure 2.4C). Also, real source-separated urine, even 
when collected from the NoMix toilet and urinals7, is diluted to some extent. Thus, the 
concentration of ammonium in real source-separated urine is very likely lower than the 
ammonium concentration (0.5 M) used in the synthetic hydrolyzed urine recipe, which 
simulates the human urine without any dilution. Moreover, if the real hydrolyzed urine is 
subjected to other pre-treatment processeses (e.g. air-stripping) to recover N-nutrients prior 
to the treatment for pharmaceuticals, the concentration of ammonium is expected to be 
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much lower. Thus, the enhanced effect of ammonium on the oxidation of pharmaceuticals 




Table 2.3 Comparison of the observed (R2 = 0.987 – 0.996) and empirical rate 
constants with/without chloride ion. 
 























SMX 0.114±0.024 6.910±1.454 0.074±0.008 7.982±0.885 7.2 
TMP 0.052±0.008 3.141±0.479 0.035±0.003 3.759±0.321 8.2 
NAP 0.124±0.007 7.482±0.400 0.084±0.009 9.048±0.975 9.0 
CBZ 0.058±0.011 3.515±0.676 0.040±0.003 4.244±0.326 9.4 
Note: 
When [Cl-] = 0 M, pKa3 = 7.227  (HFeO4-) = 0.0165 at pH 9.0 
When [Cl-] = 0.1 M, pKa3 = 6.971  (HFeO4-) = 0.0092 at pH 9.0 
Figure 2.4(A) Effect of inorganic ions on Fe(VI) oxidation of pharmaceuticals. 
Initially, [pharmaceutical] = 10.0 M, [Fe(VI)] = 300.0 M, [Cl-] = 0.1 M, [HCO3-] = 
0.25 M, [ammonium]= 0.01 M (n = 3 for HCO3- group and n = 2 for the rest groups); 
Effect of ammonium on Fe(VI) oxidation of SMX in phosphate buffer (B) and in 
synthetic hydrolyzed urine (C) (n = 2). Initially, [SMX] = 10.0 M, [Fe(VI)] = 300.0 
M, [ammonium] = 0-0.05 M. All reactions were at pH 9.0 and 25.0 C. 
 35 
The difference (%) refers to the relative standard deviation between the two mean values of 




2.4.1.3 Effect of Bicarbonate 
Compared to PB9, bicarbonate (0.25 M) in PB9 had little effect on the Fe(VI) oxidation 
of CBZ, NAP, and TMP, but significantly increased the degradation rate of SMX by Fe(VI) 
(Figure 2.4A). This enhanced effect is a significant contrast to the strong scavenging effect 
of bicarbonate on ●OH-based AOPs135-136 and has not been reported in the literature. 
Further experiments were conducted with different concentrations of bicarbonate, and the 
empirical rate constants (kobs/α(HFeO4
-) were obtained. As shown in Figure 2.5A, a strong 
linear correlation between the empirical rate constant (kobs/α(HFeO4
-) of SMX oxidation 
by Fe(VI) and bicarbonate concentration was observed, indicating a truly enhanced effect 
of bicarbonate without the ionic strength influence. The bicarbonate enhancement effect 
was observed not only for SMX but also in the oxidation of other SAs (sulfamethazine 
(SMZ) and sulfamethizole (SFZ)) by Fe(VI). As Figure 2.5B shows, the empirical rate 
constants of Fe(VI) oxidation of SMX and SMZ increased by 2.5-4.1 folds in the presence 
of 0.25 M bicarbonate compared to those without bicarbonate, whereas a similar magnitude 
of rate enhancement for the Fe(VI) oxidation of SFZ required a higher bicarbonate 




Figure 2.5 (A) Effect of bicarbonate concentration on Fe(VI) oxidation of SMX; n = 3 
(B) Effect of bicarbonate on Fe(VI) oxidation of different SAs. Initially, [SA] = 10.0 
M, [Fe(VI)] = 300.0 M, [HCO3-] = 0-1.0 M, pH = 9.0, T = 25.0 C, n = 2 for SMZ 
and SFZ, and n = 3 for SMX. R2 = 0.989 – 0.995 for the rate constants. 
 
 
Figure 2.6 Effect of ammonium on degradation of SMX in 10.0 mM phosphate 
bufferInitially, [SMX] = 10.0 M, [Fe(VI)] = 300.0 M, [ammonium]= 0 - 0.5 M, pH 
= 9.0,  T = 25.0 C, and n = 2 Note: “ammonium” is defined as the sum of NH3 + NH4+. 
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2.4.2 Elucidating the Bicarbonate Enhancement Effect  
The new discovery that bicarbonate can enhance the Fe(VI) oxidation of SAs compared 
to that in the absence of bicarbonate suggests that bicarbonate may induce a new reaction 
mechanism, which requires further investigation. Previous work by Chen and Hoffman 
found that sulfur-containing compounds can react rapidly with CO3
●- ,154 which may 
explain the bicarbonate enhancement effect on the Fe(VI) oxidation of SAs. However, 
electron paramagnetic resonance (EPR) study was conducted using DMPO (SI Text S2), 
and the results excluded the generation of CO3
●- in the Fe(VI)+bicarbonate system ( Figure 
2.7). Therefore, the mechanism of bicarbonate enhancement effect required elucidation. In 













2.4.2.1 Reaction Stoichiometry  
Experiments showed that the oxidation of SMX by Fe(VI) in the presence of 
bicarbonate exhibited different reaction stoichiometry compared to that in the absence of 
bicarbonate. A previous study155 reported that the oxidation of SMX by Fe(VI) followed a 
stoichiometry of 4:1 for [Fe(VI):[SMX], which led to the evolution of one mole of oxygen 
per mole of SMX accompanying reduction of Fe(VI) to Fe(III) (eq. 2.8). However, a 
Figure 2.7 EPR spectra of the reaction solutions by Fe(VI) treatments with or 
without bicarbonate. Note: No obvious EPR signals were observed. 
(Experimental conditions: [Fe(VI)]0 = 300.0 μM, [HCO3-] = 250.0 mM, [DMPO]0 
= 100.0 mM, pH = 9.00 ± 0.05). 
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reaction stoichiometry of 3:1 for [Fe(VI)]:[SMX] was observed in the presence of 0.25 M 
bicarbonate (Figure 2.8A), and Fe(II) was identified as the likely end product of Fe(VI) 
reduction based on Fe(II)-phenanthroline complex observed at 510 nm (Figure 2.8B). This 
reaction is shown in eq. 2.9.   
                           4 𝐹𝑒(𝑉𝐼) + 𝑆𝑀𝑋 → 4 𝐹𝑒(𝐼𝐼𝐼) + 𝑂2 + 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑠                                         (2.8) 
               3 𝐹𝑒(𝑉𝐼) + 𝑆𝑀𝑋 + 𝐵𝑖𝑐𝑎𝑟𝑏𝑜𝑛𝑎𝑡𝑒 → 3 𝐹𝑒(𝐼𝐼) + 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑠                         (2.9) 
On the basis that the reaction stoichiometry was changed in the presence of bicarbonate, 
it strongly suggested that the presence of bicarbonate affected the electron transfer 
processes of Fe(VI), likely involving different Fe intermediates and leading to different 
end products of Fe(VI) (i.e., Fe(III) vs. Fe(II), respectively). Additionally, the lower 
reaction stoichiometry in the presence of bicarbonate is a favorable finding, because it 
indicates a lower Fe(VI) demand and higher reaction efficiency in degrading the same 
amount of SMX. 
Figure 2.8 (A) Plot of consumption of SMX in reaction with Fe(VI) in the presence of 
0.25 M bicarbonate at pH 9.0. (B) Absorbance-time curve of Fe(VI) oxidation of SMX 
in the presence of 0.25 M bicarbonate and 4.0 mM 1,10-phenanthroline at pH 9.0; 
initially, Fe(VI) = 210.0 μM and [SMX] = 10.0 μM. 
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2.4.2.2 Reactive Moiety of SMX  
To determine the initial attack of Fe(VI) on SMX, reactions of substructure compounds 
(3-amino-5-methylisoxazole (AMI), 3,5-dimethylisoxazole (DMI), 4-aminophenyl methyl 
sulfone (APMS), and aniline) with Fe(VI) were examined in the presence and absence of 
bicarbonate at pH 9.0.  As Figure 2.9 shows, when bicarbonate was absent, AMI and DMI 
were much less reactive to Fe(VI) (kobs = 6.2 × 10
-2 and 4.7 × 10-2 min-1) than APMS and 
aniline (kobs = 9.9 × 10
-2 and 4.0 × 10-1 min-1), which suggested SMX’s aniline moiety 
(rather than the isoxazole ring moiety) with higher susceptibility to be attacked by Fe(VI). 
When comparing the Fe(VI) only vs. Fe(VI)+bicarbonate systems, the smaller empirical 
rate constants were observed in AMI and DMI, whereas larger empirical rate constants 
were observed in aniline and APMS (containing aniline moiety) in the presence of 
bicarbonate. This result further indicated that the aniline moiety of SMX is most likely 
involved in the oxidation by Fe(VI) with the presence of bicarbonate. It also confirmed that 
the aniline moiety is the crucial site so that the similar bicarbonate enhancement effect was 
observed in Fe(VI) oxidation of other SAs. In other words, bicarbonate enhancing the 








Figure 2.9 Degradation of AMI (A), DMI (B), APMS (C) and aniline (D) by Fe(VI) 
with and without bicarbonate. Initially, [Substrate] = 10.0 M, [Fe(VI)] = 300.0 M, 
[HCO3-] = 0.25 M, pH = 9.0, T = 25.0 C, and n = 2.  
 
2.4.2.3 Oxidation Products (OPs) of SMX in Fe(VI) only and Fe(VI)+Bicarbonate 
systems  
The OPs of SMX in Fe(VI) only and Fe(VI)+bicarbonate systems at pH 9.0 were 
analyzed by LC-HRMS. Structural assignments of each OP were performed by product ion 
scans based on its MS/MS spectrum and the proposed fragments. A total of seven OPs of 
SMX were identified and named as OP-98, OP-123, OP-267, OP-269, OP-283, OP-285 
and OP-299 according to molecular weight. MS/MS spectra and possible structures of 
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fragments of SMX and its OPs and the evolution of their peak areas are presented in 
Figures 2.11-2.12. Even though OP-98, OP-123 and OP-285’s MS/MS spectra were not 
available, the products’ evolution profiles in Figures 2.11 and 2.12 indicated high 
abundance of these three products during the reaction and their distribution growth over 
reaction time. The molecular compositions of these OPs were suggested by good mass error 
(< 3 ppm) between the experimental and theoretical m/z values, shown in Table 2.4. For 
the fragment analysis, SMX with a m/z value of 254.05936 and retention time of 4.510 min 
has four major product ions at m/z 156.01144, 99.05586, 108.04486, and 92.05013, which 
are proposed to correspond to the cleavage of S-N bond with the generation of two former 
fragments, loss of SO (48 Da from m/z 156.01144), and subsequent loss of O (16 Da from 
m/z 108.04486), respectively (Figure 2.13a). As a representative product, OP-269 with a 
protonated species at m/z 270.05740 and chromatographic retention time at 4.397 min was 
proposed to be hydroxylation of aniline group in SMX molecule. This structure was 
tentatively confirmed by four major product ions at m/z 172.00618, 99.05589, 124.03966, 
and 108.04493. These MS/MS fragments were formed via similar patterns with SMX. 
The proposed degradation pathways of SMX in Fe(VI) only and Fe(VI)+bicarbonate 
systems are shown in Scheme 1. Both systems shared similar pathways I and III. In 
pathway I, cleavage of the S-N bond generated OP-98 (AMI), which was also observed in 
other SMX oxidation systems using chlorine,156 ozone, and permanganate.157 In pathway 
III, the initial attack on the aniline group of SMX produced hydroxylamine product (OP-
269) via a single electron-transfer mechanism.158 Later, this resulting hydroxylamine group 
will further collapse to nitroso group (OP-267), which can be further oxidized into nitro 
group (OP-283). Afterward, OP-283 can be hydrolyzed in the benzene ring part with OP-
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299 generated, all of which are consistent with the previous study.155 The similar products 
found in Fe(VI) only system and Fe(VI)-bicarbonate system were also confirmed in 
acid113- and sulfite159-activated Fe(VI) systems, suggesting these generated iron 
intermediates (Fe(V) or Fe(IV)) could not change the OP species but alter the oxidation 
rate due to superior oxidation ability of  Fe(V)106, 160 or Fe(IV).161 
However, OP-123 (nitrobenzene) was found to be a new product in both systems, 
indicating Fe(VI)’s ability to break the S-C bond during the reaction. Pathway II only 
observed in Fe(VI)+bicarbonate system suggested bicarbonate-complexed Fe(VI) can 
initiate the ring-opening reaction in the isoxazole moiety in SMX by attacking the C=C 
double bond via hydroxylation, which was also observed in the oxidation of flumequine by 
ammonia-complexed high-valent iron species (Fe(V) or Fe(IV)).111 
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Figure 2.10 Proposed reaction pathways of Fe(VI) oxidation of SMX in the 
absence/presence of bicarbonate. Initially, [SMX] = 10.0 M, [Fe(VI)] = 300.0 M, 




Table 2.4 Accurate mass measurement of SMX and its oxidation products (OPs) in 




































































Figure 2.11 Peak area of SMX products by Fe(VI) in 10.0 mM PB solution at pH 9.0. 












Figure 2.12 Peak area of SMX products by Fe(VI) in 0.25 M bicarbonate solution at 
















Figure 2.13 The LC/MS/MS spectra of SMX (a) and its OPs (b, OP-299; c, OP-283; 












2.4.2.4 Fe(VI) Oxidation of ABTS in the Presence of Bicarbonate 
 Colorless ABTS can be oxidized via the one-electron transfer mechanism to yield 
ABTS●+, a stable radical with intense green color. Therefore, ABTS has been widely used 
for quantification of different types of oxidants, such as percarboxylic acid,162 bromine, 
chlorine163, and Fe(VI)164, owing to its rapid reaction and simple spectrophotometric 
measurement with high sensitivity. In the reaction between Fe(VI) and ABTS, a 
stoichiometry of 1:1 between Fe(VI) loss and ABTS●+ generation was determined, and 
Fe(V) was proposed as the major iron intermediate species.145, 164 The produced Fe(V) 
undergoes subsequent self-decay in phosphate buffer solution since the stoichiometry 
between Fe(VI) and ABTS consumption was also found to be 1:1,122, 164 indicating 
phosphate-complexed Fe(V) favors its reaction towards H2O (self-decay) instead of 
ABTS.122  
Herein, ABTS was chosen as a model compound to investigate the bicarbonate effect 
on Fe(VI) oxidation, especially when Fe(V) was involved. Four different buffer solutions 
(phosphate (10.0 mM) or bicarbonate (10.0, 100.0, or 250.0 mM)) were used to understand 
how Fe(V) generated in situ from Fe(VI) oxidation of ABTS might behave differently with 
different buffer ions. In 10.0 mM phosphate buffer, the stoichiometry between Fe(VI), 
ABTS and ABTS●+ was 1:1.06:0.99 (Figure 2.15), which agreed well with the expected 
1:1:1.122, 164 Interestingly, the reaction stoichiometry between Fe(VI), ABTS and ABTS●+ 
was found to be 1:1.25:1.29 (i.e. close to 1:1.3:1.3) in 10.0 mM bicarbonate solution 
(Figure 2.14A). This discrepancy with 1:1:1 suggested that bicarbonate-complexed Fe(V) 
could react with ABTS and generate an equimolar amount of ABTS●+ in contrast to the 
rapid self-decay of phosphate-complexed Fe(V). When the bicarbonate concentration was 
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increased to 100.0 mM (Figure 2.14B), the stoichiometric ratio between Fe(VI) and ABTS 
was still larger than 1. However, ABTS●+ generation was comparatively lower than ABTS 
consumption, especially at higher Fe(VI) concentrations, and this phenomenon became 
even more pronounced when bicarbonate concentration was increased to 250.0 mM 
(Figure 2.14C). The above results suggested that bicarbonate-complexed Fe(V) continued 
to shift its reactivity from H2O to ABTS or (and) ABTS
●+, which subsequently generated 
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Figure 4. Reaction stoichiometries between Fe(VI), ABTS and ABTS●+ in different bicarbonate  6 
A B C 
Figure 2.14 Reaction stoichiometries between Fe(VI), ABTS and ABTS●+ in 
different bicarbonate solutions. Initially, [ABTS]0 = 100.0 M, [Fe(VI)]0= 0-20.0 
M, pH = 9.0, T = 25.0 C, n = 2 and buffer condition: (A) 10.0 mM; (B) 100.0 mM; 













2.4.2.5 Complexation of Fe(VI) and SAs  
         Fe(VI) complexation with amines and hydroxylamines was investigated by 
Hornstein,165 which first identified the intermediary Fe(VI)-imido complex quickly formed 
during Fe(VI) oxidation of aniline using UV-vis spectrophotometry. Later, Zimmermann13 
examined the efficiency of Fe(VI) oxidation of a range of organic micropollutants and their 
model compounds. They discovered that SMX and aniline showed a much stronger pH-
dependence with oxidation rate constant (k) increasing by more than four orders of 
magnitude when pH was decreased from 11.0 to 5.0, which could not be explained by the 
Figure 2.15 Reaction stoichiometries between Fe(VI), ABTS and ABTS●+ in 10.0 




speciation variation of SMX and aniline according to their pKa values. Instead, they 
proposed a Fe(VI)-NH2-R intermediate complex quickly formed before actual oxidation 
occurred, and new acid-base equilibria were assigned to these complexes with new pKa 
values in order to explain their new speciation behavior. Sharma et al.166 tried to use 
Mossbauer spectroscopy to directly detect the intermediate complexation between Fe(VI) 
and SMX or aniline. However, the Mossbauer spectroscopy of frozen sample in mixed 
reaction solution in 10 s cannot differentiate the complexed/uncomplexed forms of Fe(VI) 
if there is no valence state change. As a result, there was no direct evidence of this complex 
formation.   
the complexation of Fe(VI) and SAs was observed at 390 nm using UV-Vis 
spectrophotometry. The complexation constants (K) were calculated using the Benesi-
Hildebrand equation (eq. 2.10-2.11) based on the measured differences in absorbance (A) 
and molar absorptivity ().147-148 Detailed complexation titration study is described in SI 
Text S4. 











                                                (2.10)                
                                where     ∆ε = ε(Fe(VI) +  SA) −  ε(SA) −  ε(Fe(VI))                (2.11) 
The complexation of Fe(VI) and SAs was observed in Figure 2.16. In the absence of 
bicarbonate, the complexation ratio for Fe(VI):SA was 1:2 for all three SAs, since the linear 
relationship was only obtained in the form of eq. (4). The complexation constants K1:2 were 
determined to be 7.7 × 105 M-2 for SMX-Fe(VI)-SMX, 3.1 × 107 M-2 for SMZ-Fe(VI)-
SMZ, and 1.41 × 106 M-2 for SFZ-Fe(VI)-SFZ (Table 2.5).   
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Complexation of Fe(VI) and SAs behaved differently in the presence of bicarbonate 
(Figure  2.17). The complexation ratio of Fe(VI):SA changed from 1:2 to 1:1 when 
bicarbonate concentration was increased from 0 M to 0.05 M for SMX and SMZ, and to 
0.25 M for SFZ. The complexation constants K1:1 were determined using eq. (5). As Table 
2.5 shows, Fe(VI)-SFZ complex displayed the smallest K1:1 value (26 M
-1), in comparison 
to the other two complexes (166 M-1 for Fe(VI)-SMX and 275 M-1 for Fe(VI)-SMZ), 
indicating the weakest complexation between Fe(VI) and SFZ in the presence of 
bicarbonate. This result was also consistent with the fact that bicarbonate enhancement 
effect was shown at a higher bicarbonate concentration for SFZ compared to the other two 











Figure 2.16 UV-vis spectra of SMX (A), SMZ (B) and SFZ (C) complexation with 
Fe(VI) within 15 s, [SA] = 0 - 600.0 M, [Fe(VI)] = 100.0 M, [PB] = 10.0 mM (pH 
9.0). Inset: Linear relationship by plotting 1/[SA]2 versus 1/Δ(Absorbance); (D) The 







Figure 2.17 UV-vis spectra of SMX (A), SMZ (B) and SFZ (C) complexation under 
different bicarbonate concentrations with Fe(VI) within 15 s, [SA] = 0 - 440.0 M, 
[Fe(VI)] = 100.0 M, [PB] = 10.0 mM (pH 9.0). Inset: Linear relationship by plotting 
1/[SA] versus 1/Δ(Absorbance); (D) The summary of K1:1 and absorptivities of 








Table 2.5 Complexation constant K, molar absorptivity  and complexation ratio 
between Fe(VI) and SAs in the absence and presence of bicarbonate at pH 9.0. 
 
Fe(VI) Complexation with SAs 
Fe(VI) Complexation with SAs 

















ε(Fe(VI)-SA) at 390 
nm, M-1cm-1 
SMX 7.70 × 105 977 0.05 166 1722 
SMZ 3.10 × 107 387 0.05 275 1257 
SFZ 1.41 × 106 528 0.25 26 552 
a 0.05 M total bicarbonate for SMX and SMZ; 0.25 M total bicarbonate for SFZ. 
  
 
2.4.3 Proposed Mechanism for the Bicarbonate Enhancement Effect  
On the basis of all the results obtained, it is hypothesized that bicarbonate likely 
competes with SA for one coordinative site of Fe(VI), thereby reducing the number of SA 
molecules complexed to Fe(VI) from 2 to 1. Moreover, bicarbonate-complexed Fe(VI) will 
undergo one-electron transfer to produce bicarbonate-complexed Fe(V) and anilino 
radical158 upon oxidation of SAs. A few studies have demonstrated ligand species will 
affect high-valent iron species (Fe(V) or Fe(IV)) reactivity to the substrate.167-170 It is also 
worthwhile to note that permanganate (Mn(VII)), a similar hypervalent transition-metal 
oxidant to Fe(VI), showed enhanced reactivity to triclosan171 and phenolic compounds172 
in the presence of selected ligands (e.g. phosphate, EDTA and humic acids), because these 
highly active aqueous manganese intermediates (e.g. Mn(III)) formed in situ upon Mn(VII) 
reduction) were stabilized by complexation with the ligands via lowered Mn(III)/Mn(II) 
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redox potential. Otherwise, these active manganese intermediates would disproportionate 
spontaneously in the absence of ligands. Therefore, it is very likely that bicarbonate can 
also stabilize the intermediate Fe(V) species produced from Fe(VI) via complexation and 
reducing redox potential and prolonging Fe(V)’s lifetime, thereby preventing rapid 
spontaneous self-decomposition of Fe(V) and facilitating oxidation rate of SAs. 
Significantly, experimental studies have shown higher stability of Fe(IV)-carbonate 
complex than that of Fe(IV)-pyrophosphate complex.173-174 Furthermore,  the hypothesis 
proposed herein can also be supported by the previous discussion of ABTS oxidation by 
bicarbonate-complexed Fe(V) and extremely high self-decay rate constant of Fe(V) found 
in phosphate/borate buffered systems (i.e. 1.5 × 107 M-1 s1).175  
      Additional experiments involved with ρ-toluidine and N,N-dimethylaniline (DMA) 
were conducted to investigate the alinine-specific enhanecement effect from bicarbaonte-
complexed Fe(V). In Figure 2.18, similar but even stronger enhancement effect was 
observed for ρ-toluidine in the presence of bicarbonate while there was no obvious 
enhancement effect for DMA. This can be explained by bicarbonate-complexed Fe(V) 
oxidation selectivity towards aromatic primary amine. Because the aromatic primary amine 
group, if activated by the electron donating group at the para-position, will likely become 
even more reactive towards bicarbonate-complexed Fe(V). On the other hand,  if the 
aromatic primary amine was subsituted with two methyls,  it lost its reactivity to Fe(V) due 
to the steric hinder effect. This statement can be supported by the fact that bicarbonate 
enhancement effect was only observed in SAs (containing aniline) among a few of 
pharmaceuticals chosen in this study. It was also reported that Fe(V) reactivities with 
amino acids (e.g., glycine, alanine and aspartic) were 3 – 5 orders of magnitude higher than 
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with α-hydroxy acids and organic acids with α-CH2 groups
74, which confirmed Fe(V) is a 
selective oxidant towards amine-specific structure. Considering the bicarbonate stabilizing 
effect on Fe(V), bicarbonate- complexed Fe(V) is more likely to oxidize more reactive 
amine species – aromatic primary amines. 
Figure 2.18 Degradation of p-toluidine (A) and DMA (B) by Fe(VI) with and without 
bicarbonate. Initially, [Substrate] = 10.0 M, [Fe(VI)] = 300.0 M, [HCO3-] = 0.25 M, 


























Figure 2.19 Stopped-flow UV-Vis spectra of Fe(VI) and SMX in the presence 
of 0.25 M bicarbonate. [Fe(VI)] = 300.0 µM, [SMX] = 10.0 µM, pH = 9.0 (10.0 




Stopped-flow UV-Vis spectrometry was used to capture the stabilized Fe(V) spectra in 
the bicarbonate buffered system. According to Figure 2.19, Fe(V) characteristic peak at 
380 nm73 was not observed within 0.1 s. It is because bicarbonate ion will not increase the 
stability of Fe(V) to the dead time of the stopped-flowed instrument (i.e., 10 ms). Even 
though there is no direct evidence of bicarbonate stabilization effect on iron/manganese 
intermediate species owing to their very short lifetime, a few studies found similar 
phenomenon in bicarbonate-Fe(II)176-178 and bicarbonate-Mn(II)179-180 complex systems, 
where bicarbonate ligand lowered the Fe(III)/Fe(II) redox potential from 0.77 V (vs. NHE) 
to 0.085 V (vs. NHE) and the Mn(III)/Mn(II) redox potential from 1.19 V (vs. NHE) to 
0.63 V (vs. NHE). Moreover, similar bicarbonate enhancement effect was observed during 
Mn(VII) oxidation of bisphenol A.181  Additionally, potential generation of other iron 
intermediate species (e.g., Fe(IV)) during the reaction that may also contribute to the 
degradation of SMX cannot be completely ruled out at this time. Therefore, more research 
is needed to delineate the role of Fe(IV) in Fe(VI)+bicarbonate system. 
2.5 Environmental Significance  
The extensive occurrence of pharmaceuticals in the aquatic environment and potable 
water supplies demands more efficient treatment of these micropollutants from the urine 
source. Unlike the strong scavenging effects of chloride, ammonium and bicarbonate in 
SHU on ●OH and SO4
●--based AOPs (e.g., indirect photolysis of TMP by UV/H2O2 and 
UV/PDS was decreased by ~ 4 times in SHU without organic metabolites compared to that 
in PB9)135-136 and ozonation64 from previous studies, Fe(VI) application in degrading 
pharmaceuticals in SHU showed promising results by displaying mild inhibitory effect 
from chloride, and enhancement effect from ammonium (when [Fe(VI)]:[ammonium] ratio 
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is higher than 1:167) and bicarbonate. Moreover, this study is among the first to identify 
and analyze the enhanced effect of bicarbonate on Fe(VI) oxidation of sulfonamides. EPR 
study excluded the generation of CO3
●- in Fe(VI)+bicarbonate system. The stoichiometry 
study between Fe(VI), ABTS and ABTS●+ revealed distinctively different reactivities 
between bicarbonate-complexed Fe(V) and phosphate-complexed Fe(V). This new 
finding, not only casts doubts on the ABTS spectrophotometric method for Fe(VI) 
determination in bicarbonate buffer solutions, but also sheds light on active iron 
intermediate species (Fe(V)) using bicarbonate to achieve unexpected enhanced oxidation 
rate. Overall, the effective destruction of pharmaceuticals in urine at the source using 
Fe(VI) could be an attractive option to minimize energy-intensive treatment required at 
centralized wastewater facilities to remove these micropollutants, and reduce their potential 
ecological harm in environmental waters and drinking water. However, to 
comprehensively understand the performance of Fe(VI) oxidation of pharmaceuticals in 
hydrolyzed human urine, more research is needed to investigate other urine constituents to 
fill the gap between the synthetic urine and real urine, and to validate the removal efficacy 








CHAPTER 3. PHARMACEUTICALS DEGRADATION BY FE(VI) 
IN SYNTHETIC HYDROLYZED URINE: IMPACTS OF 
ORGANIC CONSTITUENTS  
3.1 Abstract 
Treatment of human urine is an emerging approach to minimize environmental 
pharmaceutical contamination. This study investigated the application of ferrate(VI) 
(FeVIO4
2-, Fe(VI)) oxidation to degrade pharmaceuticals (i.e., carbamazepine (CBZ), 
naproxen (NAP), sulfamethoxazole (SMX), and trimethoprim (TMP)) in synthetic 
hydrolyzed human urine, with the emphasis on the effects of urine endogenous organic 
metabolites. Creatine and hippuric acid showed limited scavenging effects. Creatinine 
(CRE) was first discovered to significantly enhance the oxidation rates of CBZ, TMP, 
SMX, and other amine-containing compounds by Fe(VI). Fe(IV) was proposed as the 
major intermediate reactive iron species in the Fe(VI)+CRE system, based on the DFT 
calculation and experimental measurements. A kinetic model involving Fe(IV) 
contribution in the decay of the pharmaceuticals was developed for the first time to 
successfully describe the pharmaceutical removal in the Fe(VI)+CRE system. Moreover, 
the model was used to predict the rate constants of the Fe(IV)-CRE complex reacting with 
different compounds, which ranged from (9.3±0.4) to (6.9±0.4 × 102) M-1∙s-1. Overall, this 
study further demonstrated the promise of Fe(VI) oxidation to degrade pharmaceuticals in 
hydrolyzed urine owing to the enhanced effects from urine constituents. This study also 
advanced the mechanistic and kinetic understanding of enhanced oxidation involving high-
valent iron intermediate species. 
 65 
3.2 Introduction 
 Among all the wastewater streams that are directed into wastewater treatment 
plants, human urine has been regarded as a minuscule yet critical component, i.e., at only 
0.6% by volume but contributing to more than 64% of pharmaceuticals, 80% of nitrogen, 
and 50% of phosphorus on a mass basis.129, 182-183 Thus, the treatment of source-separated 
urine has emerged as a disruptive innovation to the status quo approach to wastewater 
management because it can be efficient in recovering nutrients into usable fertilizers and 
destructing pharmaceutical micropollutants. 
To date, research regarding the removal of pharmaceuticals and their metabolites in urine 
is still limited. Nanofiltration membranes,37 strong-base anion exchange resins,61-62 
electrodialysis,184 struvite precipitation,21, 63 and biochar134 have been investigated 
previously. All of the above methods, however, only physically separate pharmaceuticals 
from urine and generate pharmaceutical wastes that still need to be treated. Ozonation,185 
UV/H2O2, and UV/peroxydisulfate (PDS)
135-136 were investigated for destruction of 
pharmaceuticals in urine; however, the efficiency of these treatment processes was 
significantly decreased by the strong scavenging effects of the urine constituents, 
particularly from the high concentrations of ammonium, bicarbonate, and chloride. In 
contrast, our recent study unveiled the use of ferrate(VI) (FeVIO4
2-, Fe(VI)) for oxidizing 
pharmaceuticals in hydrolyzed urine, and observed that inorganic constituents (e.g., 
ammonium and bicarbonate) could enhance the degradation of pharmaceuticals by 
Fe(VI).117 However, the potential effects of common organic metabolites in urine on the 
Fe(VI) oxidation of pharmaceuticals still remained unknown and required additional 
investigation. In general, the occurrence of organic metabolites in human urine has not 
been taken into account in the synthetic urine recipes employed in many previous studies, 
and, as a result, the influence of common organic metabolites on the oxidative removal of 
pharmaceuticals in urine has been neglected or poorly understood. 
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Data on endogenous metabolites in human urine are mostly from the medical literature and 
are almost exclusively for fresh urine. More than 2651 human urine metabolites have been 
identified,45 with creatinine (CRE), creatine, hippuric acid, citric acid, glycine, taurine, and 
L-cysteine being the most prevalent and at the highest concentrations (1–15 mM).45-47 A 
decrease in chemical oxygen demand (COD) was reported in stored urine upon the 
transformation of fresh urine to hydrolyzed urine, suggesting that endogenous metabolites 
were degraded to some extent during aging of urine.48 Even so, CRE, creatine, and hippuric 
acid (structures in Table 3.1) were still among the most concentrated organic metabolites 
founded in hydrolyzed urine.141, 186 Therefore, these three compounds were selected in this 
study to represent the common endogenous metabolites in urine.  
CRE is a cyclic amino acid with a five-membered ring, a guanidine group and a peptide 
bond (Table 3.1). Creatine, on the other hand, a linear amino acid (Table 3.1), has been 
found in muscle and brain tissues, which facilitates the recycling of adenosine triphosphate 
(ATP) to supply the energy to human bodies. CRE was formed from conversion of creatine 
and phosphocreatine in muscles. Then, it would be diffused through tissues into blood 
serum and removed by kidney through glomerular filtration into urine at a steady rate of 
around 2% of total CRE per day.187 While serum CRE level is often used as an indicator 
of renal function with its normal range at 40−150 µM,188 the urine CRE is typically 
measured during standard urine drug test to indicate diluted urine and potentially 
adulterated specimens,189 due to its relatively stable chemistry and ubiquitous 
concentrations. The urine CRE level can vary based on gender, and a greater muscle mass 
usually correlates to a higher concentration of CRE found in urine. The typical 
concentration of urine CRE was at 1.7–19.5 mM (mean value of 6.4 mM) and 2.3–23.5 
mM (mean value of 8.5 mM) for women and men, respectively,187 which supported the 
gender-dependent urine CRE concentration cut-offs in urine analysis. In this study, the 
concentration of 7.4 mM was chosen for CRE in the synthetic hydrolyzed urine considering 
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its resistance to microbial degradation and other reported clinical records.141, 186 
Interestingly, creatine concentration was observed to increase after urine hydrolysis, and a 
value of 1.28 mM was chosen to represent its level in hydrolyzed urine.141, 186  
Hippuric acid, the glycine conjugate of benzoic acid (Table 3.1), is a common biomarker 
for high-dose exposure to certain toxic aromatic compounds such as toluene,190 as well as 
a measure of renal clearance to indicate disease states including diabetes, impaired renal 
function, gastrointestinal disease, etc.191 However, elevated levels of hippuric acid can be 
also associated with dietary consumption of phenolic compounds such as tea,192 fruits, and 
wine.193 These phenols can be converted to benzoic acids and then to hippuric acid via the 
reactions with glycine before excreting into urine. The typical hippuric acid concentrations 
in men’s fresh urine ranged at 0.59–3.07 mM.194 Based on around 90% degradation of 
hippuric acid in hydrolyzed urine after four weeks of storage,141, 186 a value of 0.17 mM 
was selected in this study to represent its concentration. 
While many studies have investigated removal of contaminants from water by Fe(VI),91, 
96-100, 103-104 only limited efforts were dedicated to understanding the mechanisms of Fe(VI) 
oxidation reactions involving high-valent iron intermediate species, i.e., Fe(V)/Fe(IV). In 
recent years, there has been increasing attention on the enhanced role of Fe(V)/Fe(IV) 
during Fe(VI) oxidation in the presence of inorganic activators such as ammonia,111 
acid,112-113 sulfite/thiosulfate,114-116 bicarbonate,117 Fe(II)/Fe(III),118 and Mn(II).120 
However, previous research mainly relied on qualitative analysis of possible reactive 
species generated (radical vs. Fe(V)/Fe(IV)), and the kinetic behaviors (self-decay vs. 
oxidation of substrates) of Fe(IV)/Fe(V) in the oxidation process remained unclear. As will 
be shown later, urine CRE can act as an “activator” to generate high-valent iron 
intermediate species. 
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Therefore, the objective of this paper was to assess the efficacy of Fe(VI) to remove 
pharmaceuticals in synthetic hydrolyzed urine matrix with naturally existing organic 
metabolites and to fully elucidate the kinetic behaviors of high-valent iron intermediate 
species (i.e., Fe(IV)/Fe(V)) during Fe(VI) oxidation in the presence of CRE. Four 
pharmaceuticals (i.e., carbamazepine (CBZ), naproxen (NAP), trimethoprim (TMP), and 
sulfamethoxazole (SMX)) that are frequently detected in the environment3, 5, 140 were 
selected as the representative contaminants. Experiments were conducted using synthetic 
hydrolyzed urine (SHU)141-142 with modifications or buffered solutions to delineate the 
specific effects of CRE, creatine, and hippuric acid. To the best of our knowledge, the 
finding of the organic activator – CRE – in the Fe(VI) oxidation is among the first. 
Additionally, this paper fully examined the role of Fe(IV) species in the Fe(VI)+CRE 
system by new kinetic model simulation and predicted the rate constants between Fe(IV) 
species and several substrates. 
3.3 Materials and Methods 
3.3.1 Chemicals and Reagents 
Carbamazepine (CBZ), naproxen (NAP), sulfamethoxazole (SMX), 3,5-
dimethylisoxazole (DMI), 3-amino-5-methylisoxazole (AMI), 2,4-diamino-5-
methylpyrimidine (DAMP), 3,4,5-trimethoxytoluene (TMT), methyl phenyl sulfoxide 
(PMSO), aniline, methyl phenyl sulfone (PMSO2), para-chlorobenzoic acid (pCBA), 
creatinine (CRE), creatine, hippuric acid, and trimethoprim (TMP) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Potassium ferrate(VI) (K2FeO4) was synthesized by 
a wet chemical method 195-196 with high purity (98%) in Dr. Virender Sharma’s lab at Texas 
A&M University (TAMU) and shipped to Georgia Tech (GT). All chemicals were of 97% 
or greater in purity and used directly without further purification. Reagent-grade deionized 
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(DI) water (resistivity > 18 mΩ∙cm) was prepared from a Nanopure Millipore (Billerica, 
MA) water purification system. The stock solutions of individual pharmaceuticals were 
prepared in phosphate buffer (10.0 mM) at pH 9.0 at concentrations of 50.0 M (CBZ, 
NAP), 200.0 M (TMP and pCBA), 250.0 M (DMI, AMI, DAMP, TMT, aniline, PMSO, 
and PMSO2), or 800.0 M (SMX). The stock solutions were freshly prepared prior to the 
experiments, stored at 5 C, and used within one week. 






Creatinine (CRE) C4H7N3O 113.1 
pKa1 = 4.8 
pKa2 = 9.2 
 
 
Creatine C4H9N3O2 131.1 
pKa1 = 3.8 
pKa2 = 12.7 
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Aniline C6H7N 93.1 pKa = 4.63 
 
 
3.3.2 Reaction Matrices 
SHU was prepared similarly to the previous studies117, 135, and the composition is listed 
in Table 3.2. Briefly, SHU contained 0.5 M total ammonia (NH3 + NH4
+), 0.25 M total 
carbonate (HCO3
- + CO3
2-), 0.1 M chloride, 7.40 mM CRE, 1.28 mM creatine, 0.17 mM 
hippuric acid, as well as Na+, K+, SO4
2- and phosphate. Solution pH was adjusted to 9.0 
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using concentrated solutions of NaOH and NaH2PO4. To evaluate the effect of individual 
urine constituents, phosphate buffer (10.0 mM) solution at pH 9.0 (PB9) was spiked with 
specific urine constituent at various concentrations, and compared with the PB9 control 
matrix without urine constituents. 
 
 





Creatinine 113.12 7.40 
Creatine 131.13 1.38 
Hippuric acid 179.17 0.17 
NaCl 58.44 60.00 
Na2SO4 142.04 15.00 
KCl 74.55 40.00 
NH4OH 35.04 250.00 
NaH2PO4 119.98 13.60 




3.3.3 Oxidation Experiments  
 The procedures of Fe(VI) oxidation of different pharmaceuticals at different reaction 
matrices followed those described in our recent study.117  Briefly, PB9 and modified PB9 
(50.0 mL) were first spiked with the target pharmaceutical (10.0 M). Then, 2.97 mg of 
potassium ferrate(VI) solid was weighed and added immediately to the reaction solution 
(achieving 300.0 M) to initiate the oxidation process. Sample aliquots were taken from 
the reaction solution at predetermined time intervals and quenched immediately by sodium 
thiosulfate (2.5 mM).38 Solution pH was checked before and after the reaction by a pH 
meter (Accumet Research AR 20) and change was never larger than 0.2 pH unit. 
Degradation of substrates and generation of methyl phenyl sulfone (PMSO2) were 
monitored by high performance liquid chromatography (HPLC)-diode array detection 
(DAD), and the transformation products of SMX by Fe(VI) were analyzed using solid-
phase extraction (SPE) followed by HPLC-high resolution mass spectrometry (LC-HRMS) 
analysis.  
3.3.4 Analytical Methods 
An Agilent 1100 series HPLC system equipped with a UV diode array detector (DAD) 
and a Zorbax SB-C18 column (2.1 mm × 150 mm, 5 μm) was used to monitor the loss of 
parent compounds of pharmaceuticals. Detection wavelengths for SMX, DMI, AMI, 
aniline, TMP, CBZ, NAP, PMSO, CRE, TMT, DAMP, pCBA, and PMSO2 were set at 
275, 210, 230, 236, 254, 285, 231, 230, 234, 210, 210, 234, and 230 nm, respectively. 
Gradient elution was used with (i) 0.1% (v/v) formic acid and methanol for SMX, AMI, 
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CBZ, NAP, DAMP and TMT; (ii) 0.1% (v/v) formic acid and acetonitrile for TMP, DMI, 
aniline, PMSO and PMSO2; and (iii) 10 mM oxalic acid and acetonitrile for pCBA. 
The oxidized products (OPs) of SMX by Fe(VI) in the presence or absence of CRE 
were identified using solid phase extraction (SPE), followed by liquid chromatography-
high-resolution/accurate mass (HR/AM) spectrometry (SPE-LC-HRMS) analysis. The 
reaction solutions withdrawn at certain degradation times (0, 3.0, 6.0, 10.0, and 15.0 min) 
were filtered by 0.45 µm glass-fiber filters and then concentrated by a Visiprep SPE 
apparatus (Supleco, USA) with Waters Oasis HLB cartridges (WAT106202, 6 cc/200 mg). 
Before extraction, each HLB cartridge was sequentially conditioned with 5 mL methanol 
and 5 mL water. Then, the cartridge was loaded with 100 mL sample, washed with 5 mL 
water, and vacuum dried for 5 min. Finally, the extracted degradation products were 
obtained by eluting the cartridge with 2 × 2 mL methanol. The degradation products were 
kept in sealed vials and shipped with ice overnight to TAMU, where the samples were 
analyzed by LC-HRMS. The full-scan analysis of untargeted products was performed on a 
Q Exactive Plus OrbiTrap mass detector (Thermo Scientific, Waltham, MA) coupled to a 
binary pump HPLC (Ultimate 3000, Thermo Scientific) in a positive ion mode using an 
electrospray ion (ESI) source. For data acquisition, the sheath, aux and sweep gasses were 
set at 50, 10 and 1, respectively. The spray voltage was set to 4 kV, and the S-lens RF was 
set to 50. The aux gas heater and capillary temperatures were maintained at 375 C and 
350 C, respectively. Full MS spectra were obtained at 70,000 resolution (m/z 200) with a 
scan range of m/z 50-750. Full MS → ddMS2 scans were obtained at 35,000 resolution 
(MS1) and 17,500 resolution (MS2) with a 1.5 m/z isolation window and a stepped NCE 
(20, 40, and 60). Samples were maintained at 4 °C before injection. The injection volume 
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was 10 µL. Chromatographic separation was achieved on a Hypersil GOLDTM C18 
selectivity LC column (50 mm × 2.1 mm, particle size 3 μm) at 25 °C using a solvent 
gradient method. The mobile phase was water (0.3% formic acid) (A) and methanol (B). 
The gradient method used was 0-2 min (10% B to 80% B), 2-3 min (90% B to 20% B), 3-
26 min (90% B), 26-27 min (10% B), and 27-35 min (10% B). The flow rate was 0.2 
mL/min. Sample acquisition was performed by Xcalibur (Thermo Scientific). The high-
resolution MS data were processed using Compound Discoverer 2.1 software (Thermo 
Scientific) and online molecular structure libraries (i.e., m/z cloud and ChemSpider). 
The low-temperature electron paramagnetic resonance (LT-EPR) analysis was carried 
out at 75 K on a Bruker ELEXSYS-II E500 spectrometer (Rheinstetten, Germany). The 
possible formation of organic radicals was determined using POBN (10.0 g/L) as the spin 
trap reagent. All spectra were recorded after freezing the aqueous samples with liquid 
nitrogen. The operating parameters were set as: X-band frequency, 9.4 GHz, center field, 
3350.0 G; sweep width, 900.0 G; sweep time, 30 s; attenuation, 25.0 dB; scan times, 10. 
3.3.5 Density Functional Theory (DFT) Calculation  
All DFT calculations were conducted by Gaussian 09W software (Gaussian Inc.) with 
the unrestricted M06 DFT functional and 6-311++G** basis set. The solvent effect was 
considered using the PCM model with water. The molecular structures of the reactants 
(HFeVIO4
- and CRE) and the products (HFeVO4
2- and CRE radical via one-electron transfer 
mechanism; HFeIVO3
- and hydroxylated CRE via two-electron transfer mechanism) were 
optimized and confirmed by no imaginary frequency. The change of Gibbs free energy 
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(∆G, kJ/mol) between the reactants and products was calculated to assess the spontaneity 
of both one-electron transfer and two-electron transfer reactions. 
3.3.6 Goodness-of-Fit of the Kinetic Model 
The goodness-of-fit between simulated and experimental values was quantified by 
calculating the Theil’s inequality coefficient (TIC) 197, which is expressed as follows, 
𝑇𝐼𝐶 =   









where yi represents the simulated data points and yi,m represents the measured data points.  
A value of the TIC lower than 0.3 198-200 indicates a good agreement between the 
model prediction and the measured data.  
3.4 Results and Discussion 
3.4.1 Impacts of Organic Metabolites on Pharmaceutical Degradation by Fe(VI)  
Experiments using PB9 spiked with CRE, creatine or hippuric acid individually were 
conducted to evaluate their effects on the Fe(VI) oxidation of pharmaceuticals. As shown 
by the pseudo-first-order rate constants (kobs in s
-1, R2 > 0.985) in Figure 3.1A, CRE 
significantly enhanced the degradation of pharmaceuticals by Fe(VI), especially for the 
cases of CBZ, TMP, and SMX, whereas creatine and hippuric acid had minimal impacts 
on the removal efficiency of the four pharmaceuticals by Fe(VI).  
To better understand the enhanced effect of CRE on the oxidation of pharmaceuticals 
by Fe(VI), SMX was chosen as the model compound to test the impact of CRE 
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concentration on its removal efficiency by Fe(VI). The kobs increased linearly as the CRE 
concentration was increased from 0 to 4000 M (Figures 3.1B and 3.3) and it reached the 
plateau with a slight decrease after the increase in CRE concentration above 4000 and up 
to 9000 M. This mild inhibitory effect was likely due to the scavenging effect by a high 
dosage of CRE, considering that the rate constant between Fe(VI) and CRE is relatively 
low at (3.8 ± 0.1) × 10-2 M-1∙s-1 at pH 9.0 (Figure 3.2) (corresponding kobs = 2.32-6.40  
10-4 s-1 at 4−15 mM of CRE). The relatively low chemical reactivity of CRE was also 
confirmed in a previous study,201 in which CRE in human urine could not be oxidized by 



















Figure 3.1(A) Effect of organic metabolites on Fe(VI) oxidation of pharmaceuticals. 
Initially, [pharmaceutical] = 10.0 µM, [Fe(VI)] = 300.0 µM, [CRE] = 7.4 mM, 
[creatine] = 1.28 mM, [hippuric acid] = 0.17 mM, and n = 2. (B) Effect of CRE on 
Fe(VI) oxidation of SMX. Initially, [SMX] = 10.0 µM, [Fe(VI)] = 300. 0 µM, [CRE] = 












3.4.2 Elucidating the Enhanced Effect of CRE  
3.4.2.1 Reactive Moiety  
To determine the likely initial attack position(s) on the pharmaceuticals by Fe(VI) in 
the presence of CRE, the substructure compounds of TMP (i.e., 2,4-diamino-5-
methylpyrimidine (DAMP) and 3,4,5-trimethoxytoluene (TMT)) and SMX (i.e., 3-amino-
5-methylisoxazole (AMI), 3,5-dimethylisoxazole (DMI), and aniline) were investigated for 
their reactions with Fe(VI) in the presence and absence of CRE at pH 9.0. For the subunits 





Figure 3.2(A) Relative logarithmic concentration of Fe(VI) as a function of reaction 
time during Fe(VI) oxidation of CRE at pH 9.0 (10.0 mM phosphate buffer). (B) 
Linear plot of the pseudo-first-order rate constant for the decrease of Fe(VI) vs. the 
initial CRE concentration. Initially, [CRE] = 3.0–15.0 mM, [Fe(VI)] = 300.0 M, 
pH = 9.0 (10.0 mM phosphate buffer), 25.0 C, n = 2, reaction time = 30 min and 
R2 = 0.975-0.997. 
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confirmed by a previous study.202 Even in the presence of CRE (0−500.0 µM), there was 
no noticeable degradation of TMT observed in the Fe(VI)+CRE system. On the other hand, 
DAMP, the subunit containing the amine group in TMP, showed the enhanced effect from 
CRE as seen in Figure 3.3, where kobs increased 3.1 times when CRE concentration was 
increased from 0 to 4000 µM. For the subunits of SMX, degradation of DMI by Fe(VI) 
was inhibited by the presence of CRE, where kobs decreased from 4.6×10
-2  to 2.9×10-2 min-
1 when CRE concentration increased from 0 to 4000 µM (Figure 3.4B), while AMI, with 
its amine group substituting the methyl group in DMI, showed a strong positive linear 
relationship between kobs and CRE concentration (Figure 3.3). This amine-structure-
specific effect from CRE could be further confirmed by Fe(VI) oxidation of aniline, a 
subunit of SMX, in the presence of CRE. As Figure 3.4C shows, the kobs of degradation of 












Figure 3.3 Effect of CRE on Fe(VI) oxidation of pharmaceuticals and their 
substructure compounds. Initially, [target compound] = 10.0 M, [Fe(VI)] = 
300.0 M, [CRE] = 0−4.0 mM, pH = 9.0 (10.0 mM phosphate buffer), 25.0 C, n 























kobs = 0.41 ± 0.02 min-1 R2=0.98 
 
 
kobs = 0.48 ± 0.07 min-1 R2=0.97 
 
kobs = 1.51 ±  0.18 min-1 R2=0.98 
kobs = 0.046 ± 0.001 min-1 R2=0.99 
 
 




Figure 3.4 Fe(VI) oxidation of (A) TMT, (B) DMI, and (C) aniline in the presence 
of different initial concentrations of CRE. Initially, [test compound] = 10.0 µM, 
[Fe(VI)] = 300.0 µM, pH = 9.0 (10.0 mM phosphate buffer), 25.0 C, n = 2. 
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3.4.2.2 Role of Radical Species  
Several studies203-206 have found that imidazole and CRE, when complexed with 
specific metal ions (e.g., Cu2+ and Fe3+), can display peroxidase activity to activate H2O2 
and generate hydroxyl radical (●OH). It is also interesting to note that Fe(III) and H2O2 are 
considered two major products generated from the self-decay of Fe(VI), as well as the 
reaction of Fe(VI) with organic substrates.207 Therefore, it is reasonable to hypothesize that 
CRE, when complexed with Fe(III) produced from Fe(VI) reduction, may show catalytic 
activity to promote the generation of highly reactive ●OH from H2O2, which can also be 
produced from Fe(VI) reduction. Para-chlorobenzoic acid (pCBA) was chosen as the 
quencher for ●OH for its inert reactivity to high-valent iron species (Fe(VI)/Fe(V)122 and 
Fe(IV)208) and high reactivity to ●OH  with a second-order rate constant of 5×109 M-1∙s-1 at 
pH 8.209As Figure 3.7 shows, the degradation trends of SMX were similar in the presence 
or absence of pCBA. Therefore, the results ruled out the possible generation of ●OH in the 
Fe(VI)+CRE system. 
3.4.2.3 Role of Iron Intermediate Species  
High-valent iron species (e.g., Fe(IV),210-212 Fe(V),213 and Fe(VI)214) were reported to 
be reactive with sulfoxide ( e.g., dimethyl sulfoxide (DMSO) and methyl phenyl sulfoxide 
(PMSO)), generating corresponding sulfones ( e.g., dimethyl sulfone (DMSO2) and methyl 
phenyl sulfone (PMSO2)) via an oxygen atom transfer (OAT) step under both acidic and 
alkaline conditions. This reaction pathway differs dramatically from the radical-based 
oxidation pathway, which normally turns DMSO or PMSO into their ●OH-induced 
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products (e.g., CH3SO2H
211). Thus, PMSO was used as the probe compound to investigate 
the involvement of high-valent iron intermediate species. 
As Figure 3.7B shows, PMSO was completely oxidized to PMSO2 by Fe(VI) in the 
presence of 0–4.0 mM CRE, which further eliminated the possibility of radical 
involvement in the Fe(VI)+CRE system and agreed with the above results based on radical 
quencher (i.e., pCBA) experiments. In the presence of CRE, PMSO degradation and 
PMSO2 generation were accelerated with increased concentrations of CRE, especially 
within the first 15 min, which further verified that Fe(IV) and/or Fe(V) were likely 
responsible for the enhanced rates observed in the Fe(VI)+CRE system based on the 
superior oxidation capability of Fe(V)106/Fe(IV)215 to Fe(VI). However, the conversion 
percentage of PMSO suffered at the higher dosage of CRE (4.0 mM vs. 0.5 mM) from 15 
min to 55 min, which was most likely due to outperformance of the reaction between 
Fe(V)/Fe(IV) and the oxidized products of CRE. 
It has been reported that the oxidation of substrate (X) by Fe(VI) can occur by several 
possible pathways.86, 99, 107-109 Steps include but are not limited to: (i) 1-e- transfer to form 
Fe(V) and a radical, with Fe (V) reacting to form oxidized substrate (X(O)) and Fe(III); (ii) 
OAT process to produce Fe(IV) and an oxygen atom added to substrate (X(O)); (iii) Fe(V) 
and Fe(IV) can then yield different final reduced species (i.e., Fe(II) or Fe(III) or both 
Fe(II) and Fe(III)) via 1-e- and 2-e- pathways through self-decomposition or/and further 
oxidation of substrate (X). Some studies have offered insights on the mechanisms of Steps 
i and ii, in which the 1-e- transfer reductants (R(1)) or 2-e
- transfer reductants (R(2)) were 
determined through theoretically correlating the reaction rate constants of Fe(VI) with 
substrates to the 1-e- or 2-e- thermodynamic reduction potentials.86, 110   
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To further confirm the role of CRE in the Fe(VI)+CRE system as R(1) or R(2), the low-
temperature electron paramagnetic resonance (LT-EPR) measurement with N-(4-
pyridylmethylene)-tert-butylamine-N,N’-dioxide (POBN) as the spin trap reagent was 
conducted to probe the formation of CRE radical as well as ●OH216 in the system. This 
approach158 has been applied in the Fe(VI)+aniline system, in which the anilino radical was 
observed during Fe(VI) oxidation of aniline, and thus Fe(V) was speculated as the major 
reactive iron intermediate species followed by the mechanism of Step i. However, 
according to Figure 3.5, no obvious signal was detected, indicating that it was less likely 
that Fe(V) and CRE radical were involved in the Fe(VI)+CRE system. This result also 
further confirmed the absence of ●OH, which agreed well with the quencher experiment 
using pCBA (Figure 3.7A). On the other hand, the DFT calculations were performed to 
examine the favorable step of the reaction between Fe(VI) and CRE to further confirm the 
role of CRE as R(1) or R(2). Based on the optimized geometries of all species involved (e.g., 
Fe(VI), Fe(V), Fe(IV), CRE radical, and CRE-O adduct), the changes of Gibbs free energy 
(ΔGoCal) and activation energy (ΔG⧧Cal) were calculated for R1 and R2, respectively. As 
Figure 3.6  shows, R1 had a negative Gibbs free energy value (ΔG0Cal = -6.37 kJ/mol) with 
a lower activation energy (ΔG⧧Cal = 3.18 kJ/mol) as compared to R2 (ΔG0Cal = 196.71 
kJ/mol and ΔG⧧Cal = 8.66 kJ/mol). This indicated the spontaneity of two-electron transfer 
reaction and involvement of Fe(IV) as the major reactive oxidant followed in the 
mechanism of Step ii. This result also agreed with the prediction that amine-containing 








Figure 3.5 LT-EPR spectra of the reaction solutions by Fe(VI) treatment with CRE. 
Note: No obvious EPR signals were observed. (Experimental conditions: [Fe(VI)]0 = 





























Figure 3.7(A) Effect of pCBA on Fe(VI) oxidation of SMX in the presence or absence 
of CRE. Initially, [SMX] = 10.0 M, [Fe(VI)] = 500.0 M, [CRE] = 7.4 mM, [pCBA] 
= 100.0 M. pH = 9.0 (10.0 mM phosphate buffer), 25 C, and n = 2. (B) PMSO 
oxidation and PMSO2 production in the Fe(VI)+CRE system. Initially, [PMSO] = 15.0 
M, [Fe(VI)] = 300.0 M, [CRE] = 0–4.0 mM, pH = 9.0 (10.0 mM phosphate buffer), 
25 C, and n = 2.  
 
Figure 3.6 Changes of Gibbs free energy for one-electron and two-electron 
transfers of the initial reaction between HFeVIO4- and CRE. 
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3.4.2.4 Oxidized Products (OPs) of SMX by Fe(VI) only and Fe(VI)+CRE Systems 
 The OPs of SMX in the Fe(VI) only and Fe(VI)+CRE systems at pH 9.0 were analyzed 
by LC-HRMS. Structural assignments of each OP were performed by product ion scans 
based on its MS/MS spectrum and the proposed fragments. A total of five OPs of SMX 
were identified and named as OP-98, OP-267, OP-269, OP-283, and OP-299 according to 
molecular weight. MS/MS spectra and possible structures of fragments of SMX and its 
OPs are presented in  Figure 3.8. The molecular compositions of these OPs were suggested 
by good mass error (< 3 ppm) between the experimental and theoretical m/z values, shown 
in Table 3.3. For the fragment analysis, SMX with a m/z value of 254.05911 and a retention 
time of 4.579 min has four major product ions at m/z 156.01125, 99.05574, 108.04473, and 
92.05001, which are proposed to correspond to the cleavage of S-N bond with the 
generation of two former fragments, loss of SO (48 Da from m/z 156.01125), and 
subsequent loss of O (16 Da from m/z 108.04473), respectively (Figure 3.8A). As a 
representative product, OP-269 with a protonated species at m/z 270.05402 and a 
chromatographic retention time at 4.495 min was proposed to be formed via hydroxylation 
of aniline group in SMX molecule. This structure was tentatively confirmed by four major 
product ions at m/z 172.00616, 99.05574, 124.03943, and 108.04472. These MS/MS 
fragments were formed via similar patterns with SMX. 
The proposed degradation pathways of SMX in the Fe(VI) only and Fe(VI)+CRE 
systems are shown in Figure 3.9. Both systems shared similar reaction pathways (i.e., 
Pathways I and II). In Pathway I, cleavage of the S-N bond generated OP-98 (AMI), which 
was also observed in other SMX oxidation systems using chlorine,156 ozone, and 
permanganate.157 In Pathway II, the initial attack on the aniline group of SMX produced 
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hydroxylamine product (OP-269) via a single electron-transfer mechanism.158 Later, this 
resulting hydroxylamine group will further collapse to nitroso group (OP-267), which can 
be further oxidized into nitro group (OP-283). Afterward, OP-283 can be hydrolyzed in the 
benzene ring part with generation of OP-299, all of which are consistent with the previous 
study.155 The similar products found in the Fe(VI) only system and the Fe(VI)+CRE system 
were also confirmed in acid,113 sulfite,159 and bicarbonate117-activated Fe(VI) systems, 
suggesting these generated iron intermediates (i.e., Fe(V) or Fe(IV)) could not change the 
OP species but alter the oxidation rate due to superior oxidation ability of  Fe(V)106, 160 or 
Fe(IV).161 
There were no apparent differences in products distribution for the degradation of SMX 
by the Fe(VI) only and Fe(VI)+CRE systems based on the identifiable products in this 
study. Cleavage of the S-N bond, oxidation of the aniline group, and hydroxylation of the 
benzene ring of SMX were found to be the main transformation pathways, which were 
consistent with previous studies.117, 155  
 The similar products found in the Fe(VI) only and Fe(VI)+CRE systems were also 
observed in ammonium-,111 acid-,113 bicarbonate-,117 and sulfite159-activated Fe(VI) 
systems, indicating that these generated or complexed iron intermediate species 































Figure 3.8 The LC/MS/MS spectra of SMX (A) and its OPs (B, OP-267; C, OP-269; 




Figure 3.9 Proposed reaction pathways of Fe(VI) oxidation of SMX in Fe(VI) only 
and Fe(VI)+CRE systems. Initially, [SMX] = 10.0 µM, [Fe(VI)] = 500.0 µM, [CRE] = 





3.4.3 Reactions Involved in Pharmaceutical Degradation in Fe(VI)+CRE System  
As discussed above, Fe(IV) is considered as the major reactive species contributing to 
the enhanced removal rate of pharmaceuticals in the presence of CRE. Seven major 
reactions (Eqs. 1-5 in Table 3.4) are proposed for pharmaceutical degradation in the 
Fe(VI)+CRE system. Equation 1 represents the generation of Fe(IV) from the reaction of 
Fe(VI) and R(2) CRE. Equation 2 shows the complexation between Fe(IV) and CRE, a very 
good bioligand. This speculation is consistent with the fact that CRE behaves as a strong 
stabilizing ligand for various metal ions (e.g., Cu(II),203 Ni(II),217 Ag(I),217 Zn(II),218 
Pt(II),218 and Fe(III)204). Recently, Fe(III) has also been used in a non-enzymatic 
electrochemical technique for urine CRE sensing due to the Fe(III)-CRE complex verified 
with UV analysis.219 Moreover, the non-heme type of Fe(IV)-oxo intermediates (e.g., αKG-
C3 halogenase and tourine dioxygenase) have been well-documented in biological 
systems220-222 and one of the non-heme ligands complexed with the iron center is histidine, 
which shares the same imidazole structure with CRE. These two pieces of evidence made 
the complexation of Fe(IV) and CRE quite plausible even though direct measurement of 
the Fe(IV)-CRE complex could not be achieved by using a stopped-flow system with UV-
vis spectrophotometry (Figure 3.10).The difficulty to detect Fe(IV)-CRE complex might 
be due to: 1) The unstable nature of highly reactive Fe(IV) species in the aqueous system, 
and 2) Much slower generation rate constant of Fe(IV) at 3.8×10-2 M-1∙s-1 in the 
Fe(VI)+CRE system compared to previous studies that successfully captured Fe(IV)-
carbonate and Fe(IV)-pyrophosphate complexes using a pulse radiolysis technique to 
generate Fe(IV) hydroxide from Fe(III) at the rate constant of 8.5×107 M-1∙s-1.173-174 In this 
study, CRE is proposed as both a reactant and an organic ligand in the Fe(VI)+CRE system, 
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which can be supported by the fact that less than 5% of CRE was consumed in the course 
of the reaction as a reactant (Figure 3.13), while >95% of CRE remained was expected to 
function as organic ligands to stabilize Fe(IV). Equations 3a–3c represent the fates of 
generated Fe(IV)-CRE, continuing reacting with CRE (Eq. 3a), OPs of CRE P1 (Eq. 3b) 
or the pharmaceutical (Eq. 3c). Meanwhile, the Fe(IV)-CRE complex could undergo 
bimolecular decay (Eq. 4) according to a previous study on the pyrophosphate-complexed 
and carbonate-complexed form of Fe(IV).173-174 Equation 5 represents the Fe(VI) reaction 
with the pharmaceutical, where k5 was derived based on dividing the kobs by Fe(VI) 
concentration (300.0 M) under pseudo-first-order reaction condition in the absence of 





















SMX C10H11N3O3S 254.05911 254.05994 -2.28 
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Table 3.4 Proposed reactions in the Fe(VI)+CRE system (CRE = creatinine; P = product; PhA = pharmaceutical). 
  
Note: Reaction 2 does not indicate a 1:1 complexation between Fe(IV) and CRE but a generalization of metal-ligand complex  
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Table 3.5 Parameters and rate constants between target compounds and Fe(IV)-CRE in the Fe(VI)+CRE system derived from 








































TMP 1.00 0.982 0.877   1.1×10-1 1 6.4 ± 0.2 694.2 ± 42.1 
SMX 0.93 0.976 0.819 1.1×10-1 0.1 5.6 ± 0.5 336.6 ± 22.6 
DAMP 0.58 0.993 0.512 0.67×10-1 0.1 3.8  ± 0.02 114.1 ± 5.0 
CBZ 0.43 0.999 0.380 0.63×10-1 0.5 3.4 ± 0.1 65.0 ± 2.9 


























Figure 3.10 Stopped-flow UV-Vis spectra of Fe(VI) and CRE. [Fe(VI)] = 300.0 µM, 
[CRE] = 4.0 mM, pH = 9.0 (10.0 mM phosphate buffer), reaction time = 0.01 s (A), 0.1 









3.4.4 Kinetic Investigation of Fe(IV)-CRE Generation and Utilization Model  
Considering the experimental conditions used in this study, Reactions 3a and 3b are 
likely negligible in the initial stage of the reaction, where the concentrations of CRE and 
its OP P1 are lower than 4000 M. Therefore, a simplified Fe(IV)-CRE generation and 
utilization model (similar to the MGU model used in a previous study225), coupled with the 
losses of Fe(VI) and pharmaceutical, is proposed including Eqs. 1, 2, 3c, 4, and 5 in Table 
3.4. In this model, Fe(IV), generated via a two-electron transfer reaction between Fe(VI) 
and CRE with a rate constant k1, is proposed to complex with CRE at the rate constant of 
k2.  It was reported that the rate constant of complex formation ranged from 500 to 7.5×10
4 
M-1∙s-1 for organics and ferrous (Fe(II)) and ranged from 2.1×105 to 9.6×107 M-1∙s-1 for 
organics and ferric (Fe(III)).223-224 Sensitivity analysis was conducted by varying the k2  
value (Figure 3.11). The degradation of pharmaceuticals (e.g., TMP and AMI) was 
independent of the magnitude of k2 ranging from 10
2 to 108 M-1∙s-1; thus, k2 was estimated 
to be >102 M-1∙s-1.  The Fe(IV)-CRE formed in-situ would react with the pharmaceutical 
with a rate constant k3c. The utilization rate parameter 1/α is introduced to be the ratio 
between the amount of Fe(IV)-CRE utilized for oxidation of pharmaceutical and the total 
Fe(IV)-CRE generated from Reaction 2. It is evident that 1/α should be less than 100%, 
since some of the formed Fe(IV)-CRE complex can undergo self-decomposition at an 
unknown rate. Therefore, Eqs. 3.2, 3.3, 3.4, and 3.5 were included in the simplified 
Fe(VI)+CRE system with the introduction of 1/α. 
              HFeVIO4
-+ CRE → HFeIVO3
- + P1    
                                                                                                         (3.2) 
              HFeIVO3
-+ CRE → HFeIVO3
--CRE  (i.e. Fe(IV)-CRE)                                                               (3.3) 
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              HFeIVO3
--CRE + PhA → FeIII(OH)3(aq) + P3                                                       (3.4) 
              HFeVIO4
- + PhA → FeIII(OH)3(aq) + P5                                                                                                  (3.5)      
where PhA = pharmaceutical and P = product. 
Considering k2 is at least four orders of magnitude higher than k1, all the produced 
Fe(IV) was expected to form Fe(IV)-CRE immediately in the presence of an excess amount 
of CRE. Thereby, the overall Fe(IV)-CRE accumulation rate can be expressed as follows: 
     
 
 At the steady state, 
𝑑[𝐹𝑒(𝐼𝑉)−𝐶𝑅𝐸]
𝑑𝑡




𝑘1[𝐹𝑒(𝑉𝐼)][𝐶𝑅𝐸] = 𝑘3𝑐[𝑃ℎ𝐴][𝐹𝑒(𝐼𝑉) − 𝐶𝑅𝐸]                                                       (3.7) 
 The degradation of pharmaceutical can be expressed as follows: 
      
                          
  Combining Eqs. 7 and 8, 
   𝑘𝑜𝑏𝑠 =
𝑘1[𝐹𝑒(𝑉𝐼)]
𝛼[𝑃ℎ𝐴]
[𝐶𝑅𝐸] +  𝑘5 [𝐹𝑒(𝑉𝐼)]  =  𝑚 [CRE]  +  𝑏                                                (3.9) 
 where 𝑚 =
𝑘1[𝐹𝑒(𝑉𝐼)]
𝛼[𝑃ℎ𝐴]
 and 𝑏 = 𝑘5[𝐹𝑒(𝑉𝐼)] = 𝑘𝑜𝑏𝑠
′  of pharmaceutical degradation in the 
absence of CRE. 
𝑑[𝐹𝑒(𝐼𝑉) − 𝐶𝑅𝐸]
𝑑𝑡












= 𝑘1[𝐹𝑒(𝑉𝐼)][𝐶𝑅𝐸] − 𝛼𝑘3𝑐[𝑃ℎ𝐴][𝐹𝑒(𝐼𝑉) − 𝐶𝑅𝐸]                                        (6) 
𝑑[𝑃ℎ𝐴]
𝑑𝑡















= −𝑘3𝑐[𝐹𝑒(𝐼𝑉) − 𝐶𝑅𝐸][𝑃ℎ𝐴] − 𝑘5[Fe(VI)][PℎA] = −𝑘𝑜𝑏𝑠[𝑃ℎ𝐴]                    (8) 
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           Based on the experimental condition that k1 = 3.8×10
-2 M-1∙s-1 and [Fe(VI)]/[PhA] 





𝑚 ( 𝑖𝑛 𝑀−1𝑠−1）
1.14
.      
As Figure 3.3 shows, a linear relationship between CRE concentration and kobs was 
observed for all five compounds. According to the slope m and intercept b, the Fe(IV)-
CRE utilization rate 1/α can be calculated. The higher 1/α is, the faster substrate 
degradation should be due to the increasing amount of Fe(IV)-CRE available to react with 
the substrate. This was true according to the calculated 1/α, where TMP responded to the 
enhanced effect of CRE more sensitively with the highest utilization rate of 88%, while 
AMI responded to this effect more stagnantly with the lowest utilization of 18%. This 
simple model can be also validated by less than 1% of difference between the measured 
𝑘𝑜𝑏𝑠
′   and calculated b. Although this simplified model contains several assumptions and 
may be further refined, the model does allow for the determination of Fe(IV)-CRE 
involvement with different substrates based on 1/α, which indicates its reaction selectivity 
towards electron-rich moieties such as amine-containing compounds. 
        By adopting the simplified Fe(VI)+CRE system, a kinetic model was developed and 
applied to the degradation of compounds at different CRE concentrations via least-squares 
nonlinear regression with constant error model using Simbiology Version 5.7 in MATLAB 
2018 (The Math Works, Inc.) to derive k3c values (Figure 3.12 and Table 3.5). The 
calculated TIC based on Figure 3.14 and Table 3.6 confirmed the good fit of model 
simulations with the measured compound degradation data, with the TIC values ranging 
from 0.01 to 0.09, and the simulated αk3c values ranged at 53.3−791.6 M
-1∙s-1 and 
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successfully predicted the removal rates of five compounds within the first 15 min, which 
validated the proposed kinetic model involving the Fe(IV)-CRE species. Moreover, the 
derived rate constant k3c ranging from (9.3±0.4) to (6.9±0.4 × 10
2) M-1∙s-1 agreed well with 
other Fe(IV) oxidation studies that reported the range at 102-104 M-1∙s-1.226-227 It is 
necessary to mention that the complexed Fe(IV) is expected to display lower reactivity 
compared to un-complexed Fe(IV) since most of ligands will lower their metal pairs’ redox 
potential by stabilizing it with a longer life time.117, 177-178, 180, 228 This may explain why the 
derived rate constants between Fe(IV)-CRE and substrates under alkaline condition in this 
study lied near the lower end of the experimental values between Fe(IV) and substrates 








Figure 3.11 Effect of k2 value on the kinetic modeling of pharmaceutical 
degradation. Experimental conditions: [PhA] = 10.0 µM, [Fe(VI)] = 300.0 µM, 
[CRE] = 4.0 mM, and pH = 9.0 (10.0 mM phosphate buffer). Note: The lines 




















Table 3.6 Correspondence between the measured and simulated pharmaceutical data 
in the Fe(VI)+CRE system at pH 9.0 based on the Theil’s Inequality Coefficient (TIC). 
 
TIC (number of data points) 
Figure 3.12 Measured and predicted degradation of substrates by the Fe(VI)+CRE 
system. Symbols: measured data; Lines: model calculation. Error bars represent one 
standard deviation of data. Initially, [substrate] = 10.0 M, [Fe(VI)] = 300.0 M, 








TMP SMX DAMP CBZ AMI 
[CRE]0 = 0 μM 14-16 0.04(16) 0.01(14) 0.03(16) 0.03(16) 0.02(16) 
[CRE]0 = 300.0 or 
500.0 μM 
14-16 0.04(16) 0.01(14) 0.03(16) 0.02(16) 0.02(16) 
[CRE]0 = 1000.0 
μM 
14-16 0.05(16) 0.02(14) 0.05(16) 0.03(16) 0.02(16) 
[CRE]0 = 2000.0 
μM 
14-16 0.03(16) 0.06(14) 0.04(16) 0.03(16) 0.03(16) 
[CRE]0 = 4000.0 
μM 
14-16 0.07(16) 0.07(14) 0.04(16) 0.04(16) 0.06(16) 








Figure 3.13. Degradation of CRE in Fe(VI)+CRE system. Experimental conditions: 
[SMX] = 10.0 µM, [Fe(VI)] = 300.0 µM, [CRE] = 0.1-1.0 mM, and pH = 9.0 (10.0 











































Figure 3.14 Statistical analysis of the goodness of fitting between simulated and 
experimental results for (A) TMP, (B) SMX, (C) DAMP, (D) CBZ, and (E) AMI. 
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3.5 Environmental Significance  
The extensive occurrence of pharmaceuticals in the aquatic environment and potable water 
demands more efficient treatment of these micropollutants from the urine source. Fe(VI) 
application to chemically remove such micropollutants in hydrolyzed urine could stand out 
because of its resistance to the scavenging effects of urine matrix and advantageous 
enhancement effects from several major urine constituents such as bicarbonate,117 
ammonia,111, 117 and CRE. This paper, for the first time, reports the enhancement of Fe(VI) 
oxidation by CRE and quantitatively explains the enhancement effect by the generation of 
high-valent iron intermediate species (i.e., Fe(VI)-CRE) using a generation-and-utilization 
kinetic model. Based on this kinetic model, the rate constants between substrates and 
Fe(VI)-CRE can be successfully derived. This approach can be conceptually useful to 
probe the kinetic behaviors of iron intermediate species in the Fe(VI)-reductant agent 
system. This model may be further used to evaluate the reactivity of Fe(IV) towards more 
micropollutants with distinctive function groups, and serve as the bridge for mechanistic 
investigation and optimization of application of Fe(VI) oxidation. In addition, future 
research should evaluate the effects of other urine constituents (e.g., other organics or 
partially degraded organic matter) on the Fe(VI) oxidation reaction, optimization of Fe(VI) 
oxidation of pharmaceuticals in real urine, as well as how the pharmaceutical degradation 




CHAPTER 4. KINETIC INVESTIGATION OF FE(VI) 
OXIDATION MECHANISMS: FE(VI) DECAY SYSTEM  
4.1 Abstract 
The kinetics and mechanisms of self-decay of ferrate(VI) (FeVIO4
2-, Fe(VI)) over the 
entire pH range from acidic to basic pH range need to be understood to assess the ability 
of Fe(VI) to oxidize pollutants at different pHs. Mechanism of self-decay of Fe(VI) has 
been extensively examined under acidic to neutral pH conditions. However, Fe(VI) self-
decay at alkaline pH (e.g., pH 9.0 or higher) is poorly understood. This study performed 
kinetic and modeling studies of the Fe(VI) decay at pH 9.0 and 10.0. Our research revealed 
that the decay of Fe(VI) followed first-order kinetics (i.e., unimolecular decay) at pH 9.0 
and 10.0, and the order changed to 3/2-order at pH 7.0 due to the different species of Fe(VI) 
(FeO4
2- versus HFeO4
-). Results of unimolecular decay mechanism through water attack 
(WA) were supported by density functional theory (DFT) calculations, which indicated 
unfavorable dimerization of FeO4
2- through oxo-coupling (OC) under alkaline conditions. 
The WA on the monomeric FeO4
2- was proposed due to its lower activation barrier 
compared to OC. Kinetic simulation of Fe(VI) decay involving Fe(V) and Fe(IV) 
successfully predicted Fe(VI) disappearance and H2O2 generation (a product) under varied 
conditions. The decay of FeO4
2- was different from the second-order kinetics of protonated 
Fe(VI) species (H2FeO4 and HFeO4
-). Our results will aid in comprehending oxidation 




Over the past decade, ferrate(VI) (FeVIO4
2-, Fe(VI)), a powerful oxidizing agent with a 
standard potential of 2.2 V in acid solution and 0.7 V at alkaline condition 229, has emerged 
as a novel oxidant to remove contaminants from water 116, 143, 230-231. The oxidation ability 
to remove pollutants is generally determined by the competing rate constants of the reaction 
between Fe(VI) with pollutants (X) (Eq. 4.1) and simultaneous self-decay of Fe(VI) (Eq. 
4.2 or 4.3): 
Fe(VI)  + X → Products        (4.1) 
Fe(VI) + H2O  → Products       (4.2) 
Fe(VI) + Fe(VI) → Products       (4.3) 
It is imperative to know whether the self-decay is first-order (Eq. 4.2), second-order 
(Eq. 4.3), or both to assess the ability of Fe(VI) to oxidize pollutants 232. For example, if 
Fe(VI) self-decay is first-order, the half-life of Reaction R2 would be independent of 
Fe(VI) concentration. Comparatively, the half-life of Reaction R3 would be inversely 
related to Fe(VI) concentration. The rates of the reactions of Fe(VI) with pollutants (i.e., 
Reaction R1) are highly pH-dependent in the acidic to basic pH range. The oxidative 
removal of pollutants by Fe(VI) over the entire pH range may be understood by knowing 
the pH dependence of the self-decay of Fe(VI). Many studies have been conducted in acidic 
to neutral pH on the decay of Fe(VI) in water, but similar information in basic medium is 
scarce. Information on the self-decay of Fe(VI) under basic pH has become important in 
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our research, in which we have sought to remove pharmaceuticals from the alkaline 
systems (e.g., hydrolyzed human urine samples 117). 
Fe(VI) is unstable in aqueous solution under acidic conditions 233-234 and could react 
with H2O to produce Fe(III), O2 
146 and H2O2 
145 as the final products. The mechanism for 
Fe(VI) self-decomposition at very acidic condition (e.g., pH 1.0-3.0) has been proposed 
recently 235. It includes the formation of a diferrate(VI) and subsequent intramolecular oxo-
coupling, which results in the production of O2 and diferryl(IV) species, on the basis of the 
study of 18O isotope effects on kinetics and computational method based on the density 
functional theory (DFT). This mechanism has been extended to near-neutral pH (pH 1.0-
8.3) with a minor modification that was changed from direct O2 formation to H2O2 stripping 
as the intermediate step to form diferryl(VI), according to the experimental evidence of 
H2O2 generation 
145. Recently, Chen and co-workers 207 also confirmed the second-order 
reaction of Fe(VI) decay at pH 8.0, based on the linear relationship between the initial 
Fe(VI) decay rate and [Fe(VI)]2. However, the mechanism of Fe(VI) self-decay at alkaline 
conditions (e.g., pH 9.0 or 10.0) has been poorly understood even though the optimal 
working pH for Fe(VI) may be at 9.0 after compromising between the Fe(VI)’s self-decay 
rate and oxidizing capability 138-139. 
Herein, the reaction kinetics of Fe(VI) self-decay at alkaline conditions (particularly 
pH 9.0) were carefully examined experimetnally, and the mechanism was proposed and 
validated by DFT calculations. A kinetic model including Fe(VI) and intermediate iron 
species (i.e., Fe(V) and Fe(IV)) was developed to predict Fe(VI) decay and H2O2 
generation at pH 9.0 to quantitatively assess the involvement of the intermediate iron 
species. 
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4.3 Materials and Methods 
4.3.1 Chemical and Reagents 
The horseradish peroxidase (HRP) and 2,2'-Azino-bis(3-ethylbenzthiazoline-6-
sulfonic acid) (ABTS) were purchased from Sigma-Aldrich. Solid potassium ferrate(VI) 
(K2FeO4) was synthesized using a wet chemical method and has a purity of more than 98%. 
All chemical standards were of at least 97% in purity. Reagent grade deionized (DI) water 
(resistivity >18 mΩ cm) was obtained from a Nanopure Millipore (Billerica, MA) water 
purification system. Stock solutions of Fe(VI) (0.2-1.2 mM) were freshly prepared by 
dissolving solid samples in 10.0 mM phosphate buffer (PB) at different pH 7.5, 9.0, and 
10.0. 
4.3.2 Self-decomposition Kinetics 
Freshly-prepared Fe(VI) stock solution and PB solution were mixed according to the 
required initial concentrations of Fe(VI) (100.0-700.0 M) in 50 mL volume in amber 
borosilicate bottles with constant magnetic stirring at room temperature (25 C). It was 
found that a higher initial concentration of Fe(VI) (e.g., 1700.0 M) could lead to increase 
of solution pH from 9.05 to 9.95 after 2 h reaction, which could affect the Fe(VI) self-
decay rate significantly. Thus, the initial Fe(VI) concentrations were chosen to be within 
100.0-700.0 M in the investigation of Fe(VI) self-decay kinetics for the duration of 216 
min. Samples aliquots were taken at predetermined time intervals (6-15 min) from the 
batch reactor, and immediately (within 5 s) analyzed at 510 nm wavelength using a UV-
vis spectrophotometer (εFe(VI), 510 nm = 850 M
-1∙cm-1 at pH 7.5 236, and εFe(VI), 510 nm = 1150 
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M-1∙cm-1 at pH 9 and 10 236-237). Solution pH was checked before and after the reaction by 
a pH meter (Accumet Research AR 20) and change was never larger than 0.3 pH unit (i.e., 
within 9.0-9.3) during reaction, owing to the relatively low initial Fe(VI) concentrations 
employed.  
Four fitting models for Fe(VI) decay were used in this study, which are given below 
(Eqs. 4.4-4.9): 
1st-order kinetics (unimolecular decay):              
𝑑[𝐹𝑒(𝑉𝐼)]
𝑑𝑡
=  −𝑘 [𝐹𝑒(𝑉𝐼)] 
𝐼𝑛[𝐹𝑒(𝑉𝐼)] = 𝐼𝑛[𝐹𝑒(𝑉𝐼)]0 − 𝑘𝑡 
 2nd-order kinetics (bimolecular decay): 
𝑑[𝐹𝑒(𝑉𝐼)]
2 𝑑𝑡






+ 2 𝑘𝑡 
3/2-order kinetics:  
2 𝑑[𝐹𝑒(𝑉𝐼)]
3 𝑑𝑡

















































The fourth fitting model (Eqs. 4.10 - 4.11) is a mixed 1st and 2nd order kinetics which 
was introduced to simulate the Fe(VI) decay at pH 2.53 -9.31 by previous studies 146, 238: 
                    
𝑑[𝐹𝑒(𝑉𝐼)]
𝑑𝑡
=  −𝑘1[𝐹𝑒(𝑉𝐼)] − 𝑘2 [𝐹𝑒(𝑉𝐼)]
2                                                            (4.10) 









) exp 𝑘1𝑡 −
𝑘2
𝑘1
                                                                   (4.11) 
where t is time of the decay of Fe(VI), and k1 is the rate constant of the 1
st-order decay of 
Fe(VI) while k2 is the rate constant of the 2
nd-order decay of Fe(VI). 
4.3.3 Measurement of the Initial Decay Rate 
In order to determine the order of self-decay reaction, a series of measurements of the 
initial rate (v) of the reaction with different initial Fe(VI) concentrations (100.0-2000.0 
M) were made to obtain the reaction order (n) (Eq. 4.12). Considering the decay rate of 
Fe(VI) at alkaline conditions is relatively slow, the time (tobs) that it took from initiating 
the reaction to observing 0.005 absorbance unit change (ΔAbs = 0.005) was recorded and 
the initial decay rate v was calculated by dividing Δ[Fe(VI)] with tobs. Then, log[v] was 
plotted against log[Fe(VI)] based the initial rate method, and the slope of this linear 
regression line was the reaction order (as shown in Eq. 4.13). 
𝑣 = 𝑘 [𝐹𝑒(𝑉𝐼))]𝑛 
log 𝑣 = log 𝑘 + 𝑛 log[𝐹𝑒(𝑉𝐼)] 
4.3.4 Detection of H2O2 Generation  
In order to validate the kinetic model proposed in this study, H2O2 concentration was 
monitored by the HRP-ABTS method similar to that described previously 239. 
                  (S10)  
 
                  (S10)  
 














4.3.5 Density Functional Theory (DFT) Calculation  
4.3.5.1 Model species  
Di-protonated species (H2FeO4), monoprotonated species (HFeO4
-), and non-
protonated species (FeO4
2-) were the three major species considered for the DFT 
calculations. All these species were reported to be in triplet state according to the magnetic 
susceptibility measurements 240 and previous DFT calculations 241-242. 
4.3.5.2 DFT calculations 
All the calculations were performed using Gaussian 09 program 243. The unrestricted 
formalism of B3LYP, which has shown good performance in the calculations of transition-
metal mediated reactions, was used for the open-shell calculation. Due to the involvement 
of iron atom, different basis sets were used for higher accuracy. LanL2DZ basis set was 
used for the Fe atom and the 6-311++G** basis set was used for the other atoms. Since the 
experiments of Fe(VI) oxidation reactions were usually carried out in aqueous phase, the 
dielectric effect of water solvent was incorporated using an integral equation formalism 
polarized continuum model (IEFPCM model). First, geometry optimization for energy 
minima was performed, and the subsequent vibrational frequency analyses were carried 
out using the same basis set to get the thermodynamic corrections and related energy 
values. 
Multiple transition states for O-O bond formation with ferrate(VI) were identified using 
the same parameters stated above. Transition states (only one imaginary frequency) were 
then corroborated by analyzing the energy minima (zero imaginary frequency) of the 
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reactant and product states using an intrinsic reaction coordinate (IRC) calculation. The 
Mulliken spin density was then derived from these structures and used for later analysis. 
In this study, the bond dissociation energy (BDE) for Fe-O(H) bond was calculated for 
elucidating the possibility of dimerization of deprotonated Fe(VI). BDE has been widely 
used to measure the strength of a specific chemical bond, and it was defined as the standard 
enthalpy change when the bond is cleaved by homolysis at 298 K 244, from Eq. 4.14, as:  
A-B A+B→   
 
rxn 298 ,298 ,298 ,298(A-B) (A,g) (B,g) (A-B,g)f f fH H H H H   =  + −            (4.14) 
4.3.6 Kinetic Simulation  
 The kinetic model simulations were conducted using Simbiology Version 5.7 in 
MATLAB 2018 (The Math Works, Inc.). 
The goodness-of-fit between simulated and experimental values was quantified by 
calculating the Theil’s inequality coefficient (TIC) 197, which is expressed as follows, 
𝑇𝐼𝐶 =   
√∑ ( 𝑦𝑖 − 𝑦𝑖,𝑚)2𝑖
√∑ 𝑦𝑖
2




where yi represents the simulated data points and yi,m represents the measured data points. 
A value of the TIC lower than 0.3 198-200 indicates a good agreement between the model 
and the measured data.  
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4.4 Results and Discussion 
4.4.1 Self-decay kinetics of Fe(VI) under alkaline conditions 
According to the speciation of Fe(VI) 245, deprotonated Fe(VI) (FeO4
2- ) is the major 
species (98%) at pH 9.0 (HFeO4
- ⇌ H+ + FeO42-, pKa3 = 7.23 150). The self-decay of Fe(VI) 
was studied at pH 9.0 with the initial concentrations (i.e., [Fe(VI]0) ranging from 107 to 
434 μM (Figure 4.1). Most previous research proposed a 2nd-order reaction with respect to 
Fe(VI) for its decay 89, 145, 235. However, the Fe(VI) decay data fitted better with the 1st-
order kinetics with more consistent rate constants and higher R2 values compared to the 
2nd-order kinetics (See Table 4.1). The mixed 1st and 2nd order kinetics were also utilized 
to simulate the Fe(VI) decay data but could not obtain meaningful rate constants (Table 
4.2), indicating that the assumption (i.e., FeO4
2- can initiate 1st- and 2nd-order decays in 








































Figure 4.1 Self-decay of Fe(VI) at pH 9.0 by fitting with 1st-order kinetics (A) and 
2nd-order kinetics (B).  
 
Figure 4.2 Self-decay of Fe(VI) at pH 7.5 by fitting with 1st-order kinetics (A) and 








Next, the method of initial rate was used to determine the order (n) of the self-decay of 
Fe(VI) . In Figure 4.4A, the linear relationship was observed only between the initial rate 
and [Fe(VI)] at pH 9.0, which was consistent with the rate law v = kinitial[FeO4
2-] (kinitial = 
4.8×10-5 s-1 at pH 9.0). As Figure 4.4A inset shows, no linearity was seen between the 
initial rate and [Fe(VI)]2, further suggesting that the rate was first-order with respect to 
[Fe(VI)]. The same phenomenon was also observed at pH 10.0 (Figure 4.4B). The above 
evidence strongly suggested that Fe(VI) decomposition under alkaline conditions (pH 9.0 
and 10.0), where FeO4
2- dominates, followed the 1st-order kinetics rather than the 2nd-order 
decay kinetics proposed in other previous studies 89, 145. Therefore, it is plausible that the 
protonation of Fe(VI) could alter the decay reaction order, i.e., the deprotonated form 
follows 1st-order reaction (unimolecular decay), and the protonated form follows 2nd-order 







Figure 4.3 Relationship between the initial Fe(VI) decay rate and initial Fe(VI) 
concentration at pH 7.5 (A); Plot of self-decay of Fe(VI) at pH 7.5 by fitting with 
3/2-order kinetics (B). 
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To test the above hypothesis, Fe(VI) decay at pH 7.5 was investigated at varied initial 
concentrations of Fe(VI) because deprotonated and mono-protonated Fe(VI) (53% FeO4
2- 
and 47% HFeO4
-) coexisted under such condition. When attempting to fit the data with 1st- 
or 2nd-order kinetics, neither could fully depict satisfactorily the Fe(VI) self-decay (Figure 
4.2 and Table 4.1). For 1st-order reaction, the rate constant was not significantly affected 
by the initial Fe(VI) concentrations but R2 deteriorated to 0.91 when [Fe(VI)]0 was 
increased to 695 µM. For 2nd-order reaction, the better R2 values were observed but the rate 
constants were changed from 1.10 to 5.51 M-1∙s-1 at different levels of [Fe(VI)]0. Thus, both 
kinetic models failed to describe Fe(VI) decay at pH 7.5.  
 










107 -4.86×10-6 11.07 0.999 
208 -5.2×10-4 11.18 0.999 
302 -8.18×10-4 10.64 0.999 
379 -1.43×10-3 9.92 0.999 
434 -2.79×10-3 8.72 0.997 
k avg -1.11×10-3 10.40  
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Figure 4.4 Relationship between the initial Fe(VI) decay rate and initial [Fe(VI)] at 
pH 9.0 (A) and 10.0 (B) in 10.0 mM phosphate buffer. [Fe(VI)]0 = 101.0 – 1220.0 μM; 
n = 2; Insets show the corresponding plot of initial rate vs. [Fe(VI)]2. 
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Table 4.2 Derived rate constants for Fe(VI) self-decay at pH 9.0 and 7.5 using 1st, 2nd and 3/2-order kinetics. 
 
 pH 9.0 pH 7.5 
[Fe(VI)]0 
(μM) 
k1st (s-1) R2 for k1st 
k 2nd 
 (M-1∙s-1) 
R2 for k2nd 
[Fe(VI)]0 
(μM) 
k1st (s-1) R2 for k1st 
k 2nd 
(M-1∙s-1) 
R2 for k2nd 




107 1.67×10-4 0.973 1.01 0.951 201 1.0×10-3 0.988 5.51 1.000 8.22×10-2 0.997 
208 1.89×10-4 0.981 0.61 0.958 331 1.4×10-3 0.972 4.12 0.998 7.56×10-2 0.990 
302 2.07×10-4 0.981 0.48 0.955 397 1.6×10-3 0.964 3.39 0.996 6.80×10-2 0.984 
379 2.17×10-4 0.981 0.40 0.967 502 1.4×10-3 0.948 2.35 0.988 5.40×10-2 0.972 
434 2.16×10-4 0.988 0.35 0.965 695 1.6×10-3 0.913 1.10 0.958 3.16×10-2 0.938 
k avg 1.99×10-4  0.57  k avg 1.4×10-3  1.50  6.23×10-2  
STD 9.5%  40%  STD 15%  47%  28%  
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The order of this reaction was then determined and was found to be ~ 3/2 (shown by the 
regression slope in Figure 4.3A). After fitting the data into the 3/2-order kinetics, the better 
values of R2 were obtained (i.e., 0.94-0.99) and the more consistent rate constants (an 
average value of 6.23×10-2 s-1 with 28.8% deviation) were observed (Table 4.2). This 
phenomenon can be explained by the coexistence of similar concentrations of deprotonated 
and mono-protonated Fe(VI) species. Similarly, previous studies have attempted to use the 
mixed 1st- and 2nd-order kinetics to describe Fe(VI) self-decay under acidic-to-neutral 
conditions and found that the 2nd-order kinetics began to dominate the decay pathway as 
pH was decreased 146, 246. 
4.4.2 Mechanistic investigation based on the DFT calculations 
Since dimerization of two Fe(VI) to form diferrate(VI) has been proposed as the major 
step to initiate the bimolecular decay under acidic-to-neutral conditions 145, 235, 247, 
unimolecular decay of Fe(VI) under alkaline condition is expected to follow a different 
decay pathway. The DFT calculations were employed to elucidate the Fe(VI) decay 
mechanism under this condition. 
Table 4.3 shows the optimized geometries of different Fe(VI) species in aqueous 
solution. The calculated Fe-O distance (1.65 Å) and Fe-O-Fe angle (109.5o) for FeO4
2- in 
water were in good agreement with the X-ray structure of K2FeO4 
248. By comparing the 
LUMO energy levels based on the B3LYP method, it was evident that the oxidizing ability 
of Fe(VI) species became stronger upon protonation because of the increased electron-
accepting ability of H2FeO4 and HFeO4
-, which agrees well with the pH dependence of 
Fe(VI) reactivity derived from experiments 249. These results validated the use of 
 121 
DFT/B3LYP method combined with mixed basis sets. Furthermore, protonation influenced 
the bond length between Fe and O. Compared to the 1Fe-2O distance of 1.65 Å in FeO4
2-, 
the corresponding 1Fe-2O(H) increased to 1.742 Å and 1.801 Å in H2FeO4 and HFeO4
- 
after protonation. Such increase in 1Fe-2O(H) distance resulted in much easier bond-
breaking reactions in aqueous phase. The calculated 1Fe-2O(H) dissociation energy also 
increased with deprotonation, which indicated that 1Fe-2O(H) bond became more difficult 
to break at higher pH.  
The calculated free energy barriers (Figure 4.5) suggested that the thermodynamics of 
condensation and dimerization changed from favorable (-1.0 kcal/mol, compared to -1.3 
kcal/mol calculated by Sarma et al. 235) to unfavorable (272.1 kcal/mol) along the 
deprotonation. This is due to FeO4
2- species having (i) a shorter Fe-O(H) distance and a 
higher bond dissociation energy, and (ii) a stronger intermolecular electrostatic repulsion. 
Ma and coworkers 250 reported an accelerating effect of Ca2+ on Fe(VI) decay at pH 9-10, 
and demonstrated unfavorable dimerization of FeO4
2- species unless in the help of metal 
cations such as Ca2+ to bridge two FeO4
2- ions. Note that Sarma et al. 235 also found that, at 
very low pH (~ 1), Fe(VI) decay was ruled by 1st-order kinetics and the calculated free 
energy for the formation of diferrate(VI) became positive (9.27 kcal/mol), indicating 
unfavorable situation to initiate dimerization for tri-protonated Fe(VI) (H3FeO4





Figure 4.5 Free energy calculated for the formation of diferrate from mono-











Fe(VI) self-decay process in aqueous phase can also be regarded as water oxidation, 
where the rate-limiting O-O bond formation is critical to elucidate the reaction pathway. 
Formation of O-O bond in Fe(VI) can be achieved either through oxo-coupling (OC) in 
Fe(VI)’s oxo ligands or water attack (WA) reaction that may involve high-energy 
electrophilic intermediates 251-255. Both possible mechanisms were examined by locating 
their corresponding transition states (TS) and perform intrinsic reaction coordinate (IRC) 
analysis using the DFT method. In Table 4.4, monomeric Fe(VI) reaction pathways were 
designated according to spin state, protonation level and mechanisms of O-O bond 
formation. For example, the TS for OC with the monoprotonated HFeO4
- via the 
unrestricted triplet is designated as 31OC. The activation barriers noted as ΔG⧧Cal are also 
shown in Table 4.4. The results showed that O-O bond formation was more favorable for 
HFeO4
- with the lower ΔG⧧Cal values observed in 
31OC (42.5 kcal/mol) and 31WA (25.1 
kcal/mol) in comparison to the deprotonated FeO4
2- (62.3 kcal/mol in 30OC or and 58.8 
kcal/mol in 30WA). A similar result was also observed when comparing the O-O bond 
formation for H3FeO4
+ and H2FeO4, where ΔG⧧Cal value increased with the decreasing 
protonation levels 235. On the other hand, it is notable that WA for FeO4
2- had relatively 
lower activation barrier in TS compared to OC (58.8 vs. 62.3 kcal/mol). A similar trend 
was also reported previously for HFeO4
- (27.8 kcal/mol (WA) vs. 37.4 kcal/mol (OC) 207), 
H2FeO4 (30.2 kcal/mol (WA) vs. 41.0 kcal/mol (OC) 
235) and H3FeO4
+ (20.8 kcal/mol 
(WA) vs. 24.5 kcal/mol (OC) 235). These findings confirmed that, unlike OC, which 
occurred in diferrate molecules at lower pH, monomeric deprotonated ferrate (FeO4
2-) in 
alkaline solution was more likely to initiate WA to complete the O-O bond formation.  
 124 
The Mulliken spin analysis of water attack (WA) on deprotonated Fe(VI) (FeO4
2-) 
shown in Table 4.5 suggested that, before the WA, the spin density was mostly spread over 
the one tetrahedral iron center (1Fe) with some evenly distribution on the surrounding oxo-
ligands. Upon WA, spin seems to be transmitted from 6O to the reactive ferryl (1Fe-2O). 
In the Fe(V) product (the structure shown in Table 4.5), the spin density has been mostly 
transferred to the center iron atom (1Fe). Accordingly, the Fe(VI) decay reaction under 
alkaline condition was proposed in Scheme S2. Aligning with the WA mechanism, the 
monomeric FeO4
2- received the H2O molecule attack by involving the addition of ●OH and 
●H, concertedly, to two oxo-ligands, respectively. The formed O-O bond in the Fe(V) 
intermediate species subsequently underwent hydrolysis by liberating one H2O2 and 
producing the Fe(IV) species. 
 




Charge  0 -1 -2 
Spin State Triplet Triplet Triplet 
 Relative Gibbs Free 
Energy (Kcal/mol) 




36.3 45.8 53.2 
LUMO (eV) -5.15 -3.44 -1.95 















Table 4.3 Optimized geometries of Fe(VI) species based on DFT calculations 
(bond length in Å). 
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Table 4.5 Mulliken spin distribution in the reactant (R), product (P) and transition 
state (TS) of Water Attack (WA) reaction of deprotonated Fe(VI). 
Table 4.4 Free energy barriers to oxo-coupling (OC) and water attack (WA) 



















25.1 42.5 58.8 62.3 
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4.4.3 Kinetic model of Fe(VI) self-decay: Involvement of Fe(IV) and Fe(V) 
A kinetic model including Equations 1-10 in Figure 4.8 and Table 4.6 was used to 
simulate the Fe(VI) decay behavior at pH 9.0 under various experimental conditions. 
Fe(VI), as well as H2O2 (one of the major end products of Fe(VI) decay), were 
experimentally measured and the results were used to validate the kinetic model. Even 
though FeO4
2- is the dominant species at pH 9.0 (98% FeO4
2- vs. 2% HFeO4
-), the 
contribution of HFeO4
- may not be negligible if it has relatively high reaction rates with 
substrates. Therefore, HFeO4
- was include in Equations 1b, 2b, and 7b to fully delineate 












Table 4.6 Reactions of self-decay of Fe(VI) at pH 9.0. 
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Note: Since there was limited information about Fe(IV) speciation, FeIVO32- is the proposed 
chemical formula of Fe(IV) and reactions 3-6 and 8 from previous work are modified accordingly 









Figure 4.7  Measured and predicted H2O2 formation and Fe(VI) disappearance 
during Fe(VI) decay in a phosphate buffer (10.0 mM) at pH 9.0 for varying initial 
Fe(VI) concentrations. [Fe(VI)]0 = 150.0 (A), 243.0 (B) and 430.0 μM (C); n = 2; 
Symbols: measured data; Lines: model calculation. Error bars represent one 
standard deviation of data. 
 
 
             
(B) 
 
          
(B) 
 
          
(B) 
 




            
(C)  
 
          
(C)  
 
           
(C)  
















            
(C)  
 
            
(C)  
 




            
(C)  
 
            
(C)  
 
            
(C)  
 129 
Table 4.7 Correspondence between the measured and simulated pharmaceutical data 
in Fe(VI)+CRE system at pH 9.0 based on the Theil’s Inequality Coefficient (TIC). 
 
Experimental Condition Number of data points 
TIC 
Fe(VI) H2O2 
[Fe(VI)]0 = 150.0 μM 14 0.03 0.16 
[Fe(VI)]0 = 243.0 μM 14 0.04 0.22 
[Fe(VI)]0 = 430.0 μM 14 0.05 0.16 




  Equation 1a represents the initiation of FeO4
2- self-decomposition from WA, generating 
one Fe(IV) species and one H2O2. This reaction was identified in our study and occurred 
via 1st-order kinetics with its kinitial to be 4.8×10
-5 s-1 (in Figure 4.4). According to the 
proposed reaction pathway in Figure 4.6, WA can be deemed as the addition of one ●OH 
and one proton to two separate oxygen ligands in Fe(VI) to form a hydrolyzed Fe(V) 
intermediate species. After stripping one H2O2 via one electron transfer from the central 
iron atom, one deprotonated Fe(IV) species is formed. Equation 1b, on the other hand, 
shows the bimolecular decay of HFeO4
- via OC, which has been carefully examined 
previously 145. It’s possible that Fe(VI) may react with H2O2 (Eq. 2a and 2b) and their 
species-specific rate constants were evaluated and modeled by Rush et al. 247 according to 
experimentally measured pH-dependent apparent rate constants. The reaction rate constant 
between HFeO4
- and H2O2 was determined to be 1.7×10
2 M-1∙s-1 (Eq. 2b). However, 
negligible reaction between FeO4
2- and H2O2 was found in their study (Eq. 2a), because 
oxidation of H2O2 requires prior coordination of peroxide to the metal to initiate inner-
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sphere electron transfer but FeO4
2-, owing to a slower oxygen exchange rate 233 compared 
to that of its protonated counterparts (i.e., HFeO4
-, H2FeO4, and H3FeO4
+), could not 
achieve such ligand-substitution, let alone the electron-transfer process afterwards 247. 
The newly formed Fe(IV) species can undergo dimerization to form di-Fe(IV) (Eq. 3) 
and then subsequently self-decomposed to Fe(III) and H2O2  (Eq. 4), based on the kinetic 
study of Fe(IV)-pyrophosphate complex by the pulse radiolysis at pH 10.0 173. The reaction 
rate constants of Equations 3 and 4 at pH 9.0 were estimated to be similar to the reported 
values at pH 10.0 in the phosphate buffer solution. Fe(IV) oxidation of H2O2 (Eq. 5) has 
only been studied at acidic pH 0 (i.e., FeIVO2+ + H2O2, k = 1.0×10
4 M-1∙s-1) 161 or at pH 10 
in 0.1 M pyrophosphate (Fe(IV)-pyrophosphate complex + H2O2, k = 3.9×10
5 M-1∙s-1) 173. 
Since the speciation of Fe(IV) under different pH conditions is poorly known (pKa = 9.6 
for Fe(IV)-pyrophosphate complex 173), it is difficult to quantify the pH effect on k5 in 
phosphate-buffered condition in our study. Based on the sensitivity analysis of k5 in the 
Fe(VI) decay model (Figure 4.9), the lower bound (1.0×104 M-1∙s-1) was found to best fit 
the experimental data, especially for H2O2 generation. This estimated value is also aligned 
well with the reaction rate constant between Fe(V) and H2O2 (k10 = 4.0×10
5 M-1∙s-1 105), 
which was usually 1-2 orders of magnitude higher than its Fe(IV) counterpart 110. Fe(IV) 
can also react with Fe(II) (Eq. 6) in acidic perchlorate and alkaline pyrophosphate solutions 
and the reported rate constants between Fe(IV) and Fe(II) were 3.56×104 M-1∙s-1 (FeIVO2+ 
+ Fe(II) at pH 1.0 257) and 1.6×106 M-1∙s-1 (Fe(IV)-pyrophosphate complex + Fe(II) at pH 
10.0 173), respectively. Based on the sensitivity analysis of k6 (Figure 4.10), Fe(VI) decay 
and H2O2 generation are independent of the magnitude of k6 ranged from 3.56×10
4 M-1∙s-1 
to 1.6×106 M-1∙s-1, thus k6 was estimated to be ~10
6 M-1∙s-1, closer to the upper limit. 
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The reaction between Fe(VI) and Fe(II) (Eq. 7a and 7b) was considered to be the bridge 
between different iron species, where Fe(V) and Fe(III) were the end products. Previous 
research has evaluated the oxidation of Fe(II) by Fe(VI) using the stopped-flow 
spectrophotometer at pH 5.0 and its rate constant was much greater than 5.0×106 M-1∙s-1 
145. Meanwhile, it was found that Fe(II) reduced Fe(VI) at a rate of 105 M-1∙s-1 at alkaline 
condition 256. Based on the sensitivity analysis of k7a (Figure 4.11), Fe(VI) decay and H2O2 
generation are independent of the magnitude of k7a ranged from 10
4 M-1∙s-1 to 108 M-1∙s-1. 
Therefore, an estimated rate constant (~105 M-1∙s-1) was assigned to this reaction (Eq. 7a), 
which is one order of magnitude lower than its Fe(IV) counterpart k6 and two orders of 
magnitudes lower than its mono-protonated Fe(VI) counterpart k7b (~10
7 M-1∙s-1, Eq. 7b) 
validated by model simulations in a previous study 145. Fe(II) was also speculated to 
generate Fe(IV) in the presence of H2O2 (Eq. 8) in the Fenton system at neutral pH 
condition, and the rate constant between Fe(II) and H2O2 was reported to be 5.9×10
3 M-1∙s-
1 at pH 7.0 211 with very limited information under alkaline conditions. Based on the 
sensitivity analysis of k8 (Figure 4.12), Fe(VI) decay and H2O2 generation are independent 
of the magnitude of k8 ranged from 0 M
-1∙s-1 to 104 M-1∙s-1 and started to shift when k8 was 
increased to 105 M-1∙s-1 or higher. Thus, k8 was estimated to be around 10
2 M-1∙s-1, closer 
to the lower bound. This also indicated the regeneration of Fe(IV) from Fe(II) could be 
neglected during Fe(VI) self-decay, considering the relatively small k8 observed in Fenton 
reaction at neutral pH condition 211. 
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Figure 4.8 Reaction scheme of self-decay of Fe(VI) at pH 9.0. (Note: The numbers in 














Figure 4.9 Kinetic modeling of the effect of k5 on H2O2 generation and Fe(VI) 
disappearance. (Experimental conditions: [Fe(VI)]0 = 430.0 μM, pH 9.0 and reaction 










Figure 4.10  Kinetic modeling of the effect of k6 on H2O2 generation and Fe(VI) 
disappearance. (Experimental conditions: [Fe(VI)]0 = 430.0 μM, pH 9.0 and reaction 
time = 216 min). Note: The lines representing k6 = 3.56 ×104 M-1∙s-1 and 1.0 × 106 M-










Figure 4.11 Kinetic modeling of the effect of k7a on H2O2 generation and Fe(VI) 
disappearance. (Experimental conditions: [Fe(VI)]0 = 430.0 μM, pH 9.0 and reaction 










Figure 4.12 Kinetic modeling of the effect of k8 on H2O2 generation and Fe(VI) 
disappearance. (Experimental conditions: [Fe(VI)]0 = 430.0 μM, pH 9.0 and reaction 







Fe(V) self-decay kinetics also differ in different pH conditions due to its speciation: 
H3Fe
VO4 ⇌ H+ + H2FeVO4-, 5.5  pKa1  6.5; H2FeVO4- ⇌ H+ + HFeVO42-, pKa2  7.2; 
HFeVO4
2- ⇌ H+ + FeVO43-, pKa3 = 10.1 175. Based on the pulse-radiolysis study of Fe(V) 
decay in alkaline condition 175, 1st-order kinetics were found to dominate the decay path at 
pH > 11, while the 2nd-order decay was found to outcompete its 1st-order decay at lower 
pH (< 11). Later, one study of Fe(V) decay under neutral and acidic conditions found that 
bimolecular reaction (2nd-order decay) only occurred between HFeO4
2- and FeO4
3- at pH 
10-12, while unimolecular reaction (1st-order decay) became the only path for HFeO4
2-, 
H2FeO4
-, and H3FeO4 at pH < 7 
236. These phenomena were similar to the Fe(VI) decay, 
where it follows the 1st-order kinetics at very acidic pH 235 (e.g., pH 1.0) and alkaline pH 
(this study), while the 2nd-order kinetics become the major pathway in neutral conditions 
89, 145. Since HFeO4
2- is the major species for Fe(V) at pH 9.0 (i.e., pKa2 = 7.5 and pKa3 = 
10.1) 175, 1st-order decay (Eq. 9a) and 2nd-order decay (Eq. 9b) were both included to 
account for the mixed-order decay.  
In order to test how sensitive the kinetic model developed in this study reacts to Eq. 9b 
(Table 4.6), the rate constant of this equation (k9b) was varied from 0.0 to 2.0 × 10
10 M-1∙s-
1 (the upper limit of diffusion-controlled reaction rate) and the simulated H2O2 generation 
profile is shown in Figure 4.13. As shown, when k9b was increased from 0 to 1.5 × 10
9 M-
1∙s-1, the H2O2 generation profiles were overlapped with each other, indicating that Fe(V) 
bimolecular decay (Eq. 9b) contributed little to H2O2 generation. Until k9b was increased 
to diffusion-controlled reaction (~ 2 × 1010 M-1∙s-1), the H2O2 generation started to show a 
minor shift. This phenomenon can be explained by the fact that Fe(V) concentration 
determines the competitiveness of unimolecular decay vs. bimolecular decay (Eqs. 9a vs. 
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9b, Table 4.6). If the Fe(V) concentration is far lower than 3.3 × 10-7 M (the ratio of k9a/k9b), 
the unimolecular decay of Fe(V) would dominate the Fe(VI) decay pathway and this 
corresponds well to the result that the maximum Fe(V) concentration was around 4.3 × 10-
10 M under the tested reaction condition, based on the simulation shown in Figure 4.14. 
Therefore, Eq. 9b contributed little to the H2O2 generation because Fe(V) concentration 















Figure 4.13 Kinetic modeling of the effect of k9b on H2O2 generation and Fe(VI) 
disappearance. (Experimental conditions: [Fe(VI)]0 = 430.0 μM, pH 9.0 and reaction 
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time = 216 min). Note: The lines representing k9b = 0 M-1∙s-1 and 1.5 × 109 M-1∙s-1 were 
overlapped 
 
Figure 4.14  Fe(V) generation profile derived from the kinetic model prediction. 
(Experimental conditions: [Fe(VI)]0 = 430.0 μM, pH 9.0 and reaction time = 216 min). 
 
 
The resultant Fe(V) can also react with H2O2 
247 (Eq. 10) and their reactions have been 
determined previously by the premix pulse-radiolysis technique with a rate constant of 
4×105 M-1∙s-1 at pH 9.0. 
This kinetic model was applied to predict the Fe(VI) disappearance and H2O2 
generation during Fe(VI) self-decay at pH 9.0 under various experimental conditions. 
Overall, the model prediction agreed well with the experimental data according to the 
Theil’s inequality coefficient (Table 4.7), which confirmed the good fit of model 





















0.03 to 0.21. Figure 4.7 shows the generation of H2O2 and disappearance of Fe(VI) as a 
function of reaction time up to 216 min at different initial Fe(VI) concentrations. H2O2 
concentration gradually increased during the first 100 min and maintained at a relatively 
stable level until 216 min. The prediction by the kinetic model successfully captured the 
experimental data trends, confirming the robustness of this model. 
4.5 Environmental Significance 
This study addresses the knowledge gap regarding the behavior of Fe(VI) self-decay 
under alkaline conditions by elucidating the reaction kinetics and mechanisms. Results 
strongly indicate that the self-decomposition of FeO4
2- (dominant at alkaline pH 9.0-10.0 
condition) in aqueous solution follows 1st-order kinetics and occurs via WA to form the O-
O bond, which can liberate H2O2 molecule after the generation of Fe(IV). This initial step 
is followed by other iron intermediate species’ (i.e., Fe(V) and Fe(IV)) reactions with H2O 
and H2O2. The kinetic model based on the reactions amongst Fe(VI), Fe(V), and Fe(IV) 
can successfully predict the H2O2 generation trend, validating the involvement of Fe(V) 
and Fe(IV) during Fe(VI) decay and the robustness of the kinetic model. 
The findings of this study also provide a critical basis for the attempt to simulate 
intermediate iron species (Fe(V) and Fe(IV)) during Fe(VI) oxidation in more complicated 
alkaline systems (e.g., wastewater 258 and hydrolyzed human urine 117). For example, the 
kinetic model and mechanistic knowledge from this study can be further expanded and 
adapted for wastewater treatment systems, in which Fe(VI) oxidation of contaminants with 
or without activators is conducted 116, 159, 258, and is being pursued with ongoing studies. 
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CHAPTER 5. KINETIC INVESTIGATION OF FE(VI) 
OXIDATION MECHANISMS: FE(VI)-FE(III) SYSTEM 
5.1 Introduction 
In recent years, research on the applications of Fe(VI) is increasing because of its 
potential in multifunctional water treatment like coagulation, oxidation, and disinfection. 
259-260 Many investigations have been carried out to oxidize micropollutants such as 
antibiotics, β-blockers, and bisphenols.Fe(VI) could oxidize most of the micropollutants at 
significant reactivity, but some compounds of interests have shown sluggish reactivity to 
be effectively removed.110, 249 Work is in progress to activate Fe(VI) to enhance elimination 
of recalcitrant micropollutants in water. Recently, a few studies suggested that newly added 
ferric salts can promote the degradation of diclofenac (DCF) and sulfamethoxazole (SMX) 
by Fe(VI).118, 120 However, these studies were not able to fully depict the role of 
intermediate iron species formed in the Fe(VI)-Fe(III) system. 
 In this chapter, a new kinetic model involving the incorporation of interaction of Fe(VI) 
with Fe(III) into the Fe(VI) decay model proposed in chapter 4 was investigated. 
Furthermore, the Fe(VI)-Fe(III)-Substrate model was constructed to delineate the role of 
Fe(IV), generated from the interaction of Fe(VI) with Fe(III), in contributing to the 
degradation of organic substrates in the Fe(VI)-Fe(III) system. Finally, based on the results, 
a preliminary assessment was performed on the structure-reactivity relationship between 
the molecular descriptors of organic substrates and their reactivity to Fe(IV). 
5.2 Materials and Methods 
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5.2.1 Chemical and Reagents 
Ferric nitrate and 18 target compounds (atenolol (ATL), flumequine (FLU), Bisphenol-A 
(BPA), trimethoprim (TMP), sulfamethoxazole (SMX), naproxen (NAP), sulfamerazine 
(SMR), sulfamethazine (SMT), sulfamethizole (SMZ), diclofenac sodium (DIC), 
levofloxacin (LEV), methyl orange (MO), caffeine, ibuprofen (IBU), ketoprofen (KET), 
benzoic acid (BA), carbamazepine(CBZ), clofibric acid (CA)) were purchased from 
Sigma-Aldrich. Solid potassium ferrate(VI) (K2FeO4) was synthesized using a wet 
chemical method and has a purity of more than 98%. All chemical standards were of at 
least 97% in purity and used without further purification. Reagent grade deionized (DI) 
water (resistivity >18 mΩ cm) was obtained from a Nanopure Millipore (Billerica, MA) 
water purification system. 
5.2.2 Removal Experiments 
   The removal experiments of substrates by Fe(VI)-Fe(III) systems were conducted with 
duplicates in 100 mL beakers with a magnetic stirrer under constant stirring rate (400 rpm) 
and room temperature. The reactions of substrate (10.0 μM) with and without addition of 
Fe(III) (400.0 μM)  and Fe(VI) (200.0 μM) were initiated by mixing equal solution volumes 
of 10.0 mL of substrate and Fe(VI) solutions, and the reaction mixtures were maintained 
at pH 9.0 using 2.0 mM borate buffer. The reaction solutions were quenched at certain 
reaction times completely using 20 μL of 1.0 M hydroxylamine solution. Samples were 
filtered using 0.45 μm PTFE syringe filters (FisherbrandTM, Fisher Scientific) and 
transferred into 2.0 mL HPLC vials for analysis. Fe(VI) decay experiments with the 
addition different levels of Fe(III) (0-200.0 μM) was initiated by mixing Fe(VI) and Fe(III) 
 144 
solutions at equal volume of 10.0 mL, and the reaction mixtures were maintained at pH 9.0 
using 2.0 mM borate buffer. 
5.2.3 Analytical Methods 
     The concentrations of 18 organic substrates selected in this study were analyzed using 
an Agilent 1100 HPLC/diode-array detector (DAD) system equipped with an Agilent 
Zorbax SB–C18 column (2.1 × 150 mm, 5 μm).  The 18 compounds were analyzed by 
using the isocratic mobile phase: 20-80% of acetonitrile and 80-20% 0.1 % (v/v) formic 
acid in water at 0.25-0.6 mL∙min-1. Wavelengths of DAD were set at 210 nm (IBP and 
BPA), 232 nm (BA and CA), 234 nm (NAP), 254 nm (TMP and KET), 275 nm (SMX, 
SMT, SMZ, SMR, CAF, and ATL), or 285 nm (MO, LEV, DIC, CBZ and FLU). Fe(VI) 
decay was monitored at 510 nm (εFe(VI),510nm = 1.15×10
3 cm-1 M-1) using a 
spectrophotometer. 
5.2.4 Kinetic Simulation 
The kinetic model simulations were performed using SimBiology Version 5.7 in MATLAB 
2018 (The Math Works, Inc.). The rate constants were derived using the “fit mode” task 
via “non-linear least-square regression” function in SimBiology.  
5.2.5 Structure-Activity Relationship 
     The 2nd-order rate constants (k13 in M
-1s-1) between Fe(IV) and reactive target 
compounds at pH 9.0 derived from the Fe(VI)-Fe(III)-Substrate system were used to assess 
the structure-activity relationship of aromatic compounds toward Fe(IV).  
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5.2.5.1 Molecular Descriptors 
          The 29 representative molecular descriptors, including 7 quantum chemical 
descriptors (electron affinity (EA), ionization potential (IP), hardness () softness (S), 
ELUMO, EHOMO, and ELUMO-EHOMO), 17 constitutional descriptors (#C, #H, #N, 
#O, #X, #H:C, #O:C, #N:C, #N:O, #N:H, #C=C, #OH, #acid, #arom, #ringatoms, 
#nonHatoms, and DBE), 3 geometrical descriptors (electronegativity (), electrophilicity 
index (), and  dipole moment ()), and 2 kinetic descriptor ( k12 ( 2
nd order rate constant 
between Fe(VI) and substrate)  and ln k
12) were selected based on the literature reporting 
that those descriptors influence high-valent iron oxidation.261 The descriptors were 
calculated by density functional theory (DFT). Geometry optimization calculations were 
conducted using the B3LYP method with 6-31G(d,p) basis set. All descriptors and their 
formula are listed in Appendix B.  
5.2.5.2  Statistical Analysis 
   Correlation analysis (CA) and multiple linear regression (MLR) were conducted using 
SAS version 9.4 (SAS Institute, Inc. Cary, NC). CA was conducted to evaluate the 
correlation between the descriptors and the rate constants, and descriptors themselves. 
Descriptors which exhibited correlation coefficients above 0.5 with p < 0.05 were selected. 
The stepwise MLR was used to relate the descriptors chosen from CA to the rate constants. 
The stepwise regression was employed to examine a variety of regression equations by 
adding each descriptor to previous steps. 
5.3 Results and Discussion 
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5.3.1 Fe(III) Effect on Fe(VI) Self-decay 
       Fresh Fe(III) from ferric chloride solution has been reported to enhance Fe(VI) decay 
at neutral pHs (e.g., pH 7.5 and 6.2), and the Fe(III) in such cases has larger surface area 
and rougher and less granular morphologies compared to those of ferrate-resultant 
Fe(III).89, 92 This phenomenon seemed to be also true at the higher pH (9.0) in our study as 
shown in Figure 5.1a, where Fe(VI) decay rate was increased from (1.73±0.02)×10-3 min-
1 to (56.8±0.56)×10-3 min-1 (Table 5.1) when the added Fe(III) concentration increased 
from 0 to 200 M. This Fe(III) enhancement effect observed in Jiang’s study89, as well as 
in our study, indicates that only freshly added ferric ion (at 1- 4 mg/L as Fe) can accelerate 
the Fe(VI) self-decay while ferric ion resulted in-situ from Fe(VI) decomposition (referred 
to as Fe(VI)-resultant Fe(III) hereafter) cannot increase the Fe(VI) self-decay rate. 
However, this assumption cannot fully depict the increasing trend of kobs along with Fe(III) 
concentration by considering a simple reaction between Fe(VI) and Fe(III) (Figure 5.1b). 
 147 
Time, min
















































Figure 5.1   (a) Decay of Fe(VI) at different concentrations of Fe(III) in Fe(VI)-Fe(III) 
system at pH 9.0. (Experimental conditions: [Fe(VI)] = 100.0 µM, [borate buffer] = 
2.0 mM, and reaction time = 140 min) and (b) plot of calculated first-order rate 





Table 5.1 The first-order rate constants for the decay of Fe(VI) at different 
concentrations of Fe(III) at pH 9.0. (Experimental conditions: [Fe(VI)] = 100.0 µM, 
[borate buffer] = 2.0 mM and reaction time = 10 min). 
_____________________________________________________ 
Fe(III), µM  kFe(III), min
-1   r2 
_____________________________________________________ 
0   (1.73±0.02)×10-3  0.9984 
25.0   (6.26±0.08)×10-3  0.9987 
50.0   (8.86±0.12)×10-3  0.9981 
100.0   (13.8±0.49)×10-3  0.9929 
200.0   (56.8±0.56)×10-3  0.9989 
______________________________________________________ 
 
5.3.2 Kinetic Modelling of Fe(VI)-Fe(III) System (Eqs.1-11) 
      In chapter 4, a Fe(VI) decay kinetic model (eqs.1-10) with the involvement of other 
iron intermediate species Fe(V)/Fe(IV) at pH 9 was successfully constructed based on 
Fe(VI) decay and H2O2 generation profiles as well as DFT calculation, which determined 
the initiation of Fe(VI) decomposition to be unimolecular decay.  In order to quantitatively 
explain the enhanced effect of Fe(III), a kinetic model including the Fe(VI) self-decay 
system (eqs.1-10 constructed in chapter 4) and eqs. 11a-11f shown in Table 5.2 was 
constructed to simulate the Fe(VI) decay data in Figure 5.1. 
      Eqs. 11a -11f represented 6 different scenarios of interactions between Fe(VI) and 
Fe(III).  Specifically, Eq 11a indicated the newly added ferric functioned the same as the 
Fe(III) generated in situ from Fe(VI) reduction and Fe(VI) was proposed to reacting with 
the total amount of these two types of Fe(III), whereas Eqs. 11b -11f indicated Fe(VI) was 
only reacted with the newly added Fe(III) but not with the Fe(VI)-resultant Fe(III). 
Moreover, Eqs 11b and 11c proposed the reaction between Fe(VI) and Fe(III) to generate 
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two different Fe(IV) species, monomeric Fe(IV) (FeIVO3
2-), and dimerized Fe(IV) 
(Fe2
IVO6
4-), respectively. Eq. 11d proposed the reaction between Fe(VI) and Fe(III) to 
generate Fe(V). Eq. 11e proposed that Fe(V) would be the dominant oxidant to react with 
Fe(III) to generate Fe(IV), whereas Eq. 11f proposed the reaction Fe(VI) with Fe(III) to 
produce equal proportions of Fe(V) and Fe(IV) at the same time. All the equations 
discussed above covered all the possible and credible reaction scenarios between Fe(VI) 
and Fe(III). Then, Simbiology, a kinetic simulation tool in MATLAB, was utilized to 
derive the proposed rate constants via non-linear least-square regression to find the best fit 
for Fe(VI) self-decay profile shown in Figure 5.1.  
 
Table 5.2 Reactions in Fe(VI)-Fe(III)-Substrate system at pH 9.0 
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2-  + 2 FeIII(OH)3(aq) [generated from eqs. 
1-10] + 4 OH- → 3 FeIVO3







[11b]   FeVIO4
2-  + 2 FeIII(OH)3(aq) [ newly added 
Fe(III) salts] + 4 OH- → 3 FeIVO3





[11c]     FeVIO4
2-  + 2 FeIII(OH)3(aq) [ newly added 
Fe(III) salts] + 4 OH- → 1.5 Fe2
IVO6







[11d]    2 FeVIO4
2-  +  FeIII(OH)3(aq) [ newly added 
Fe(III) salts] + 2 OH- → 3 HFeVO4
2-+  H2O 




[11e]     HFeVO4
2-   +  FeIII(OH)3(aq) [ newly added 
Fe(III) salts] + 2 OH- → 2 FeIVO3
2- + 3 H2O 
5×10
8




[11f]     FeVIO4
2-  +  FeIII(OH)3(aq) [ newly added Fe(III) 
salts] + 2 OH- →  FeIVO3
2- +  HFeVO4
2- + 2 H2O 









(aq) + P12  k12  
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Note:  
1. Since there was limited information about Fe(IV) speciation, FeIVO32- is the proposed 
chemical formula of Fe(IV) and reactions 3-6 and 8 from previous work are modified 
accordingly in this study.  
2. In Equation 11b-11f, FeIII(OH)3(aq) was denoted for the newly added ferric salts, which 






   As shown in Figure 5.2, the best fitting scenario was originated from Eqs 11b, which 
indicated that Fe(VI) will only react with the newly added Fe(III) to generate monomeric 
Fe(IV), which agreed with that proposed in Jiang’s study.89 This newly added equation and 
proposed k11b (2.67×10
4 M-2s-1) could successfully simulate the Fe(VI) self-decay at 
different  Fe(III) levels, which help validate the proposed Fe(VI)-Fe(III) system. 
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Figure 5.2 Kinetic simulation of Fe(VI) decay at different level of Fe(III) based on 
Eq.11a (A), Eq.11b (B), Eq.11c (C), Eq.11d (D), Eq.11e (E) and Eq.11f (F). 
(Experimental conditions: [Fe(VI)] = 100.0 µM, [borate buffer] = 2.0 mM, and 






























5.3.3 Fe(III) Effect on Pharmaceuticals Removal in Fe(VI)-Fe(III) System 
In Figure 5.3, the removal of ATL degradation was observed to increase as Fe(III) 
concentration was increased, and this can be attributed to the oxidizing species (i.e., 
Figure 5.3 Removal of ATL by Fe(VI)/Fe(III) system at pH 9.3. (Experimental 
conditions: [ATL] = 5.0 µM, [Fe(VI)] = 100.0 µM and [borate buffer] = 2.0 mM). 
Fe(V)/Fe(IV)) generated from the Fe(VI)-Fe(III) system that can help facilitate the 
degradation of ATL. Similar enhancement effects were also found in the degradation of 
SMX and DCF in the Fe(VI)-Fe(III) system,118, 120 which confirmed the role of  high-valent 
iron intermediate species (i.e., Fe(V) and Fe(IV)) in the Fe(VI)-Fe(III) system exhibiting 
higher reactivity towards the substrates compared to Fe(VI). 
          The role of Fe(V)/Fe(IV) species in the oxidation of substrates by the Fe(VI)-Fe(III) 
system was investigated by oxidizing PMSO as a probing compound. High-valent iron 
species could selectively oxidize PMSO to PMSO2.
123 The Fe(VI) solutions were first 
mixed with PMSO, followed by addition of Fe(III) at varied concentrations. Formation of 
PMSO2 was seen and the conversion of PMSO to PMSO2 was stoichiometric (data not 
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shown). This suggests that Fe(V)/Fe(IV) species are responsible for enhancing the removal 
of pollutants by the Fe(VI)-Fe(III) system.  
         However, the oxidizing species is most likely Fe(IV) as the Fe(VI)-Fe(III) model 
suggested that the newly added Fe(III) can react with Fe(VI) to generate Fe(IV). 
Meanwhile, Fe(V) evolution profile in the Fe(VI)-Fe(III) system was found to be 
insignificant in the aspect of life-time and concentration compared to those of Fe(IV).  
5.3.4 Kinetic Modelling of Fe(VI)-Fe(III)-Substrate System (Eqs. 1-13) 
     In order to fully understand the interactions between the substrate and high-valent iron 
species (Fe(VI), Fe(V), and Fe(IV)), eqs. 12 -13 (Table 5.2) were added into the Fe(VI)-
Fe(III) system to represent oxidation of substrate by Fe(VI) and Fe(IV), respectively. Fe(V) 
oxidation of the substrates was not considered owing to the short life-time and very low 
concentration (< 9.5×10-10 M) of Fe(V) in the Fe(VI)-Fe(III) system, which rendered Fe(V) 
a less viable oxidant to promote the degradation of the substrates.       
In the kinetic simulations, the derived k12 and k13 values could successfully predict the 
degradation of ATL at varied Fe(III) level as shown in Figure 5.4, which further validated 
the involvement of Fe(IV) as the major reactive species as well as the robustness of the 
proposed Fe(VI)-Fe(III)-Substrate model. Moreover, the results also indicated the Fe(VI)-
Fe(III)-Substrate system can provide an ideal environment to investigate the reactivity and 





Figure 5.4 Kinetic simulation of ATL degradation in Fe(VI)-Fe(III) system at pH 9.3. 
(Simulation conditions: [ATL] = 5.0 µM, [Fe(VI)] = 100.0 µM and [borate buffer] = 
2.0 mM). 
5.3.5 Preliminary Assessment of Structure-Activity Relationship   
Based on the developed Fe(VI)-Fe(III)-substrate kinetic model, 18 different kinds of 
substrates were chosen to investigate the Fe(IV) reactivity towards these substrates with 
structures of different organic functional groups (Table 5.3). Firstly, the observed 1st-order 
rate constants (kobs in s
-1) were determined from experiments with the presence and absence 
of 200.0 µM Fe(III) ([substrate]0 = 5.0 µM, [Fe(VI)]0 = 100.0 µM, [Fe(III)]0 = 0 or 200.0 
µM, pH = 9.0). Then, the values of k12 and k13 (in M
-1s-1) were derived based on the 
substrate degradation profile in the presence/absence of 200.0 µM Fe(III) in the Fe(VI)-
[ATL] (M) 
k12= 0.5 M-1s-1 










Fe(III)-Substrate kinetic modelling. The derived rate constants of the substrates are shown 
in Table 5.3. 
   Interestingly, 5 substrates (IBU, KET, BA, CBZ, and CA) were found to be not 
reactive in neither the Fe(VI)-only or  Fe(VI)-Fe(III) systems. This could be explained by 
the ionization potential (IP) values of these compounds which were found to be the highest 
(0.271-0.340) among the 18 substrates chosen in the study. IP value refers to the energy 
required to remove an electron from a molecule, so it is expected that a higher IP value 
results in stronger resistance to oxidation. Moreover, Ye and co-workers261 found that there 
was a strong correlation between Fe(VI) reactivity and IP value of compounds (kapp = 34.7 
– 4.8× IP) which supported our assumption for the 5 non-reactive substrates observed in 
the Fe(VI)-only and Fe(VI)-Fe(III) systems. 
      
Table 5.3 Summary of observed 1st-order rate constants and derived 2nd-order rate 
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      To further understand the trend of reactivity observed from the 13 different compounds, 
the relationships of ln(k13) and k13 with 29 descriptors of the compounds (28 molecular 
descriptor in Table 5.4 and 2 additional descriptors of ln(k12) and k12) were evaluated. First, 
correlation analysis (CA) between ln(k13) and individual descriptors was performed. With 
a cut-off r = 0.5, #N (r = - 0.57), #N:C (r = -0.52), #N:O (r = -0.51), #OH(r = 0.70), ln k12 
(r = 0.75) and k12 (r = 0.83) showed strong correlation with ln(k13). Within the 6 descriptors 
selected by CA, 4 equations were obtained  via linear regression as shown in Table 5.5. 
Secondly, correlation analysis between k13 and individual descriptors was performed. With 
a cut-off r = 0.5, #N (r = - 0.50), #OH(r = 0.74), ln(k12) (r = 0.70) and k12 (r = 0.99) showed 
strong correlation with k13. Within the 4 descriptors selected by CA, 3 equations were 
obtained via linear regression as shown in Table 5.6. 
        It is important to point out that the statistical criteria for a good model, such as R2 (> 
0.5), F (> 15), and p (< 0.01) were not fully met in the above equations due to the relatively 
small training set (i.e., 13 substrates). Thus, future research is required to include a wider 
variety of compounds in order get a more comprehensive and validated structure-activity 
relationship. However, the preliminary assessment of the structure-activity between 30 
descriptors and Fe(IV) reactivity strongly suggested that Fe(IV) reactivity is strongly 
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dependent on its Fe(VI) counterpart’s reactivity to the substrates, and it is possible to utilize 
the widely available Fe(VI) reactivity data in the literature to predict Fe(IV) reactivity to 
organic substrates. Moreover, Fe(IV) reactivity is strongly correlated to N-atom related 
descriptors, which is not surprising since previous literature suggested that the high-valent 
intermediate iron species (Fe(V) and Fe(IV)) are inclined to attack amine-related function 
groups in aromatic compounds.167, 262-264 
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Table 5.4  The 27 QSAR descriptors used in this study ad were calculated using 

























1 lnk13 = 0.01684*k12 -10.74019 0.6838 23.79 0.0005 
2 
lnk13 = 0.01469*k12 - 0.58041*#N:C - 
11.34260 
0.7405 14.27 0.0012 
3 
lnk13 = 0.00943*k12 - 0.62172*#N:C + 
0.21194*lnk12 - 11.59139 
0.8023 12.17 0.0016 
3 
lnk13 = 1.01586*#OH - 0.41282*#N:C 
+ 0.34055*lnk12 + 11.27207 
0.825 14.14 0.0009 
# of 
Parameters Equation R² F value 
P 
value 
1 k13 = 17721*k12 - 37026 0.9993 16025.5 0.0001 
2 k13 = 17593*k12 - 13141*#N + 73344 0.9995 9714.16 0.0001 
3 
k13 = 117434*k12 - 9980.69234*#N + 
30402*#OH + 57264 
0.9996 6977.17 0.0001 
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5.4 Conclusions 
The Fe(VI)-Fe(III) reaction system was investigated to evaluate the enhancement 
effect of ferric ion on Fe(VI) self-decay at pH 9.0. The Fe(VI)-Fe(III) kinetic model 
was constructed to successfully characterize the accelerating effect of Fe(III) on 
Fe(VI) self-decay by expanding the Fe(IV)-based Fe(VI) self-decay kinetic model at 
pH 9.0 developed previously. Furthermore, the Fe(VI)-Fe(III)-Substrate kinetic 
model was constructed to evaluate the enhanced effect of ferric ion on Fe(VI) 
oxidation on 18 pharmaceuticals. The structure-activity relationships between 
compounds’ molecular descriptors and 2nd -order rate constants with Fe(IV) derived 
from the Fe(VI)-Fe(III)-Substrate system modeling were assessed. The preliminary 
assessment indicated that Fe(IV) reactivity is strongly related to N-atom related 
descriptors as well as its counterpart Fe(IV)’s reactivity.  While the preliminary 
assessment is insightful, more research is needed to build a more comprehensive and 





CHAPTER 6. KINETIC INVESTIGATION OF FE(VI) 
OXIDATION MECHANISMS: FE(VI)-ABTS SYSTEM  
6.1 Abstract 
     To quantitatively probe iron intermediate species (Fe(V)/Fe(IV)) in Fe(VI) oxidation, 
this study systematically investigated the reaction kinetics of Fe(VI) oxidation of 2,2'-
azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) at different ratios of 
[ABTS]0/[Fe(VI)]0 (i.e., >1, =1, and <1) in pH 7.0 phopshate (10 mM) buffered solution. 
Compared to literatures, a more comprehensive and robust kinetic model for the Fe(VI)-
ABTS system including interactions between high-valent iron species (Fe(VI), Fe(V), and 
Fe(IV)), ABTS and ABTS●+ radical was proposed and validated. The oxidation of ABTS 
by Fe(VI) (k = (5.96±0.9%)×105 M-1s-1), Fe(V) (k = (2.04±0.0%)×105 M-1s-1) or Fe(IV) (k 
= (4.64±13.0%)×105 M-1s-1) proceeds via one-electron transfer to generate ABTS●+, which 
is subsequently oxidized by Fe(VI) (k = (8.5±0.0%)×102 M-1s-1), Fe(V) (k = 
(1.0±40.0%)×105 M-1s-1) or Fe(IV) (k = (1.9±17.0%)×103 M-1s-1) via two-electron (oxygen 
atom) transfer to generate colorless ABTSox. At [ABTS]0/[Fe(VI)]0  > 1, experimental data 
and model simulation both indicated the reaction stoichiometric ratio of Fe(VI):ABTS●+ 
increased from 1:1 to 1:1.2 as [ABTS]0 was increased. Furthermore, the Fe(VI)-ABTS-
Substrate model was developed to sucessfully determine reactivity of Fe(V) to different 
subtrates (k = (0.7-1.42)×106 M-1s-1). Overall, the improved Fe(VI)-ABTS kinetic model 
provides a useful tool to quantitatively probe Fe(V)/Fe(IV) behaviors in Fe(VI) oxidation 
and gains new fundamental insights. 
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6.2 Introduction 
 Over the past decade, Fe(VI) has emerged as a novel oxidant to remove 
contaminants and micropollutants from water.196, 249 While numerous studies have been 
conducted to evaluate the performance of Fe(VI) in removing different contaminants, 
relatively limited efforts have been devoted to understanding the mechasims of Fe(VI) 
oxidation reactions that involve iron intermediate species (i.e., Fe(V) and Fe(IV)) 
generated via one- or two-electron transfer pathways.105-106 Recently, researchers have 
focused on the discovery of activated-Fe(VI) systems in which activitors (e.g., ammonia,111 
acid,112-113 sulfite/thiosulfate,114-116 bicarbonate,117 Fe(II)/Fe(III),118 Mn(II)120 and carbon 
nanotube121) can enhance the degradation of substrates or even facilitate the removal of 
substrates resistant to Fe(VI) oxidation. However, the previous work heavily relied on 
qualitative analysis of possible reactive species formed in-situ (radical vs. Fe(V)/Fe(IV)) 
via quencher experiments and/or electron paramagnetic resonance (EPR) spectroscopic 
techniques, and only limited studies122-123 have attempted to quantitatively investigate the 
kinetic behaviors of Fe(V)/Fe(IV) for their self-decays vs. oxidation of substrates.  
         The previous studies, even though having managed to predict the Fe(V)/Fe(IV) 
reactivity to the substrates based on a simplified Fe(VI)-activator system, were unable to 
further precisely describe the Fe(V)/Fe(IV) behaviors. The limitation was mainly due to 
the difficulty in quantifying the possible chain reactions between iron species and 
activators, which required the accurate measurement of activator-based radicals (e.g., 
S2O3
●2-,  SO3
●- , and SO4
●-)143 formed by one-electron transfer from Fe(VI). Comparatively,  
2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) can be oxidized by Fe(VI) 
to generate a persistent green-colored radical, ABTS●+, that can be easily measured by 
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spectrophotometric measurement with high sensitivity.164 This Fe(VI)-ABTS system could 
provide a tool to delineate the generation and fate of iron intermediate species Fe(V)/Fe(IV) 
in aqueous solution as it has been successfully utilized to explore Fe(V) reactivity under 
different buffer solutions (borate, phosphate,122 and bicarbonate117). 
       ABTS has been used in quantitative determination of several oxidants (e.g., 
percarboxylic acid,162 bromine, chlorine,163 Cr(VI),265 and Mn(VII)266-267) because the 
colorless ABTS can quickly react with these oxidants via one-electron transfer to yield 
green-colored ABTS●+ (Eq. 6.1). The generated ABTS●+ can be further oxidized to ABTS2+ 
(Table 6.1) (Eq. 6.2) via one-electron transfer by excess oxidants (e.g., Ce(IV), Cr(VII) 
and Mn(VII)) in the presence of acid.268 It is also possible ABTS●+ can be further oxidized 
to colorless sulfoxide/sulfone-containing products (Eq. 6.3) via the oxidation of sulfur 
moiety in ABTS●+ (Table 6.1) by certain oxidants (e.g., H2O2, peroxomonosulfate, and 
peroxodiphospshate).269 Meanwhile, it was  reported that chlorine270 could oxidize ABTS●+ 
via consecutive electron transfers to form transient ABTS2+ intermediates via one-electron 
transfer, which can be further rapidly oxidized to colorless products (Eq. 6.4) .  
ABTS –→  ABTS●+ + 
 e-                                                                                                                                                 (6.1)       
ABTS●+ → ABTS2+ + 
 e-  
                                                                                                                                             (6.2)           
ABTS●+ → ABTSox(colorless) 
                                                                                                                                                     (6.3)      
ABTS●+ → [ABTS2+]intermediate→ ABTSox(colorless) 
                                                                                                   (6.4)                                                                                                                                                                                                                                                                                              
       The Fe(VI)-ABTS system was initialy proposed as a new method to determine the low 
concentration of Fe(VI) using excess ABTS under a reaction stoichimetric ratio of 1:1 
between Fe(VI) and ABTS●+.164 The reaction kinetics between Fe(VI) and ABTS 
generating Fe(V) and ABTS●+ ([ABTS]0/[Fe(VI)]0 > 10) was then explored by a stopped-
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flow spectroscopy,145 which could capture the rapid formation of colored ABTS●+ and 
determine the reaction rate constant via pseudo-first-order fitting. The stoichimetric ratio 
of 1:1:1 among Fe(VI), ABTS, and ABTS●+ was also confirmed.145 Later, ABTS was used 
as an activator to enhance the degradation of diclofenac by Fe(VI) ([ABTS]0/[Fe(VI)]0 < 
0.2) and the enhancement was attributed to the faster oxidation by ABTS●+ formed in-
situ.119 Recently, Fe(VI)-ABTS system at [ABTS]0/[Fe(VI)]0 = 1 was proposed to be a 
Fe(V)-only system based on the assumption that there were negigible reactions between 
Fe(V)/Fe(IV) and ABTS●+.271 However, the kinetic information of reactive intermediate 
species (i.e., Fe(V), Fe(IV), ABTS●+ and  ABTS2+) in Fe(VI)-ABTS system was still 
missing. 
Therefore, on the basis that Fe(VI)-ABTS can be a useful system to evaluate 
Fe(V)/Fe(IV), the objective of this study was to formulate and validate an improved 
comprehensive model for the Fe(VI)-ABTS system that can quantitatively describe the 
kinetic behaviors of Fe(V)/Fe(IV) at a broad range of [ABTS]0/[Fe(VI)]0 ratios. New 
experimental data were obtained by monitoring ABTS/ABTS●+ evolution profiles by the 
stopped-flow spectroscopy due to the fast reactions. Simulations from the kinetic model 
were also compared with results from previous literatures122, 145, 271 at different reaction 
conditions. Finally, the Fe(VI)-ABTS-Substrate system was proposed to probe the 
reactivity of Fe(V) to three substrates (carbamazepine (CBZ), propranolol (PPL), and 
methyl phenyl sulfoxide (PMSO)) based on experimental data from a previous study.271 
From this work, new insights were gained by the improved kinetic simulation of 
Fe(V)/Fe(IV) in the Fe(VI)-ABTS system, which helped clarify some inconsistencies in 
previous studies. 
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6.3 Materials and Methods 
6.3.1 Chemicals and Reagents  
2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) and potassium 
peroxydisulfate (PDS) was purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Potassium ferrate(VI) (K2FeO4) was synthesized by a wet chemical method 
195-196 with high 
purity (98%) in Dr. Virender Sharma’s lab at Texas A&M University (TAMU) and shipped 
to Georgia Tech (GT). All chemicals were of 97% or greater in purity and used directly 
without further purification. Reagent-grade deionized (DI) water (resistivity > 18 mΩ∙cm) 
was prepared from a Nanopure Millipore (Billerica, MA) water purification system. 
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6.3.2 Oxidation of ABTS by Fe(VI)  
Reaction kinetics between Fe(VI) and ABTS at varied [Fe(VI)]0/[ABTS]0 molar ratios 
at pH 7.0 were captured by a stopped-flow spectrophotometer that supported millisecond 
acquisition rates and was equipped with a UV-vis detector (The Olis RSM 1000). Fe(VI) 
solutions were freshly prepared in 0.2 mM borate buffer (pH > 9.2) at varied concentrations 
of 11−100 M while ABTS solutions were freshly prepared in 20 mM phosphate (pH = 
6.95) at varied concentrations of 11−400 M. To achieve a desired [Fe(VI)]0/[ABTS]0 
ratio, different concentrations of Fe(VI) and ABTS solutions were rapidly mixed in a 1:1 
volumetric ratio to initiate the reaction and the stopped-flow spectrophotometer was 
operated at the scan rate of 1 ms/scan (0−3.8 s), 16 ms/scan (0−5 s), or 32 ms/scan (0−50s) 
for the different reaction durations. Solution pH was confirmed separately by a pH meter 
(Accumet Research AR 20) from mixing equal volumes of Fe(VI) (pH 9.2) and ABTS 
solution (pH 6.95), and the final pH was consistently at 7.0±0.05. 
 At the lower concentrations of ABTS (<100 µM), the formation of ABTS●+ and the 
consumption of ABTS were determined by monitoring the absorbance at 415 nm 
(εABTS●+,415nm = 3.4×10
4 cm-1 M-1) and 340 nm (εABTS,340 nm = 3.66×10
4 cm-1; εABTS●+,340 nm 
= 5.9×103 cm-1 M-1), respectively, and their concentrations were calculated based on a 
previous study.122 At the higher concentrations of ABTS (150 and 200 µM), only the 
formation of ABTS●+ was measured due to absorbance at 340 nm being too strong. The 
initial concentration of Fe(VI) prior to the experiment was determined by its absorbance at 
510 nm (εFe(VI),510nm = 1.15×10
3 cm-1 M-1) using a UV-vis spectrophotometer.  
6.3.3 Oxidation of the Mixture of ABTS and ABTS●+ by Fe(VI).  
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A mixed solution of ABTS and ABTS●+ was prepared by incomplete oxidation of 
ABTS by peroxydisulfate (PDS) ([ABTS]0/[PDS]0 = 2) which had ~34% yield rate of 
ABTS●+ in our study, in agreement with the yield rate in a previous study.272  Reaction 
kinetics of Fe(VI) oxidation of the mixture of ABTS and ABTS●+ were studied following 
the similar procedures as described above. 
6.3.4 Kinetic Simulation 
The kinetic simulation was conducted by using the SimBiology version 5.7 in 
MATLAB 2018.  
Parameter Estimation: Based on the available values, the “Scan” task in SimBiology 
was deployed to guess the proposed k values manually, and then the predict k values with 
standard error was refined by using the “Fit Data” task via the least-square non-linear 
regression with constant error model. 
Model Validation: The goodness-of-fit between simulated and experimental values was 
quantified by calculating the Theil’s inequality coefficient (TIC),197  the normalized root 
mean square error (NRMSE), and the model efficiency (ME)273 which 
are expressed as follows, 
𝑇𝐼𝐶 =   
√∑ ( 𝑦𝑖 − 𝑦𝑖,𝑚)2𝑖
√∑ 𝑦𝑖
2











𝑀𝐸 =   1 −
∑ ( 𝑦𝑖 − 𝑦𝑖,𝑚)
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where yi represents the simulated data points; yi,m represents the measured data points; n 
represents the number of observed values; yM represents the average of the simulated data 
points; ymax represents the maximum of the measured data points; ymin represents the 
minimum of the measured data points.  
A value of the TIC lower than 0.3,198-200  and a value of ME closer to 1.0,273-274 indicate 
a good agreement between the model prediction and the measured data. 
Sensitivity Analysis: The local sensitivity analysis of all k values on all the species 
under the different reaction conditions were performed using “Sensitivity Analysis” task 
with “Full” normalization to evaluate if all k values are influential and which of them are 
most significant at certain reaction conditions. During the local sensitivity analysis, the 







, where Ci is the 
concentration of species i; kj is the reaction rate constant of reaction j; and t is the time 
point. To measure the impact of one specific reaction rate constant, kj, on a particular 







𝑡 , by summing all the 
time-dependent coefficients over the reaction time. To measure the impact of one specific 
reaction rate constant, kj, on all the species, the overall sensitivity coefficient was calculated 







𝑡𝑖 , by summing all the time-dependent coefficients of all species over the 
reaction time. The higher sensitivity coefficient indicates this reaction rate constant is more 
dominant in the evolution of certain species or overall simulation results.275-276 
6.4 Results and Discussion 
6.4.1 Kinetic Simulation of Fe(VI) Self-Decay System (Eqs. 1−8) at pH 7.0 
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      Fe(VI) self-decay at pH 7.0 has been carefully examined in the study by Lee et al.145 
and a kinetic model including Eqs. 1−7 was proposed (Table 6.2). This kinetic model was 
able to accurately predict the Fe(VI) decay as well as H2O2 generation when initial Fe(VI) 
concentration ranged from 10 to 310 µM in phosphate buffered solution. As described 
previously,145 Eq. 1 represents the initiation of Fe(VI) decay in which dimerization of two 
mono-Fe(VI) occurs to produce two Fe(IV) and two H2O2. The formed Fe(IV) can continue 
to react with H2O2 to produce Fe(II) and O2 (Eq. 2) via a concerted two-electron transfer 
pathway. On the other hand, Fe(VI) can also react with newly generated Fe(II) from Eq. 2 
to yield Fe(V) and Fe(III) (Eq. 3). Fe(V) can undergo self-decomposition via 1st (Eq. 4) 
and 2nd (Eq. 5) order decays, as well as reaction with H2O2 (Eq. 6). Eq. 7 represents Fe(VI) 










Table 6.2  Proposed reactions in the Fe(VI)-ABTS-Substrate system (Substrate = PMSO, PPL, and CBZ). 
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Figure 6.15C 















 is the proposed chemical formula of Fe(IV). 
             3. Eqs. 1-7 were based on Lee’s study145 
             4. N.A. = Not Available. 
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However, Fe(IV) decay was ignored in the previous model by Lee et al. due to very limited 
available kinetic information.145 Other research has reported that the Fe(IV) species can 
undergo di-molecular decay to generate Fe(III) and H2O2
  at a rate constant around 106 M-
1s-1 based on the kinetic study of Fe(IV)-pyrophosphate by the pulse radiolysis at pH 
10.0.173 Therefore, we added Eq. 8 to present this additional sink for Fe(IV) species (Table 
6.2). According to the sensitivity test of k8 (Figure 6.1) in Fe(VI) self-decay system (Eqs. 
1−8), Fe(VI) decay and H2O2 generation were independent of the magnitude of k8 ranged 
from 0 to 103 M-1s-1, which indicated a narrower range of k8 at pH 7.0 and provided a more 


















Figure 6.1 Sensitivity test of k8 in Fe(VI) decay system (Eqs. 1-8) at different Fe(VI) 
concentrations. (A) [Fe(VI)]0 = 10.0 µM, (B) [Fe(VI)]0 = 310.0 µM. Symbols: measured 
data recreated from Lee’s study in Figure 6; Line: model simulation using equation 1-




6.4.2 Kinetic Formulation of Fe(VI)-ABTS System (Eqs. 1−14) at pH 7.0   
We added Eqs. 9−14 (Table 6.2) into the Fe(VI) self-decay system to represent the 
possible interactions between high-valent iron species (Fe(VI), Fe(V), and Fe(IV)) and 
ABTS species (ABTS and ABTS●+). Eqs. 9−11 represent ABTS oxidation by Fe(VI), 
Fe(V), and Fe(IV), respectively, via one-electron transfer pathway to generate ABTS 
cation radical (ABTS●+), which were confirmed by previous studies.122, 145  Lee et al.145 
confirmed the 1:1:1 stoichiometric ratio for Fe(VI):ABTS:ABTS●+ in Eq. 9 and Huang et 
al.122 confirmed the contribution of Fe(V) and Fe(IV) in Fe(VI)-ABTS system via kinetic 
modelling. Eqs. 12−14 represent further oxidation of ABTS●+ by Fe(VI), Fe(V), and 
Fe(IV), respectively, likely via oxygen transfer pathway to generate colorless products 
(ABTSox) by attacking the sulfur moiety of ABTS
●+. This statement was confirmed by the 
study by Xue et al.271 in which colored product ABTS2+, that could be generated from 
ABTS●+ via one-electron transfer, could not be found in the reaction between Fe(VI) and 
ABTS●+. The observed exponential decay of ABTS●+ and linear relationship between the 
calculated kobs vs. [Fe(VI)]0 confirmed the first-order dependence on [ABTS
●+] and 
[Fe(VI)] in Xue’s study,271  which validated the proposed Eq. 12 in Fe(VI)-ABTS system. 
It is reasonable to assume Fe(V) and Fe(IV) can display similar oxidation mechanism (Eqs. 
13−14) to Fe(VI) since high-valent iron species (e.g., Fe(IV),210-212, 278 Fe(V),213 and 
Fe(VI)214, 278) are known to convert sulfides and sulfoxides to corresponding sulfoxides and 
sulfones via oxygen atom transfer or two-electron transfer.  
H2O2 generated from Fe(VI) self-decay could possibly react with ABTS/ABTS
●+ 
species. However, ABTS oxidation by H2O2 was usually catalyzed in the presence of 
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peroxidase (e.g., lactoperoxidase280 and horseradish peroxides281) or acid,269 and oxidation 
of ABTS●+ by H2O2 was reported to be minimal in the absence of acids.
269 Thus, the 
contributions of these reactions were not considered in Fe(VI)-ABTS system due to the 
reaction condition applied in this study (i.e., pH 7.0 with no peroxidases). 
         In order to estimate the rate constants k9−k14, two different reaction conditions 
([ABTS]0/[Fe(VI)]0 > 1 vs. [ABTS]0/[Fe(VI)]0 < 1) were employed to probe k9−k11 and 
k12−k14, respectively. 
6.4.2.1  [ABTS]0/[Fe(VI)]0 > 1 (Eqs. 1−11)  
By creating reaction conditions where [ABTS]0 was 8.6−36 times of [Fe(VI)]0, the 
contribution of Eqs.12−14 in influencing ABTS●+ generation profile could be negligible 
since Fe(VI) was expected to only react with ABTS in such conditions, which was 
supported by sensitivity analysis discussed later in Table 6.11. By deploying the least-
square non-linear regression with constant error model in SimBiology, k9−k11 were 
successfully derived as shown in Table 6.2 and Figure 6.2. According to the statistical 
analysis (ME = 0.997 and NRMSE = 1.41×10-2) of the experimental and simulated ABTS●+ 
concentrations (Figure 6.3) and goodness-of-fit based on the TIC (0.01−0.03) (Table 6.3), 
the predicted values for k9−k11 could successfully capture ABTS
●+ evolution in excess 
ABTS condition within 0.8 s.  
It should be noted that the experimental value of k9 between Fe(VI) and ABTS was 
reported to be 1.2×106 M-1s-1 at pH 7.0 via pseudo-first-order kinetic fitting, which was 
~1.8 times of the simulated rate constant (5.96×105M-1s-1) obtained from kinetic modeling 
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of this study. The main reason for this discrepancy could be explained by the simplified 
reaction (i.e., only between Fe(VI) and ABTS) considered in experiments conducted by 
Lee et al.145 and Dong et al.119 which could possibly overplay the role of Eq. 9 in ABTS●+ 
generation as Eqs.10−11 could also contribute to ABTS●+ generation from the oxidation of 
additional ABTS by Fe(V) and Fe(IV). It’s also necessary to point out that the study by 
Huang et al.122 reported the modelled k value of 1.1×106 M-1s-1 between Fe(VI) and ABTS 
in 10 mM phosphate buffer based on a kinetic model including Eqs. 2, 4, 5, 9, 10, and 11.  
       Moreover, a linear relationship between log k (1-e- transfer) and the one-electron 
standard reduction potential (E(1)
0) (log k(1-e-) = 6.39 (±0.05) – 1.83 (±0.04)  E(1)
0) was 
initially developed based on the reactions between HFeO4
- and six inorganic compounds105 
via 1-e- transfer pathway and later expanded to the k between HFeO4
- and six organosulfur 
compounds282 by Sharma and co-workers. By utilizing this robust equation, k9 was 
predicted to be 4.7×105 M-1s-1 based on E(1)
0 = 0.43 V for ABTS/ABTS●+,268 which was 
closer to the modelled value (5.96×105 M-1s-1) in this study. This result further suggests 






















Figure 6.3 Statistical analysis between the simulated and observed data from Figure 
1. Slope referred to the red line, derived from linear regression of the simulated and 
observed values. 
 
Figure 6.2 Kinetics of Fe(VI) oxidation of excess ABTS: [ABTS]0 = (A) 150.0 µM 
and (B) 200.0 µM. Symbols: average value of parallel measurements with error bars 
representing one standard deviation (too small) and only selected data points shown 
to improve visibility; Line: model simulation. Experiments: n = 3, pH = 7.0, 10.0 










































Figure 6.4 Two-stage kinetics of excess Fe(VI) oxidation of ABTS: [Fe(VI)]0 = (A) & 
(B) 30.0 µM and (C)&(D) 50.0 µM. Solid (ABTS) and open (ABTS●+) symbols: average 
value of parallel measurements with error bars representing one standard deviation 
(too small) and only selected data points shown to improve visibility; Line: model 
simulation. Experiments: n = 2, pH = 7.0, 10.0 mM phosphate buffer, and 25.0 C. 
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6.4.2.2 [ABTS]0/[Fe(VI)]0 < 1 (Eqs. 1−14) 
By creating reaction conditions where [Fe(VI)]0 was 2−6 times of [ABTS]0, the 
contribution of k12−k14 can be quantitatively evaluated by incorporating the subsequent 
reactions between high-valent iron species and ABTS●+ (Eqs.12−14). Following a similar 
fashion, k12−k14 were successfully derived as shown in Table 6.2 and Figure 6.4. 
According to the statistical analysis (ME = 0.989−0.992 and NRMSE = 1.53×10-
2−3.21×10-2) of the experimental and simulated ABTS●+ concentrations (Figure 6.5) and 
goodness-of-fit based on the TIC (0.02−0.07) (Table 6.3), the derived values for k12−k14 
could successfully predict ABTS●+ formation in the beginning (0 to 1.2 or 2.0 s) and its 
subsequent decomposition later (0−50 s).  
The reaction of ABTS with excess Fe(VI) followed two-stage oxidation with rapid 
generation of ABTS●+ in the first stage and further slow degradation of ABTS●+ in the 
second stage, which was also suggested by Xue’s study.271 The proposed Fe(VI)-ABTS 
model by our study further confirmed this assumption where k9 controlled the ABTS
●+ 
generation in the first 0.2 seconds while k12 controlled the subsequent ABTS
●+ degradation 
in the following reaction time until 50 seconds as the sensitivity analysis showed in Table 
6.11. 
Even though the apparent rate constant between Fe(VI) and ABTS●+ was reported to 
be 2.33×103 M-1s-1, 271 which is ~2.7 times of simulated value (8.5×102 M-1s-1) in our study, 
it can be ascribed to the  reaction solution of ABTS●+ generated in Xue’s study.271 In Xue’s 
study,271 ABTS●+ solution was prepared by dissolving 7.0 mM ABTS with 2.45 mM 
potassium persulfate (PDS), resulting in incomplete oxidation of ABTS since the 
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stoichiometric ratio between PDS and ABTS is 1:2.272 Thus, it is reasonable to assume 
Fe(VI) was oxidizing ABTS and ABTS●+ simultaneously in Xue’s study, where the 
apparent k2nd  between Fe(VI) and ABTS
●+ was likely overestimated owing to elevated 
ABTS●+ concentration existed by fast conversion of ABTS to ABTS●+ in the first stage. 
This can also be supported by experimental and simulated data of Fe(VI) oxidation of a 
mixture of ABTS and ABTS●+ generated from PDS/ABTS solution in our study as 




Slope = 0.97  
ME = 0.992 
NRMSE = 1.53×10-2 
 
 
Slope = 0.99  
ME = 0.989 
























Figure 6.5 Statistical analysis between simulated and observed data based on Figure 
6.4. Slope referred to the red line, derived from linear regression of the simulated 




Table 6.3 Correspondence between the measured and simulated data in Fe(VI) 













     200.0 
17.5 114 0.02 
888 0.02 
11.5 114 0.03 
7.6 114 0.02 
5.5 114 0.01 
Total 456 0.02 
150.0 
17.5 108 0.01 
11.5 108 0.01 
7.6 108 0.01 
5.5 108 0.02 







Table 6.4 Correspondence between the measured and simulated data in excess Fe(VI) 





















18 130 130 0.05 0.02 
1572 0.03 
12.5 130 130 0.05 0.03 
7.0 130 130 0.07 0.05 
Total 390 390 0.05 0.03 
30.0 
15.0 132 132 0.04 0.02 
10.5 132 132 0.03 0.02 
5.5 132 132 0.04 0.04 




Table 6.5 Correspondence between the measured and simulated data in Fe(VI) 














3.75 108 0.05 0.03 
864 0.01 
7.5 108 0.03 0.02 
11.25 108 0.03 0.01 
14.8 108 0.05 0.01 















Table 6.6 Correspondence between the measured and simulated data in Fe(VI) 
oxidation of the mixture of ABTS and ABTS
● + at pH 7.0 based on the Theil’s 
















15.0 12.0 21.0 96 0.05 0.01 0.02 





6.4.3 Model Validation of Fe(VI)-ABTS System (Eqs. 1−14) at pH 7.0 
As k9−k14 were derived from two reaction conditions ([ABTS]0/[Fe(VI)]0 > 1 and 
[ABTS]0/[Fe(VI)]0 < 1), additional reaction conditions were employed in experiments to 
generate data to further validate the robustness of those proposed rate constants. 
6.4.3.1 [ABTS]0/[Fe(VI)]0 = 1 (Eqs.1−14) 
When ABTS and Fe(VI) were set to the 1:1 stoichiometric ratio at concentration 
ranging from 3.75 to 14.8 µM, the proposed Fe(VI)-ABTS model (Eqs. 1−14) could 
successfully simulate ABTS●+ generation as well as ABTS degradation (Figure 6.6A) 
based on the statistical analysis (ME = 0.992−0.998 and NRMSE = 5.27×10-2−5.67×10-2) 
(Figure 6.7) and TIC (0.01−0.05) (Table 6.5). Moreover, the kinetic simulations by the 
Fe(VI)-ABTS model in this study generated very similar results compared to those in Xue’s 
study271 ([ABTS]0 = [Fe(VI)]0 = 20 µM and pH = 7.0) (Figure 6.9), which helped validate 






































Figure 6.6(A) Kinetics of reactions between equimolar Fe(VI) and ABTS; (B),(C) & 
(D) Kinetics of Fe(VI) oxidation of a mixture of ABTS and ABTS●+. Solid (ABTS) and 
open (ABTS●+) symbols: average value of parallel measurements with error bars 
representing one standard deviation (too small) and only selected data points shown 
to improve visibility; Line: model simulation. Experiments: n = 2, pH = 7.0, 10.0 mM 















Slope = 0.97  
ME = 0.992 
NRMSE = 1.53×10-2 
 
Slope = 0.99  
ME = 0.989 
























Figure 6.7 Statistical analysis between simulated and observed data based on Figure 
6.6A. Slope referred to the red line, derived from linear regression of the simulated 








Slope = 0.91  
ME = 0.991 













Figure 6.8 Statistical analysis between simulated and observed data based on Figure 
6.6 B-C. Slope referred to the red line, derived from linear regression of the simulated 




Slope = 0.93  
ME = 0.997 






Slope = 0.90  
ME = 0.997 
NRMSE = 3.36×10-2 
Slope = 0.91  
 ME= 0.985 
























6.4.3.2 Mixture of ATBS and ABTS●+(Eqs. 1−14)  
As shown in Figure 6.6B-D, the proposed Fe(VI)-ABTS model (Eq. 1−14) could 
successfully simulate ABTS●+ generation and ABTS degradation in Fe(VI) oxidation of a 
mixture of ABTS and ABTS●+ ([ABTS]0 = 21 µM and [ABTS
●+]0 = 12 µM), based on the 
statistical analysis (ME = 0.985−0.997 and NRMSE = 2.93×10-2−3.67×10-2) (Figures 6.8) 
and TIC (0.01−0.07) (Tables 6.6). In Figure 6.6B, the limited amount of Fe(VI) (15 µM) 
was expected to only oxidize ABTS in the mixture since k9 was 3 orders of magnitudes 
higher than k12 and [ABTS]0 was 1.75 times of [ABTS
●+]0, which was confirmed by the 
experimental data where ABTS●+ and ABTS reached their plateaus around 1 second when 
Fe(VI) was completely consumed (Δ[ABTS] = Δ[ABTS●+]). Interestingly in Figure 6.6C-
D, ABTS●+ generation and Fe(VI) (30 µM)  decomposition followed two-stage kinetics. In 
the first stage shown in Figure 6.6C (0−1 s), ABTS abruptly decreased to 0 while ABTS●+ 
increased to its maximum at 33 µM, where Fe(VI) was mainly consumed by ABTS. 
Subsequently in the second stage shown in Figure 6.6D (1−50 s), ABTS●+ was observed 
to decrease from 33 to 28.3 µM as modelled Fe(VI) concentration decreased from 9 µM to 
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   (B) 
 
   (B) 
Figure 6.9 Comparison of ABTS
●+ formation (415 nm) and ABTS decomposition 
(340 nm) in Fe(VI)-ABTS system at [ABTS]0/[Fe(VI)]0 = 1. (A) Simulation results 
based on the Fe(VI)-ABTS system in this study. (B) Experimental value taken 
from Xue’s study in Figure 1. Simulation and experimental conditions: [Fe(VI)]0 
= [ABTS]0 = 20 µM, pH = 7.0, 10 mM phosphate buffer, and t = 10 s. 
 
Figure 6.10 Reaction stoichiometries of Fe(VI) oxidation of ABTS. (A) Data from 
Figure 6.3 with excess ABTS than Fe(VI); (B) Data from Figure 6.4A with equimolar 
Fe(VI) and ABTS. 
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Overall, the proposed k9−k14 values were first derived from model fitting to experimental 
data under two distinctive reaction conditions ([Fe(VI)]0/[ABTS]0 >1 and 
[Fe(VI)]0/[ABTS]0 <1) and then were further utilized to predict the evolutions of ABTS 
and ABTS●+ under other reaction conditions (i.e., [Fe(VI)]0/[ABTS]0 = 1; mixture of ABTS 
and ABTS●+) with excellent agreement based on TIC (0.01−0.07), ME (0.989−0.997), and 
NRMSE(1.41×10-2−5.67×10-2). The robustness and accuracy of the kinetic model for the 
Fe(VI)-ABTS system enabled subsequent investigation of iron intermediate species 
(Fe(V)/Fe(IV)) in similar conditions. 
6.4.4 Sensitivity Analysis of Eqs. 1−14 in Fe(VI)-ABTS System at pH 7.0  
To evaluate the importance of k1−k14 to the simulation results of the kinetic model 
developed in this study, the local sensitivity analysis of each rate constant was performed 
to understand the sensitivity of the model to k1−k14 (especially the newly proposed k9−k14) 
under the four different reaction conditions mentioned above (Tables 6.7-6.10) and the 
resulted rankings are shown in Table 6.11. 
At [Fe(VI)]0/[ABTS]0 < 1, the most impactful rate constants were k4, k5, k9, k10, and k11. 
This confirmed the contribution of Fe(V) and Fe(IV) for ABTS●+ evolution and overall 
simulation results in Fe(VI)-ABTS, which was also supported by Huang’s study.122 
Meanwhile, it implied that it is feasible to probe k9−k11 under such reaction conditions. 
     At [Fe(VI)]0/[ABTS]0 > 1, the most important rate constants for ABTS
●+ evolution were 
k2 , k4, k9, k12, k13, and k14, which rendered this reaction condition suitable to probe k12−k14. 
Interestingly, the most influential rate constant changed from k9 to k12 as the reaction 
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transitioned from the first stage (t = 1.2 s) to the second stage (t = 50 s), which corresponded 
well to ABTS●+ formation and its decomposition shown in Figure 6.4. 
      At [Fe(VI)]0/[ABTS]0 = 1, k9, k10, and k13 were the most impactful rate constants for 
ABTS●+ evolution, which was expected as Eqs. 9, 10, and 12 were the initiation for 
interaction between high-valent iron species and ABTS/ABTS●+. 
      Overall, k3, k7, and k8 were considered to be the least influential rate constants in 
Fe(VI)-ABTS system. Individual sensitivity test of k8 (not shown) also confirmed that 
simulation results were independent of k8 when ranging from 0 to 10
3 M-1s-1, which agreed 
with the overall sensitivity analysis. This indicated that the sink for Fe(IV) species mainly 
resulted from its reactions with ABTS/ABTS●+/H2O2 (k11, k14 and k2) rather than its self-
decay (k8) in Fe(VI)-ABTS system, which contradicted with a previous study
271 that 












Fe(VI) Fe(V) Fe(IV) ABTS
●+   ABTS H2O2 O2 Fe(OH)3 Fe(OH)2 ABTS(oxidized) Overall 
k1 5.85x10-7 4.21x10-7 4.81x10-6 4.11x10-8 4.46x10-9 1.35x10-6 1.74x10-6 1.23x10-8 7.45x10-6 2.61x10-7 1.67x10-5 
k2 3.54x10-5 1.26x10-5 1.97x10-4 6.06x10-6 7.06x10-7 9.38x10-6 6.28x10-4 4.92x10-6 6.07x10-2 2.07x10-6 6.16x10-2 
k3 3.66x10-5 1.34x10-5 3.15x10-6 9.12x10-7 1.06x10-7 2.95x10-7 4.55x10-7 1.66x10-6 1.19x10-2 5.32x10-7 1.19x10-2 
k4 7.86x10-4 5.70x10-2 2.94x10-2 2.25x10-3 2.60x10-4 4.66x10-3 1.57x10-2 2.56x10-3 1.32x10-2 1.91x10-2 1.45x10-1 
k5 1.56x10-3 2.15x10-2 2.66x10-2 4.10x10-3 4.65x10-4 7.67x10-3 2.00x10-2 4.17x10-3 2.28x10-2 3.15x10-2 1.40x10-1 
k6 3.70x10-5 4.39x10-3 2.03x10-3 1.15x10-4 1.37x10-5 1.93x10-3 7.71x10-2 7.83x10-5 1.97x10-3 1.08x10-3 8.88x10-2 
k7 1.49x10-8 8.67x10-9 2.61x10-7 5.74x10-9 6.7x10-10 4.26x10-8 1.55x10-8 1.35x10-9 3.16x10-7 2.02x10-8 6.87x10-7 
k8 3.65x10-7 2.30x10-7 9.73x10-7 4.73x10-8 5.48x10-9 7.26x10-8 5.27x10-6 1.69x10-8 7.28x10-7 4.27x10-8 7.75x10-6 
k9 3.45x10-1 1.79x10-1 7.61x10-2 1.43x10-2 1.19x10-3 2.14x10-2 3.51x10-2 1.99x10-2 5.36x10-2 3.08x10-2 7.75x10-1 
k10 4.05x10-3 1.84x10-2 7.10x10-2 1.09x10-2 9.58x10-4 8.01x10-3 1.31x10-2 1.48x10-3 7.04x10-2 1.41x10-3 2.00x10-1 
k11 6.10x10-4 3.25x10-4 1.20x10-1 1.17x10-3 1.22x10-4 4.04x10-6 5.37x10-4 1.53x10-3 6.24x10-2 8.38x10-4 1.88x10-1 
k12 4.47x10-5 2.83x10-5 3.52x10-5 5.16x10-6 9.01x10-8 1.17x10-5 7.61x10-6 1.79x10-7 4.75x10-5 1.91x10-3 2.09x10-3 
k13 1.07x10-5 1.28x10-3 5.65x10-4 2.57x10-4 3.92x10-6 2.57x10-4 4.76x10-4 2.39x10-5 4.33x10-4 7.70x10-2 8.03x10-2 








Fe(VI) Fe(V) Fe(IV) ABTS
●+   ABTS H2O2 O2 Fe(OH)3 Fe(OH)2 ABTS(oxidized) Overall 
k1 2.42x10-3 5.43x10-4 2.82x10-2 3.56x10-5 1.13x10-3 1.60x10-4 9.24x10-4 4.59x10-5 3.14x10-2 5.48x10-5 6.53x10-2 
k2 8.33x10-2 7.91x10-2 1.03 2.14x10-3 8.61x10-2 1.41x10-3 1.53x10-1 6.08x10-3 3.2 1.57x10-2 4.66 
k3 3.62x10-3 2.60x10-3 1.80x10-3 7.90x10-5 2.79x10-3 1.50x10-4 4.67x10-4 4.27x10-4 4.81 2.00x10-4 4.82 
k4 4.38x10-1 4.41 1.97 5.55x10-3 5.95x10-1 3.09x10-1 3.32 4.67x10-2 1.32 2.47 14.9 
k5 1.67x10-1 9.56x10-2 5.96x10-1 4.50x10-3 2.17x10-1 6.12x10-2 5.01x10-1 1.72x10-2 3.97x10-1 4.49x10-1 2.50 
k6 8.40x10-3 2.97x10-1 3.82x10-2 5.96x10-4 1.41x10-2 2.80x10-1 4.47 9.07x10-4 2.38x10-1 1.17x10-1 5.46 
k7 8.92x10-6 5.03x10-6 2.46x10-2 9.74x10-7 3.70x10-5 3.66x10-6 6.06x10-3 2.58x10-6 2.57x10-2 1.24x10-5 5.64x10-2 
k8 2.06x10-3 5.11x10-4 7.75x10-4 1.66x10-5 5.92x10-4 2.70x10-4 1.63x10-5 2.64x10-5 7.42x10-4 9.07x10-5 5.09x10-3 
k9 4.15 4.16 1.07 4.18x10-1 5.13 4.79x10-1 5.66x10-1 4.51x10-1 5.58 1.04 23.0 
k10 8.01x10-1 1.74x10-1 3.22 3.93x10-2 1.07 9.44x10-2 5.42x10-2 5.33x10-2 2.43 1.72x10-1 8.11 
k11 2.81x10-1 1.40x10-1 4.5 1.11x10-2 2.87x10-1 8.18x10-3 1.67x10-1 5.77x10-3 4.77 6.31x10-2 10.2 
k12 1.90x10-1 4.75x10-2 2.28 1.73x10-2 5.51x10-2 8.20x10-3 4.04x10-2 2.46x10-3 2.39 1.63 6.65 
k13 1.19x10-3 6.36x10-2 2.08x10-2 2.95x10-2 3.19x10-3 2.81x10-2 5.71x10-2 2.18x10-4 4.80x10-2 3.22 3.47 








Fe(VI) Fe(V) Fe(IV) ABTS
●+   ABTS H2O2 O2 Fe(OH)3 Fe(OH)2 ABTSox Overall 
k1 1.35x10-3 6.76x10-2 9.10x10-2 1.91x10-5 3.30x10-3 2.41x10-3 5.71x10-3 3.45x10-4 9.42x10-2 6.28x10-4 2.67x10-1 
k2 9.76x10-4 5.90x10-1 6.69x10-2 7.04x10-6 1.87x10-2 3.73x10-4 6.24x10-2 3.43x10-3 9.24x10-1 2.26x10-4 1.67 
k3 8.62x10-6 2.88x10-3 5.16x10-6 3.66x10-7 7.14x10-5 1.88x10-5 3.70x10-5 3.12x10-5 1.18 1.42x10-5 1.18 
k4 1.37x10-3 1.60 1.10x10-1 3.27x10-3 2.40x10-2 4.56x10-2 5.02x10-1 1.08x10-2 7.26x10-2 1.85x10-1 2.02 
k5 1.57x10-3 8.22x10-2 1.25x10-1 1.85x10-3 2.19x10-2 2.88x10-2 2.60x10-1 1.06x10-2 1.01x10-1 1.18x10-1 7.51x10-1 
k6 3.56x10-5 1.23x10-1 3.44x10-3 2.24x10-4 1.11x10-3 6.18x10-2 1.05 3.07x10-4 5.21x10-2 1.20x10-2 1.31 
k7 1.20x10-4 5.70x10-3 7.74x10-3 7.98x10-8 8.38x10-5 4.36x10-6 7.25x10-3 7.16x10-6 7.65x10-3 2.53x10-6 2.86x10-2 
k8 2.24x10-7 2.37x10-4 2.72x10-4 1.58x10-8 7.97x10-4 2.20x10-4 1.22x10-5 2.82x10-5 2.67x10-4 5.28x10-5 1.89x10-3 
k9 2.41x10-2 1.44 2.69x10-2 6.45x10-2 27.1 9.44x10-2 2.83x10-1 7.99x10-2 1.31x10-1 1.10x10-1 29.3 
k10 4.77x10-3 1.42x10-1 3.92x10-1 7.93x10-4 6.28x10-2 1.75x10-2 1.23x10-2 1.52x10-2 3.75x10-1 5.93x10-3 1.03 
k11 9.87x10-4 4.64x10-2 8.66x10-2 1.25x10-4 4.48x10-2 1.49x10-3 8.59x10-3 4.15x10-4 8.89x10-2 1.29x10-3 2.80x10-1 
k12 1.08x10-2 5.18x10-1 6.98x10-1 1.88x10-2 1.01x10-2 3.34x10-4 3.88x10-2 2.60x10-3 7.03x10-1 7.70x10-1 2.77 
k13 5.63x10-5 2.61x10-2 4.41x10-3 6.75x10-3 2.58x10-4 6.44x10-3 1.25x10-2 7.03x10-5 1.09x10-2 4.04x10-1 4.72x10-1 








Fe(VI) Fe(V) Fe(IV) ABTS
●+   ABTS H2O2 O2 Fe(OH)3 Fe(OH)2 ABTSox Overall 
k1 3.03 2.50 2.03 6.44x10-1 36.3 1.78 3.54 1.45 5.59 5.91x10-1 57.5 
k2 2.14 9.30 41.8 2.95 79.5 2.12 13.1 2.79 8.30 3.18 165 
k3 1.82x10-3 1.68x10-2 3.31x10-3 1.08x10-3 1.68 2.28x10-3 9.45x10-4 3.32x10-3 50 1.26x10-3 51.7 
k4 3.96x10-1 45.1 3.74 6.73x10-1 6.35 4.28 5.73 3.28x10-1 7.13x10-1 1.13 68.5 
k5 1.25x10-1 3.25x10-1 9.83x10-1 1.81x10-1 1.53 8.95x10-1 1.56 1.17x10-1 1.94x10-1 4.34x10-1 6.33 
k6 2.36x10-1 4.01 4.29 2.21x10-1 4.52 4.97 8.79 2.61x10-1 5.79x10-1 2.36x10-1 28.1 
k7 4.04x10-1 4.83x10-1 7.09x10-1 5.78x10-2 3.39 2.79x10-1 1.09 1.69x10-1 8.66 5.12x10-2 15.3 
k8 1.65x10-1 4.36x10-1 5.43x10-1 1.29x10-2 1.95 1.29x10-1 3.77x10-1 5.88x10-2 5.91x10-1 1.66x10-2 4.28 
k9 2.65x10-1 1.72 9.42x10-1 2.31x10-1 182 1.00 1.26 2.69x10-1 2.84x10-1 3.27x10-1 188 
k10 1.39x10-1 5.21x10-1 1.32 1.47x10-1 53.9 6.48x10-1 5.26x10-1 1.51x10-1 6.40x10-1 2.22x10-1 58.2 
k11 8.93x10-2 1.55x10-1 2.35x10-1 3.20x10-2 42.4 5.52x10-2 2.20x10-1 5.70x10-2 1.96x10-1 3.61x10-2 43.5 
k12 18.7 15.0 16.1 20.0 77.2 1.38 22.3 9.00 30.2 29.2 239 
k13 2.60x10-1 8.25x10-1 1.85x10-1 6.36x10-1 4.29 4.10x10-1 4.47x10-1 1.28x10-1 5.52x10-1 1.48 9.22 
k14 6.71x10-1 3.19 8.19 2.63 6.25 1.78 3.97 3.80x10-1 3.7 3.25 34.0 
 200 





The Rank of Sensitivity Coefficient 
[Fe(VI)]0 < [ABTS]0 
[Fe(VI)]0 = 17.5 µM, [ABTS]0 = 200.0 µM 
t = 0.08 s 
ABTS●+         k9 > k10 > k5 > k4 >k11> k13> k6> k2> k1> k14> k3> k8> k1> k7 
ABTS k9 > k10 > k5 > k4 >k11> k6> k13> k2> k14> k3> k12> k8> k1> k7 
Overall k9 > k10 > k11 > k4 >k5> k6> k13> k2> k14> k3> k12> k1> k8> k7 
[Fe(VI)]0 = [ABTS]0 
[Fe(VI)]0 = 14.8 µM, [ABTS]0 = 14.8 µM 
t = 5 s 
ABTS●+ k9 > k10 > k13 > k12 >k11> k4> k5> k2> k14> k6> k3> k1> k8> k7 
ABTS k9 > k10 > k4 > k11 >k5> k2> k12> k14> k6> k13> k3> k1> k8> k7 
Overall k9 > k10 > k4 > k11 >k5> k2> k12> k14> k6> k13> k3> k1> k8> k7 
                       Fe(VI)]0 > [ABTS]0 
[Fe(VI)]0 = 50.0 µM, [ABTS]0 = 18.0 µM 
t = 1.2 s 
ABTS●+ k9 > k12 > k13 > k4 >k5> k10> k14> k6> k11> k1> k2> k3> k7> k8 
ABTS k9 > k10 > k11 > k4 >k5> k2> k12> k1> k6> k14> k8> k13> k7> k3 
Overall         k9 > k12 > k4 > k2 >k6> k3> k10> k5> k13> k14> k11> k1> k7> k8 
[Fe(VI)]0 > [ABTS]0 
[Fe(VI)]0 =  50.0 µM, [ABTS]0 = 18.0 µM 
t = 50 s 
ABTS●+ k12 > k2 > k14 > k4 >k1> k13> k9> k6> k5> k10> k7> k11> k8> k3 
ABTS k9 > k2 > k12 > k10 >k11> k1> k4> k14> k6> k13> k7> k8> k3> k5 
Overall k12 > k9 > k2 > k4 >k10> k1> k3> k11> k14> k6> k7> k13> k5> k8 
 




6.4.5 Implication for Spectrophotometric Method of Fe(VI) Detection by ABTS  
ABTS has been widely used for quantification of different types of oxidants 162-163, 265-
267 including Fe(VI), owing to its rapid reaction and simple spectrophotometric 
measurement with high sensitivity. However, the observed 1:1:1 stoichiometric ratio 
between Fe(VI), ABTS, and ABTS●+ (Eq. 6.8) ([ABTS]0 = 73 or 80 µM, [Fe(VI)]0 < 35 
µM, and 10 mM phosphate or acetate buffer) initially reported by Lee and co-workers145, 
164 did not conform to the theoretical reaction stoichiometric ratio of 1:3 (Eq. 6.9) between 
Fe(VI) and ABTS also proposed in Lee’s study.145 Theoretically, the reduction of Fe(VI) 
to Fe(III) as the final product requires three-electron equivalents. Thus, 3 moles of ABTS 
are needed to generate 3 moles of ABTS●+ in order to provide three electron equivalents. 
Fe(VI) +ABTS→ Fe(V) + ABTS●+  
                                                                                                                              (6.8)       
Fe(VI) + 3 ABTS→ Fe(III) + 3 ABTS●+   
                                                                                                                  (6.9) 
        Lee and co-workers assumed that Eqs. 4−6 in Table 6.2, where Fe(V) can transform 
to Fe(III) via self-decay or reaction with H2O2, were the only sinks for Fe(V) formed in-
situ. However, sensitivity analysis in Table 6.11 based on the Fe(VI)-ABTS model in this 
study could not support that assumption and indicated the major sink for Fe(V) should be 
its reaction with ABTS at [Fe(VI)]0/[ABTS]0 < 1, because k10 was more influential to the 





















































Figure 6.11 (A) Kinetic simulation of Fe(VI) oxidation of excess amounts of ABTS, 
Solid line ([ABTS]0 = 24 µM), dash line ([ABTS]0 = 40.0 µM);  dot line (([ABTS]0 = 
80.0 µM)) dash-dot line ([ABTS]0 = 160.0 µM); dash-dot-dot line ([ABTS]0 = 240.0 




       Interestingly, this observed stoichiometric ratio for Fe(VI):ABTS●+ started to deviate 
from 1:1 and increased to 1:1.2 as ABTS concentration was increased in this study as 
shown in Figure 6.10 ([ABTS]0 = 150 or 200 µM, [Fe(VI)]0 < 17.5 µM, and 10 mM 
phosphate buffer). A similar stoichiometric ratio of 1:1.18 between Fe(VI) and ABTS●+ 
was also observed in Huang’s study122 ([ABTS]0 = 100 µM, [Fe(VI)]0 < 10 µM, and 10 
mM phosphate buffer). Moreover, Cyr and co-workers283 observed a similar phenomenon 
in Fe(VI)-ascorbic acid (AC) system, where high-valent irons (Fe(VI), Fe(V), and Fe(IV)) 
can transform AC to ascorbyl radical via one-electron transfer.  When the [AC]0/[Fe(VI)]0 
ratio was increased, the measured stoichiometric ratio between Fe(VI) and ascorbyl radical 
was found to increase accordingly, which resembled the trend in Fe(VI)-ABTS system. 
The above findings indicate that caution should be taken in the spectrophotometric method 
of Fe(VI) detection by ABTS, where condition of [ABTS]0/[Fe(VI)]0 > 10 may result in 
over-estimation of Fe(VI) if assuming the 1:1 reaction stoichiometry between Fe(VI) and 
ABTS●+.   
       The proposed Fe(VI)-ABTS model also indicated a similar conclusion as the above 
findings. Based on the kinetic simulations (Eqs. 1−14) under Fe(VI) concentration at 2−24 
µM and ABTS concentration at 24−240 µM, the stoichiometric ratio between simulated 
[ABTS●+] and simulated  [Fe(VI)] increased from 1:1 to 1:1.24 when ABTS concentration 
was increased from 24 to 240 µM (Figure 6.11). This model suggested that the optimal 
ratio between [ABTS]0 and maximum [Fe(VI)]0 should be lower than 2 in order to maintain 
the stable 1:1 stoichiometric ratio between Fe(VI) and ABTS●+.  
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       Meanwhile, Dong’s study119 reported that [ABTS]0/[Fe(VI)]0 > 10 was recommended 
for using the ABTS method for Fe(VI) determination in the presence of organic substrates 
(e.g., diclofenac), because an excess amount of ABTS could maintain the stability of 
ABTS●+ by inhibiting it from possible reaction with the substrate. This dilemma may 
render difficult application of the ABTS method for determination of Fe(VI) in the 
presence of substrates (e.g., amino acids, phenol, and alcohol)284 susceptible to ABTS●+ 
oxidation, unless new observed stoichiometry between Fe(VI) and ABTS●+ (i.e., >1) was 
applied when [ABTS]0/[Fe(VI)]0  was greater than 10. 
6.4.6 Implication for Fe(V)/Fe(IV) Behaviors in Fe(VI)-ABTS System  
Xue and co-workers271 systematically examined possible high-valent iron species’ 
interactions with ABTS/ABTS●+ at different ratios of [ABTS]0/[Fe(VI)]0 (e.g., >1, =1, and 
<1) at pH 4−8. However, their study did not include the Fe(V)/Fe(IV) interactions with 
ABTS/ABTS●+ based on the “possible overperformance” from competing reactions of 
Fe(V)/Fe(IV) including self-decay of Fe(V) (Eqs. 4 and 5), self-decay of Fe(IV) (Eq. 8), 
and reactions of Fe(V) (Eq. 6) and Fe(IV) (Eq. 2) with H2O2. Such assumptions may not 
be accurate because the competition among different sink pathways of Fe(V)/Fe(IV) 
depended on both reactant concentrations as well as reaction rate constants involved; 





















































Figure 6.12 Kinetic simulation of Fe(V)/Fe(IV) behaviors at different ratios of 
[Fe(VI)]0/[ABTS]0. [ABTS]0 = (A) 25 µM; (B) 50 µM; (C) 75 µM; (D) 100 µM. 

































Figure 6.13 Kinetic simulation of behaviors of possible reactive species: (A) (Fe(V); 
(B) Fe(IV) and ABTS
●+ at [ABTS]0/[Fe(VI)]0 = 0.067. Simulation and experimental 
condition: [Fe(VI)]0 = 150 µM, [ABTS]0 = 10 µM , [DCF] = 30 µM, time = 3.8 s and 
600s. Note: DCF degradation data was taken from Dong’s study.  
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By utilizing the Fe(VI)-ABTS model proposed in this study, the kinetic behaviors of 
Fe(V)/Fe(IV) can be probed. In the system where [ABTS]0/[Fe(VI)]0 ratio ranged from 0.5 
to 2.0 (Figure 6.12), Fe(V) and Fe(IV) always coexisted in the first 0.25−1.0 s. 
Interestingly, as ABTS concentration was increased, [Fe(V)]max increased from 1.79 to 3.89 
µM with its longest lifetime to be ~1 second at [ABTS]0/[Fe(VI)]0 = 1. On the other hand,  
[Fe(IV)]max increased from 0.41 to 0.72 µM and its lifetime decreased at [ABTS]0/[Fe(VI)]0 
≥ 1 while [Fe(IV)] increased dramatically to 1.26 µM within 3.8 seconds at 
[ABTS]0/[Fe(VI)]0 = 0.5.  
         The observations in Fe(V)/Fe(IV) simulations suggested both Fe(V) and Fe(IV) 
could play important roles in substrate degradation depending on the ratio of 
[ABTS]0/[Fe(VI)]0. At [ABTS]0/[Fe(VI)]0 < 1, Fe(IV) is more likely to dominate the 
substrate degradation in the long run. In Dong’ study,119 addition of a small amount of 
ABTS ([ABTS]0/[Fe(VI)]0 < 0.2) could accelerate Fe(VI) oxidation of diclofenac in the 
course of 600 s at pH 8.0, which was explained by the possible involvement of more 
powerful oxidants, Fe(V) and ABTS●+, generated from the reaction of Fe(VI) and ABTS. 
However, the kinetic simulation by the model in this study suggested a different 
explanation. As shown in Figure 6.13, Fe(V) disappeared within 0.1 s, which would rule 
out its involvement in diclofenac degradation that lasted for 300.0 s. On the other hand, 
ABTS●+ lifetime only lasted for 60 s while Fe(IV) lifetime extended for 250 s, which 
suggested the enhanced degradation of diclofenac was more likely attributable to ABTS●+ 
as well as Fe(IV). Future study is still needed to delineate and differentiate the roles of 
Fe(IV) vs. ABTS●+ in Fe(VI)-ABTS system at [ABTS]0/[Fe(VI)]0 < 0.5. 
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          At [ABTS]0/[Fe(VI)]0 > 1, Fe(V) was most likely the reactive specie responsible for 
substrate degradation considering its higher concentration (Figure 6.12) as well as higher 
reactivity to substrates compared to the counterpart of Fe(IV). At [ABTS]0/[Fe(VI)]0 = 1, 
the simulation results (Figure 6.12B) did not fully support that the reaction of ABTS with 
an equimolar amount of Fe(VI) produces a Fe(V)-only system as proposed in Xue’s 
study,271 because a lower concentration of Fe(IV) was also formed. However, Fe(V) may 
still be the most important iron intermediate species that is responsible for substrate decay, 
which will be discussed in next section. 
6.4.7 Kinetic Formulation of Fe(VI)-ABTS-Substrate System (Eqs. 1−17) at pH 7.0 
Xue and co-workers271 found the degradation of 21% of PMSO, 25% of PPL, and 13% 
of CBZ finished within first 5 s (the shortest time interval monitored in their study) in 
Fe(VI)-ABTS system with equimolar Fe(VI) and ABTS. The authors also observed 
complete transformation of oxidized PMSO to PMSO2, further confirming the roles of 
high-valent iron species (Fe(VI), Fe(V) and Fe(IV)) in degradation of such substrates. 
Therefore, the Fe(VI)-ABTS-Substrate kinetic model was constructed by incorporating the 
interaction of high-valent iron species with each substrate (Eqs. 15−17) into the Fe(VI)-
ABTS system (Eqs. 1−14). The rate constants k15 between Fe(VI) and substrate can be 
found in previous literatures.99, 278-279 Even though the rate constants of Fe(IV) with the 
substrates were unknown, Fe(IV) was reported to react with aromatic compounds (e.g., 
phenol and nitrobenzene) at a rate around 104 M-1s-1,227 which was assigned to k17. The rate 
constants k16 between Fe(V) and substrate could then be successfully derived with high 
sensitivity (Figures 6.14 and 6.15) based on the reported removal rates. Since it has been 
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reported that Fe(V) has much higher reactivity (2-3 orders of magnitude difference) than 
Fe(IV) in degradation of sulfur-containing and nitrogen-containing compounds (e.g., 
cyanate,285 thiocyanate,106 and thiourea106), it is reasonable to assume k16 > 100×k17. The 
sensitivity test of k17 in the model (Figure 6.17) further confirmed Fe(IV)’s negligible role 
in contributing to the substrate degradation since substrates’ degradation was independent 
of k17 when it was at least 2 orders of magnitude lower than its counterpart k16. Moreover, 
Fe(IV) concentration was calculated to be much lower than Fe(V) concentration at 
[ABTS]0/[Fe(VI)]0 = 1 based on Figure 6.12B, which also supported the minimal 
contribution of Fe(IV) to degradation of substrates compared to Fe(V). Moreover, the 
kinetic behavior of ABTS●+  simulated by the Fe(VI)-ABTS-Substrate model in this study 
was very similar to the ABTS●+ formation experimentally captured in Xue’s study271 

















Figure 6.14 Kinetic simulation of degradation of (A) PMSO; (B) CBZ and PPL 
within 60 s. Symbol: measured data recreated from Xue’s study in Figure 4; Line: 
simulation based on Eqs.1-17 in Table 1 of the main paper. Simulation and 
experimental condition: [Fe(VI)]0 = [ABTS]0 = 50 µM, [PMSO]0 = 10 µM, [PPL]0 

















































Figure 6.15 Sensitivity analysis of k17 in Fe(VI)-ABTS-Substrate system (Eqs 1-
17). Substrate = (A) PMSO; (B) PPL; (C) CBZ. Simulation condition: [Fe(VI)]0 = 
[ABTS]0 = 50 µM, [PMSO]0 = 10 µM, [PPL]0 = 5 µM, and [CBZ]0 = 5 µM. Note: 
Lines representing k17a = 0 and 1.25×104 M-1s-1 in A, lines representing k17b = 0 







































Figure 6.16 Comparison of ABTS
● + formation in Fe(VI)-ABTS-Substrate 
system. (A) Experimental values (absorbance at 415 nm) taken from Xue’s study 
in Figure 4. (B) Simulation results based on the Fe(VI)-ABTS-Substrate system 
in this study. Simulation and experimental condition: [Fe(VI)]0 = [ABTS]0 = 50 
µM, [PMSO]0 = 10 µM, [PPL]0 = 5 µM, [CBZ]0 = 5 µM, and t = 10s. Note: All 




































































































Figure 6.17 Kinetic simulation of degradation of (A) PMSO, (B) PPL, and (C) 
CBZ in Fe(VI)-ABTS-Substrate system based on data from a previous study. 
Simulation condition: [Fe(VI)]0 = [ABTS]0 = 50 µM, [PMSO]0= 10 µM or 









Overall, substrate degradation can be finished within 0.5 s according to the simulation in 
Fe(VI)-ABTS-Substrate system, which required further kinetic exploration to confirm such 
rapid reaction process. However, the derived k17 values (0.71×10
6−1.42×106 M-1s-1) 
between Fe(V) and aromatic substrates at pH 7.0 were in good agreement with the rate 
constants (0.22×106−1.5×106 M-1s-1) between Fe(V) and phenol/enrofloxacin simulated in 
Fe(VI)-sulfite-substrate system at pH 6.5 and 8.0,123 and the rate constant (3.8×105 M-1s-1) 
between Fe(V) and phenol determined at pH 9.0 by pre-mix stopped-flow pulse 
radiolysis.286  The agreement strongly indicated the k17 values determined in Fe(VI)-ABTS-
Substrate model were reasonable. 
6.5 Environmental Significance 
In recent years, there has been increasing attention on the enhanced roles of 
Fe(V)/Fe(IV) during Fe(VI) oxidation in the presence of various activators.111-118, 120 
However, the kinetic behaviors (self-decay vs. oxidation of substrates) of Fe(V)/Fe(IV) in 
the oxidation process remained unclear mainly due to the difficulty of direct and rapid 
measurement for those species. This study, with careful investigation of the kinetic 
behaviors of activator (ABTS) at varied reaction conditions, resulted in a comprehensive 
and robust Fe(VI)-ABTS system kinetic model, which was able to further quantitatively 
probe the Fe(V)/Fe(IV) kinetic behaviors and resolved some ambiguity or inconsistency in 
previous literatures. The findings derived from Fe(VI)-ABTS system modeling also 
provided new guidance for  the popular spectrophotometric method used for Fe(VI) 
determination by ABTS. Moreover, Fe(VI)-ABTS-Substrate system was proposed to 
evaluate the major iron intermediate species (i.e., Fe(V)) reactivity to the contaminants, 
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which can provide a simple tool to identify the selectivity of Fe(V) in the future. Overall, 
this study has systemically constructed a valid kinetic model with numerous data support 
to exam the complexity of evolution of Fe(V)/Fe(IV) in ABTS-enhanced Fe(VI) system. It 
has the potential to inspire future studies and facilitate the understanding of Fe(V)/Fe(IV) 
behaviors in other enhanced Fe(VI) systems and even uncover Fe(V)/Fe(IV) reactivity and 
selectivity to different organic pollutants based on kinetic simulation. 
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CHAPTER 7. CONCLUSIONS AND FUTURE PERSPECTIVES  
7.1 Conclusions 
7.1.1 Conclusions of Fe(VI) Application in Synthetic Hydrolyzed Urine 
         To minimize environmental pharmaceutical micropollutants, treatment of human 
urine can be an efficient approach because of the high pharmaceutical concentration and 
toxic potential excreted in urine. This study investigates the application of ferrate (Fe(VI)) 
oxidation to degrade pharmaceuticals (carbamazepine (CBZ), naproxen (NAP), 
sulfamethoxazole (SMX) and trimethoprim (TMP)) in synthetic hydrolyzed human urine.  
          Interesting new matrix effects from urine components are discovered. For inorganic 
ions, chloride slightly decreases the removal of the pharmaceuticals by Fe(VI) due to the 
ionic strength effect. Ammonia increases SMX removal when Fe(VI):ammonia ratio is 
higher than 1:833 (0.3 mM Fe(VI): 250 mM ammonia) due to activation of Fe(VI) to more 
reactive Fe(V)/Fe(IV) species. Bicarbonate significantly enhances the rate of Fe(VI) 
oxidation of sulfonamide antibiotics (SAs), changes the Fe(VI): SA complexation ratio 
from 1:2 to 1:1, and alters the reaction stoichiometry of Fe(VI) to SMX from 4:1 to 3:1. 
The bicarbonate enhancement is strongly associated with SAs’ aniline moiety.  
         For organic metabolites, creatine and hippuric acid show limited scavenging effects 
on the oxidation of pharmaceuticals (CBZ, NAP, SMX, and TMP) by Fe(VI).  However, 
creatinine (CRE) significantly enhances the oxidation rates of CBZ, TMP, and SMX by 
Fe(VI), while only limitedly impacts NAP removal. Amine-specific structures were found 
to be responsible for creatinine enhancement according to the investigation of subunits of 
TMP and SMX. Intermediate iron species Fe(IV) is proposed as the major reactive species 
in the Fe(VI)+CRE system based on DFT calculation. For the first time, a kinetic model 
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involving Fe(IV) contribution to the substrate removal is proposed and successfully 
captures the pharmaceutical removal in the Fe(VI)+CRE system. Moreover, it also predicts 
the rate constants between Fe(IV) and the substrates (50–850 M-1s-1 ), which agree well 
with reported rate constants between Fe(IV) and organic substrates.  
   Overall, the powerful oxidation capability of Fe(VI) and the enhancement effects from 
multiple urine components (e.g., ammonia, bicarbonate, and creatinine) render Fe(VI) a 
promising advanced oxidation technology for the removal of pharmaceuticals in 
hydrolyzed urine. 
7.1.2 Conclusions of Kinetic Investigation of Fe(VI) Oxidation Mechanism  
            The mechanism of self-decay of Fe(VI) has been extensively examined under acidic 
to neutral pH conditions by previous research. However, Fe(VI) self-decay at alkaline pH 
(e.g., pH 9.0 or higher) has been poorly understood.  
           This dissertation performed kinetic and modeling studies of the Fe(VI) decay at pH 
9.0 and 10.0. Our research reveals that the decay of Fe(VI) follows first-order kinetics (i.e., 
unimolecular decay) at pH 9.0 and 10.0, and the order changes to 3/2-order at pH 7.0 due 
to the different species of Fe(VI) (FeO4
2- versus HFeO4
-). Results of unimolecular decay 
mechanism through water attack (WA) are supported by density functional theory (DFT) 
calculations, which indicate unfavorable dimerization of FeO4
2- through oxo-coupling 
(OC) under alkaline conditions. The WA on the monomeric FeO4
2- is proposed due to its 
lower activation barrier compared to OC. Kinetic simulation of Fe(VI) decay involving 
Fe(V) and Fe(IV) successfully predicts Fe(VI) disappearance and H2O2 generation (a 
product) under varied conditions. The decay of FeO4
2- is different from the second-order 
kinetics of protonated Fe(VI) species (H2FeO4 and HFeO4
-). 
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       As there has been increasing attention on the enhanced roles of Fe(V)/Fe(IV) during 
Fe(VI) oxidation in the presence of various activators. However, the kinetic behaviors 
(self-decay vs. oxidation of substrates) of Fe(V)/Fe(IV) in the oxidation process has 
remained unclear mainly due to the difficulty of direct and rapid measurement for those 
species. This dissertation, with careful investigation of the kinetic behaviors of reactant 
(e.g., Fe(VI), substrates) as well reactive intermediate species (ABTS●+), results in a more 
comprehensive understanding of Fe(VI)-activated systems (i.e., the Fe(VI)-Fe(III) system 
at pH 9.0 and Fe(VI)-ABTS system at pH 7.0). 
      In the Fe(VI)-Fe(III) system at pH 9.0, the rate constant of reaction between Fe(III) and 
Fe(VI) generating Fe(IV) was derived to be 3.0×104 M-2 s-1 based on Fe(VI) decay profile 
at varied Fe(III) dosage. Based on the kinetic simulation, non-complexed Fe(IV) is 
proposed as the major intermediate species in the Fe(VI)-Fe(III) system, which provides 
an ideal environment to further probe the reactivity and selectivity of Fe(IV) reaction. 
Furthermore, the Fe(VI)-Fe(III)-Substrate system was constructed to successfully derived 
Fe(VI) and Fe(IV) reactivity to 18 different pharmaceuticals. The preliminary study of the 
structure-activity relationships between compounds’ molecular descriptors and 2nd-order 
rate constants derived from the Fe(VI)-Fe(III)-Substrate kinetic model suggests Fe(VI) 
reactivity is strongly correlated to N-atom related descriptors and can be estimated based 
on the reactivity of its Fe(VI) counterpart. 
      In the Fe(VI)-ABTS system at pH 7.0, the oxidation of ABTS by Fe(VI) (k = 
(5.96±0.9%)×105 M-1s-1), Fe(V) (k = (2.04±0.0%)×105 M-1s-1) or Fe(IV) (k = 
(4.64±13.0%)×105 M-1s-1) proceeds via one-electron transfer to generate ABTS●+, which 
is subsequently oxidized by Fe(VI) (k = (8.5±0.0%)×102 M-1s-1), Fe(V) (k = 
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(1.0±40.0%)×105 M-1s-1) or Fe(IV) (k = (1.9±17.0%)×103 M-1s-1) via two-electron (oxygen 
atom) transfer to generate colorless ABTSox. At [ABTS]0/[Fe(VI)]0  > 1, experimental data 
and model simulation both indicated the reaction stoichiometric ratio of Fe(VI):ABTS●+ 
increased from 1:1 to 1:1.2 as [ABTS]0 was increased. Furthermore, the Fe(VI)-ABTS-
Substrate model was developed to successfully determine reactivity of Fe(V) to different 
substrates (k = (0.7-1.42)×106 M-1s-1).  
     Overall, the newly formulated Fe(VI) self-decay system will help facilitate the 
understanding of oxidation power of Fe(VI) in the degradation of pollutants under alkaline 
conditions. Meanwhile, Fe(VI)-activator kinetic model (i.e., the Fe(VI)-Fe(III) system at 
pH 9.0 and Fe(VI)-ABTS system at pH 7.0) presented in this dissertation provides a useful 
tool to quantitatively probe Fe(V)/Fe(IV) behaviors in Fe(VI) oxidation and gains new 
fundamental insights. 
7.2 Future Perspectives  
     Based on the current conclusions from this dissertation, future work to advance the 
understanding of Fe(VI) application in urine treatment, as well as the activated-Fe(VI) 
system, may include the following: 
1. Currently, Fe(VI) application has been limited in synthetic urine matrix in the 
bench-scale as presented in this dissertation. Thus, it is important to use real 
hydrolyzed urine as the reaction medium to test the application of Fe(VI) in bench-
scale or even pilot-scale. The impacts of components in real hydrolyzed urine 
matrix, dilution factor, the dose/contact time of Fe(VI), the mixing variation, and 
 219 
the order of Fe(VI) application in combination with other urine treatment (i.e., 
nutrients recovery) should be examined systematically. 
2. As the Fe(VI) oxidation of pharmaceuticals is conducted, it is also necessary to 
evaluate the toxicity of oxidized products after complete elimination of  
pharmaceuticals in synthetic hydrolyzed urine as well as the real hydrolyzed urine. 
Green algae and blue-green algae (cyanobacteria) are relatively sensitive test 
organisms for pharmaceuticals287-290 and can be used as representative aquatic 
organisms to perform toxicity testing. 
3. Successful kinetic simulation of Fe(VI)-Fe(III) system and Fe(VI)-ABTS system 
in this dissertation suggests that dynamic kinetic simulation with enough 
experimental data support can serve as an effective vehicle to probe Fe(V)/Fe(IV) 
in Fe(VI) oxidation, which are usually difficult to capture experimentally. Further 
research should focus on other Fe(VI)-activated systems (e.g., Fe(VI)-sulfite 
system and Fe(VI)-ascorbate system) and compare the Fe(V)/Fe(IV) behaviors in 
parallel across different Fe(VI)-activated systems. After determining the best 
Fe(VI)-activated systems to generate Fe(V)-only or Fe(IV)-only systems, research 
should focus on exploring the Fe(V)/Fe(IV) reactivity and selectivity to a wide 
range of compound to further reveal high-valent iron species (Fe(VI), Fe(V), and 
Fe(IV)) oxidation chemistry at the mechanistic level. 
4. The Fe(VI)-Fe(III) system presented in this study suggests the addition of ferric salt 
into Fe(VI) oxidation could accelerate Fe(VI) oxidation efficacy. Therefore, ferric 
salts could play dual roles, as activator and coagulant in Fe(VI) application in water 
treatment. Considering Fe(VI) has already been reported as an effective disinfectant 
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291 to inactive a wide range of pathogens, the multifunctionality of Fe(VI)-Fe(III) 
system should be further investigated to test the feasibility of using iron-only single 









APPENDIX A. OPTIMIZED GEOMETRY OF FE(VI) SPECIES IN 
CHAPTER  4 
Optimized geometry at B3LYP level using the LanL2DZ basis set for Fe atom and the 6-
311++G** basis set for the other atoms. 
FeO42- 
Fe             -0.00027700     0.00010400     0.00005900 
O              -1.63041500    -0.01418500     0.24124500 
O               0.39245700    -1.09654600     -1.16415000 
O               0.47145600     1.50330200     -0.48020900 




Fe               0.11772000   -0.00002600     0.03822200 
O              -1.45886700     0.00065500    -0.84633800 
H              -2.15173900   -0.00038400    -0.17341100 
O               0.85891000   -1.34753400    -0.41651200 
O                0.85770800    1.34939600    -0.41275000 





Fe              0.00078800   -0.08819100     0.00242600 
O              -1.50616200    0.78589100    -0.03719900 
H              -1.67009900    1.15840200    -0.92033000 
O               0.08337000   -0.69565800     1.45586700 
O               0.12976700   -1.16813500    -1.13296000 
O               1.31350100    1.02697200    -0.24824800 




Fe             0.07625400     0.04705300    -0.07328200 
O              1.66538800    -0.86962700    -0.05627000 
H              1.49982200    -1.81189200    -0.19540700 
O             -1.35520300    -0.54058500     0.94101600 
O              -1.40775000   -0.02949000   -0.88685700 




Fe             -0.42100000   -0.07180000     0.04990000 
O               0.82554000    0.22764000    -1.03920000 
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O              -1.32140000    1.40689000     0.23522000 
O              -1.68260000   -1.15030000    -0.42430000 
O               0.89417000   -0.39710000     1.31750000 
O               2.41075000    0.11505000    -0.39900000 
H               1.92018000   -0.19270000     0.66486000 








Fe             -0.39002900   -0.01041400    0.02935100 
O               0.93276500   -0.72728300   -0.67496000 
O              -2.02640400    0.16584600   -0.84810200 
H              -1.89634000    0.60241900   -1.70081900 
O              -0.94487400   -0.85786900    1.28018300 
O               0.51451600    1.47188200    0.55205200 
O               2.51694400   -0.13831200   -0.27676800 
H               1.43154300    1.25863900    0.38069000 
H               2.66197000   -0.90439400    0.29777100 
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Compounds 
Fomula #C #H #N #O #X #H:C #O:C #N:C #N:O #N:H #C=C 
Ibuprofen C13H18O2 13 18 0 2 0 1.385 0.154 0.000 0.000 0.000 3 
Sulfamethazine C12H14N4OsS 12 14 4 5 0 1.167 0.417 0.333 0.800 0.286 4 
Naproxen C14H14O3 14 14 0 3 0 1.000 0.214 0.000 0.000 0.000 5 
BPA C15H16O2 15 16 0 2 0 1.067 0.133 0.000 0.000 0.000 6 
Sulfamethoxazole C10H11N3O3S 10 11 3 3 0 1.100 0.300 0.300 1.000 0.273 3 
Sulfamethizole C9H10N4O2S2 9 10 4 2 0 1.111 0.222 0.444 2.000 0.400 3 
Sulfamerazine C11H12N4O2S 11 12 4 2 0 1.091 0.182 0.364 2.000 0.333 4 
Trimethoprim C14H18N4O3 14 18 4 3 0 1.286 0.214 0.286 1.333 0.222 4 
Atenolol C14H22N2O3 14 22 2 3 0 1.571 0.214 0.143 0.667 0.091 3 
Levofloxacin C18H20FN3O4 18 20 3 4 1 1.111 0.222 0.167 0.750 0.150 4 
Flumequine C14H12FNO3 14 12 1 3 1 0.857 0.214 0.071 0.333 0.083 4 
Benzoic acid C7H6O2 7 6 0 2 0 0.857 0.286 0.000 0.000 0.000 3 
Diclofenac sodium C14H10Cl2NNaO2 14 11 1 2 2 0.786 0.143 0.071 0.500 0.091 6 
Ketoprofen C16H14O3 16 14 0 3 0 0.875 0.188 0.000 0.000 0.000 6 
Caffeine C8H10N4O2 8 10 4 2 0 1.250 0.250 0.500 2.000 0.400 1 
Carbamazepine C15H12N2O 15 12 2 1 0 0.800 0.067 0.133 2.000 0.167 6 
Methyl orange C14H14N3NaO3S 14 14 3 3 0 1.000 0.214 0.214 1.000 0.214 6 









Ibuprofen 0 1 1 6 15 -5 -0.010 -0.234 0.223 -656.732 -656.434 
Sulfamethazine 0 0 2 12 22 0 -0.027 -0.227 0.200 -1233.329 -1233.042 
Naproxen 0 1 2 10 17 -1 -0.035 -0.206 0.171 -767.635 -767.368 
BPA 2 0 2 12 17 -1 -0.002 -0.206 0.203 -731.700 -731.437 
Sulfamethoxazole 0 0 2 11 17 0 -0.028 -0.230 0.202 -1175.697 -1175.409 
Sulfamethizole 0 0 2 11 17 1 -0.036 -0.230 0.194 -1514.727 -1514.438 
Sulfamerazine 0 0 2 12 18 1 -0.031 -0.228 0.197 -1194.003 -1193.718 
Trimethoprim 0 0 2 12 21 -2 -0.002 -0.202 0.201 -989.013 -988.773 
Atenolol 1 0 1 6 19 -6 -0.014 -0.220 0.206 -881.950 -881.689 
Levofloxacin 1 1 4 19 26 -4 -0.047 -0.196 0.149 -1262.969 -1262.729 
Flumequine 1 1 3 13 19 -1 -0.050 -0.219 0.170 -921.035 -920.759 
Benzoic acid 0 1 1 6 9 1 -0.048 -0.261 0.212 -420.835 -420.496 
Diclofenac sodium 0 1 2 12 19 1 -0.026 -0.212 0.186 -1665.737 -1665.467 
Ketoprofen 0 1 2 12 19 0 -0.065 -0.244 0.178 -843.852 -843.549 
Caffeine 0 0 2 9 14 -1 -0.031 -0.219 0.188 -680.390 -680.102 
Carbamazepine 0 0 3 10 18 2 -0.050 -0.212 0.162 -763.586 -763.315 
Methyl orange 0 0 2 12 20 1.5 -0.085 -0.201 0.116 -1330.551 -1330.296 
Clofibric acid 0 1 1 6 14 -2 -0.031 -0.253 0.223 -1073.581 -1073.260 
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Ibuprofen 0.298 8.115 -656.681 0.052 1.403 3.356 0.124 4.759 3.374 0.296 1.682 
Sulfamethazine 0.287 7.806 -1233.302 0.027 0.740 3.533 0.129 4.273 2.585 0.387 5.498 
Naproxen 0.267 7.277 -767.610 0.026 0.694 3.292 0.138 3.986 2.413 0.414 2.697 
BPA 0.263 7.163 -731.645 0.055 1.489 2.837 0.141 4.326 3.298 0.303 1.403 
Sulfamethoxazole 0.288 7.840 -1175.656 0.041 1.116 3.362 0.128 4.478 2.983 0.335 9.289 
Sulfamethizole 0.288 7.848 -1514.699 0.028 0.767 3.540 0.128 4.308 2.621 0.382 9.596 
Sulfamerazine 0.285 7.758 -1193.977 0.026 0.700 3.529 0.129 4.229 2.534 0.395 6.159 
Trimethoprim 0.241 6.545 -988.972 0.041 1.118 2.714 0.154 3.832 2.705 0.370 2.728 
Atenolol 0.261 7.100 -881.910 0.040 1.078 3.011 0.142 4.089 2.777 0.360 4.264 
Levofloxacin 0.239 6.515 -1262.969 0.000 0.000 3.257 0.154 3.257 1.629 0.614 8.611 
Flumequine 0.276 7.497 -921.031 0.004 0.096 3.701 0.133 3.796 1.947 0.514 7.299 
Benzoic acid 0.340 9.240 -420.809 0.026 0.719 4.260 0.109 4.980 2.910 0.344 1.915 
Diclofenac sodium 0.271 7.362 -1665.707 0.030 0.827 3.267 0.136 4.094 2.565 0.390 2.576 
Ketoprofen 0.302 8.227 -843.859 -0.007 -0.187 4.207 0.121 4.020 1.921 0.521 2.818 
Caffeine 0.288 7.844 -680.352 0.038 1.021 3.411 0.128 4.433 2.880 0.347 3.796 
Carbamazepine 0.271 7.366 -763.578 0.008 0.219 3.573 0.136 3.792 2.012 0.497 3.547 
Methyl orange 0.254 6.916 -1330.583 -0.032 -0.882 3.899 0.144 3.017 1.167 0.857 10.244 
Clofibric acid 0.320 8.718 -1073.540 0.041 1.104 3.807 0.115 4.911 3.167 0.316 2.872 
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